



## **CURRICULUM VITAE !**

**Jaffer A. Ajani, M.D. !**

### **PRESENT TITLE AND AFFILIATION !**

#### **Primary Appointment**

Professor, Tenured (since 1994), Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

#### **Dual/Joint/Adjunct Appointment**

Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

### **CITIZENSHIP**

United States

### **OFFICE ADDRESS**

The University of Texas MD Anderson Cancer Center  
1515 Holcombe Blvd. #426  
Houston, TX 77030  
Room Number: FC10.3022  
Phone: 713-792-2828  
Fax: 713-745-1163

### **EDUCATION**

#### **Degree-Granting Education**

Government Medical College, Nagpur, India, MD, 1971

#### **Postgraduate Training**

Clinical Internship, Government Medical College, Nagpur, India, 1/1972-12/1972

Clinical Residency, General Surgery and Orthopedics, Government Medical College, Nagpur, India, 1/1973-5/1974

Clinical Internship, Family Practice, Altoona General Hospital, Pennsylvania State University, Altoona, PA, 7/1974-6/1975

Clinical Residency, Family Practice, Altoona General Hospital, Pennsylvania State University, Altoona, PA, 7/1975-6/1977

Clinical Internship, Internal Medicine, Tulane University School of Medicine, New Orleans, LA, 7/1977-6/1978

Clinical Residency, Internal Medicine, Tulane University School of Medicine, New Orleans, LA, 7/1978-6/1980

Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1980-6/1981

Research Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/1981-6/1982

### **CREDENTIALS**

#### **Board Certification**

Family Practice, 1/1977

Internal Medicine, 1/1979 !

Internal Medicine-Medical Oncology, 1/1983 !

**Licensures !**

**Active !**

Texas Medical Board, TX, F8389, from 1980-current

**Inactive**

N/A (Pennsylvania and Louisiana)

**EXPERIENCE/SERVICE**

**Academic Appointments**

Instructor, U.T. M. D. Anderson Cancer Center, Houston, TX, 7/1982-8/1983

Assistant Professor, Division of Cancer Medicine, U.T. M. D. Anderson Cancer Center, Houston, TX, 9/1983-8/1987

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, U.T. M. D. Anderson Cancer Center, Houston, TX, 9/1987-8/1989

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, U.T. M. D. Anderson Cancer Center, Houston, TX, 9/1989-8/1994

Instructor, Korea University Medical College, Seoul, 9/1989-8/1994

Professor, Tenured, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/1994-present

Professor, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2011-present

**Administrative Appointments/Responsibilities**

JACHO, Division of Medicine, 1/1988-1/1990

Quality Improvement Peer Reviewer, Department of GI Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA:USA, 1/1989-6/1993

Editorial Board: Faculty Newspaper, 1/1991-1/1994

Deputy Chairman, Department of Gastrointestinal Medical Oncology and Digestive Diseases, U.T. M. D. Anderson Cancer Center, Houston, TX, 2/1993-8/1994 !

Clinic Chief, Department of Gastrointestinal Medical Oncology and Digestive Diseases, U.T. M. D. ! Anderson Cancer Center, Houston, TX, 8/1994-3/1996 !

Chairman (ad interim), Department of Gastrointestinal Medical Oncology and Digestive Diseases, ! U.T. M. D. Anderson Cancer Center, Houston, TX, 8/1994-3/1996 !

Committee Chair, Institutional Review Board 1, The University of Texas MD Anderson Cancer ! Center, Houston, TX, 9/2014-present !

Associate Chair Executive IRB (IRB3). UT MDACC 2017 onwards

**Other Appointments/Responsibilities**

NCI, 6/1996

Vice-Chair, Radiation Therapy Oncology Group (RTOG), Houston, TX, 1/2000-2/2002

American Joint Commission on Cancer: Colon Cancer Task Force, 1/2001

Advisory Board, Worldwide HealthCare Services, Inc., Beaumont, TX

Member, NCI upper GI task force

Member, National Comprehensive Cancer Network (USA)

Chair, Stomach cancer staging guidelines 2017 AJCC 8<sup>th</sup> edition

Chair Gastric cancer and Esophageal cancer Panels of the NCCN from 2095-current  
Chief Scientific Officer, International Society of Gastrointestinal Oncology. 2005-current

**Endowed Positions**

N/A

**Consultantships**

N/A

**Military or Other Governmental Service**

N/A

**Institutional Committee Activities**

Faculty Classification Committee, UTMDACC, Chairman, Houston, TX, 9/1987

Conduct of Care Committee, Member, 1/1989-1/1990

The Human Surveillance Committee, Alternate Member, 1/1989-1/1990

Patient Care Information System Committee, Member, 1/1989-1/1993

Automated Medical Record Committee, Member, 1/1990-1/1993

Gastrointestinal Medical Oncology Sub-committee of the Radiation Therapy Oncology Group, Co-Chairman, Houston, TX, 1/1990

Research Medical Library Advisory Committee, Member, 1/1991-1/1993

Medical Record Committee, Member, 1/1991-1/1993

Faculty Senate Finance Committee, Member, 1/1991-1/1994

Faculty Senate Academic Strategy Committee, Member, 1/1991-1/1994

Faculty Senate, Member, 1/1991-1/1994

The Human Surveillance Committee, Full Member, 1/1991-1/1994

Advisory Committee for Search for the Head of Division of Medicine, Member, 1/1992-1/1993

Minority Subcommittee, Member, 1/1992-1/1993

Faculty Senate Academic Strategy Committee, Chairman, 1/1992-1/1994

Academic Planning Committee of the Senate, Chairman, Houston, TX, 5/1992-8/1994

Advisory Committee to Laboratory and Pathology Divisions for developing new Electronic Interface, Member, 1/1993

Pharmacy Subcommittee on Growth Factor Usage at MDACC, Member, 1/1993

Medical Oncology Strategic Planning for the Department of Gastrointestinal Medical Oncology and Digestive Diseases, Chairman, 1/1993

Nominating Committee for the Faculty Classification Committee, Member, 1/1993

Advisory Committee for E-Mail at MDACC, Member, 1/1993

1993 Brown Foundation Award Selection Committee, Member, 1/1993

Medical Oncology Committee of the Radiation Therapy Oncology Group, Chairman, Houston, TX, 8/1993

Radiology Quality Improvement Task Force, Member, 1/1994-1/1996

PRS Fringe Benefit And Compensation Committee, Member, 1/1994

Credential Committee of the Medical Staff, Member, 8/1994-3/1996

Executive Committee, Member, 8/1994-3/1996

Ambulatory Treatment Center Efficiency Assessment Committee, Member, 9/1994-1/1995

Research Strategy Committee, Member, 9/1994-12/1995  
Advisory Committee to the President on Minority Issues, Member, 9/1994-3/1996  
Ad hoc Faculty Senate Committee for Selection of the Clinical Care Awardee for 1996, Member, 1/1996 !  
The Clinical Research Committee, Member, 8/1996-1/1998 !  
The Human Surveillance Committee, Member, 8/1996 !  
The Faculty Classification Committee, Member, 9/1996 !  
The Faculty Classification Committee, Chairman, 9/1997-9/1998 !  
Committee to Honor Deceased MDACC Faculty, Member, 1/1998 !  
NCCN Upper GI Cancer Panel, Chairman, Houston, TX, 7/1998 !  
GI Cancer Center Committee, Member, 1/1999 !  
Ad hoc Committee to select the Chief of Cardiology, Member, 1/2000 !  
PRS Fringe Benefits and Compensation Committee, Member, 1/2000 !  
CME and Education Committee, Member, 1/2001 !  
Clinical Research Award Committee, Member, 1/2001 !  
Clinical Research Impact Committee, Member, 1/2003 !  
CME Committee, Member, 1/2003 !  
Executive Committee, Member, 1/2005 !  
New Patient Referral Quality Oversight Committee, Member, 1/2009 !

## **HONORS AND AWARDS**

Distinction in Applied Physics, Nagpur University, Nagpur, India, 1965  
Fellowship Award for Excellence in Clinical Oncology, U. T. M. D. Anderson Cancer Center, Houston, TX, 1981  
Cited in Best Doctors in America (National), Woodward/White Publishers, Inc, 1991  
Cited in Good Housekeeping Magazine (October 1992) as one of the Best Cancer Doctors in America, Good Housekeeping Magazine, 1992  
Cited in Best Doctors in America (National), Woodward/White Publishers, Inc., 1994  
Member of the Board, Member of the Board, 1995  
Cited in Best Doctors in America (Central Division), Woodward/White Publishers, Inc., 1996  
Listed in "International Directory of Distinguished Leadership," American Biographical Institute, 1997  
Cited in Good Housekeeping Magazine as Best Doctors in America for Colorectal Carcinoma, Good Housekeeping Magazine, 1998 !  
Benvenuto Award, U.T.M.D. Anderson Cancer Center !  
Named Best Doctor each year since 1991

## **RESEARCH**

### **Grants and Contracts**

#### **Funded**

Principal Investigator, Exploiting RhoA mutations in diffuse gastric adenocarcinoma and targeting intertwined RhoA and Yap1 pathways for therapeutic advantage., CA150334, Department of Defense (DOD), 12/1/2016-11/30/2021

Co-Investigator, 0.24 months, Immune-Suppression and Tumor-Stromal Interaction Mediated by Galectin-3 in Gastric Cancer – Implications of Novel Therapeutic Strategies, CA160433, Department of Defense (DOD), PI - Song, 7/15/2017-7/14/2019, \$400,000 (\$640,000/year)

Co-Investigator, Marker-based targeting of chemo-resistant subtype of gastric cancer discovered by proteomics, CA160616, Department of Defense (DOD), PI - Lee, 8/1/2017-7/31/2019

Principal Investigator, Discover Novel Therapeutic Strategies for Peritoneal Metastases from Gastric Adenocarcinoma, CA160455, Department of Defense (DOD), 9/1/2017-8/31/2020

**Pending**

Co-Investigator, 5%, Role of Hippo/YAP1 in Peritoneal Metastasis of Gastric Cancer- Implications for Novel Target Therapeutic Strategic, FP00004627\_Res1, NIH/NCI, PI - Shumei Song, 7/1/2019-6/30/2024, \$2,297,139 (\$287,142/year)

**Other**

N/A

**Completed**

Principal Investigator, 8%, Prediction of Pathologic Complete Response by Gene Expression Profiling in Esophageal Cancer., R01 CA138671-05, NIH/NCI, 2/1/2010-1/31/2016 (\$291,367/year)

Co-Investigator, 0.48 months, Development and Validation of Prognostic Model for Gastric Center., R01 CA150299-02, NIH/NCI, PI - Lee, 4/1/2010-3/31/2015 (\$186,750/year)

Principal Investigator, 0.12 months, Genetic and functional alterations of the c-MET RTK in cancer progression, LS2010-30147LG, Amgern Inc., 11/29/2010-11/29/2014 (\$72,637/year)

Principal Investigator, 0.12 months, An Open-Label, Multicenter Randomized, Phase 3 Study, 2010-0590, Taiho Pharma USA , 1/11/2011-1/31/2016 (\$1,171,925/year)

Principal Investigator, 0.12 months, TAIHO U.S. CONSULTANT AGREEMENT in conjunction with 2010-0590, LS2011-00034580, Taiho Pharma USA, 1/25/2011-1/31/2015 (\$1,249,088/year)

Principal Investigator, 0.12 months, An Open-label, single-center, Phase 1 / 2 Study, 2011-0489, Novartis, 8/15/2011-11/30/2013 (\$581,462/year)

Principal Investigator, 0.12 months, Genotyping and Phenotyping of Diffuse Gastric Cancer, LS2012-35803, Taiho Pharma USA, 11/18/2011-11/17/2015 (\$537,000/year)

Principal Investigator, 0.6 months, Collection and Banking of Normal and Malignant Tissue for NCI The Cancer Genome Atlas Program Gastric and Esophageal Cancer., PA12-0291, SAIC Frederick, 2/28/2013-3/31/2014 (\$548,447/year)

Principal Investigator, 0.48 months, Inhibition of Hedgehog Signaling in Gli-1 + Adeno CA of the Esoph or GE Junction., 1R01CA172741, NIH/NCI, 9/1/2013-8/31/2018

Co-Principal Investigator, 0.24 months, CDK Inhibitors as Adjunctive to 5-FU and /or Radiation in Esophageal Adenocarcinoma-Assessment of Efficacy and Predictive Biomarkers, RP140515, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Maru, 8/31/2014-8/30/2017

**Not Funded**

Principal Investigator, Esophagus SPORE: Biology of Barrett's Esophagus and Adenocarcinoma. Translational Medicine, P50CA150953-01., NIH/NCI, 12/1/2012-11/30/2017

Principal Investigator, Dual pathway inhibition in biomarker enriched patients with advanced GE cancer., 1R01CA175096-01, NIH/NCI, 4/1/2013-3/31/2018

Principal Investigator, Early Detection and Mitigation of the High -Risk Precursor to Gastric Cancer, CA170514P1, Department of Defense (DOD), 4/1/2018-3/30/2021, \$240,000 (\$150,000/year)

Principal Investigator, Targeting ARIDIA Deficiency in Gastric Adenocarcium, CA170896, Department of Defense (DOD), 7/1/2018-6/30/2020, \$400,000 (\$640,000/year)

## Protocols

### Funded

Principal Investigator, Phase I clinical and pharmacokinetic study of MDL-28,314QA administered by short intravenous infusion, DM93-099, 1993, \$336,370, Marion Merrell Dow

Principal Investigator, Phase II study of Adozelesin in advanced gastric carcinoma, 999, 1993, \$50,000, UpJohn Company

Principal Investigator, Phase I study of low-dose continuous protracted infusion of Taxol, DM93-119, 1994, \$40,000, Bristol-Myers Oncology Division

Principal Investigator, Phase II study of 120-hour Taxol infusion in patients with treated advanced colorectal carcinoma, DM93-015, 1994, \$40,000, Bristol-Myers Oncology Division

Principal Investigator, Phase II study of Taxol in patients with advanced gastric carcinoma, DM93-156, 1994, \$20,000, Bristol-Myers Oncology Division, Princeton, NJ

Principal Investigator, Phase II study of Taxol, 5-Fluorouracil, and Cisplatin in patients with advanced squamous cell carcinoma or adenocarcinoma of the esophagus, DM94-024, 1994, \$20,000, Bristol-Myers Oncology Division

Principal Investigator, Open label study of the safety and efficacy of sequential doses of Sandostatin LAR in malignant carcinoid syndrome, DM95-009, 1995, \$74,000, Sandoz Pharmaceutical, NJ

Principal Investigator, Phase II trial of Lanreotide (Angiopeptin, Somatulin) in patients with neuroendocrine carcinoma, ID94-006, 1995, \$136,290, Henri Beaufour Institute, Washington, DC

Principal Investigator, Phase III randomized trial of long-acting Sandostatin in patients with carcinoid tumors; A multi-institutional study, DM95-192, 1995, \$88,000, Sandoz Pharmaceutical, NJ

Principal Investigator, Phase II study of BR96-Doxorubicin conjugate in patients with advanced gastric carcinoma, DM95-138, 1996, \$250,761, Bristol-Myers Oncology Division

Principal Investigator, Phase II study of Lobaplatin in patients with advanced carcinoma of the esophagus, DM95-235, 1996, \$126,000, ASTA Medical

Principal Investigator, Phase II study of CPT-11 and Cisplatin in patients with metastatic or unresectable locally advanced adenocarcinoma of the stomach or gastroesophageal junction, ID97-021, 1997, \$170,000, Pharmacia

Principal Investigator, Phase II study of preoperative 5-FU, Taxol and Cisplatin followed by Concurrent 5-FU and radiotherapy in patients with potentially resectable carcinoma of the esophagus or GE junction, ID96-189, 1997, \$45,000, Bristol-Myers Oncology Division

Principal Investigator, Phase II study of Taxol (paclitaxel), carboplatin, and UFT plus Leucovorin in the treatment of patients with advanced carcinoma of the esophagus, GE junction, or stomach, ID96-315, 1997, \$245,000, Bristol-Myers Squibb Oncology

Principal Investigator, A phase II study of CPT-11 and concurrent radiation therapy in patients with locally advanced, unresectable or metastatic gastric, gastroesophageal junction, or esophageal carcinoma, ID97-311, 1998, \$85,000, Pharmacia

Principal Investigator, A phase II study of CPT-11 in patients with metastatic, unresectable carcinoid tumors or islet cell carcinoma, DM97-246, 1998, \$82,500, Pharmacia

Principal Investigator, An open label study to assess the long-term safety and tolerability of Sandostatin LAR injected at 4 week intervals for 72 Weeks in patients with malignant carcinoid syndrome, DM97-220, 1998, \$20,600, Novartis

Principal Investigator, An open label, randomized multicenter phase II/III study of Docetaxel in combination with cisplatin (CDDP) or Docetaxel in combination with 5-fluorouracil (5-FU) and CDDP compared to the combination of CDDP and 5-FU in patients with metastatic or locally, ID98-167, 1998, \$334,917, Aventis Pharmaceuticals Inc.

Principal Investigator, A phase II study of preoperative CPT-11/Cisplatin followed by concurrent 5-FU/Taxol and radiotherapy in patients with potentially respectable carcinoma of the esophagus or GE junction, DM98-349, 1999, \$143,500, Pharmacia

Principal Investigator, A phase II study of RFS-2000 (9-Nitro-Camptothecin, 9-NC) in patients with advanced gastric carcinoma, DM99-231, 1999, \$267,750, Supergen

Principal Investigator, A trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach, ID98-224, 1999, \$125,000, Bristol-Myers Squibb Oncology

Principal Investigator, A phase II study of BMS-184476 in previously treated patients with advanced adenocarcinoma involving the gastroesophageal junction or stomach, ID99-396, 2000, \$103,500, Bristol-Myers Squibb Oncology

Principal Investigator, An open-label, sequential, multi-center, multi-dose study of G17DT Immunogen in combination with Cisplatin(CDDP) and 5-Flourouracil (5-FU) in subjects with metastatic or locally recurrent gastric or gastroesophageal cancer previously untreated with chemot, DM00-015, 2000, \$274,649, Apton Corporation

Principal Investigator, Phase II study of Bryostatin-1 plus Taxol in patients with metastatic or unresectable locally advanced adenocarcinoma of the stomach or gastroesophageal junction, ID99-203, 2000, National Cancer Institute (NCI)

Principal Investigator, Non-operative therapy of local-regional carcinoma of the esophagus: A randomized Phase II study of two Paclitaxel-based chemoradiotherapy regimens, RTOG E-0113, 2001, Radiation Therapy Oncology Group (RTOG)

Principal Investigator, Phase II study of Epothilone Analog BMS-247550 in patients with metastatic gastric adenocarcinoma previously treated with a Taxane, DM00-413, 2001, \$188,647, Bristol-Myers Squibb Oncology

Principal Investigator, Phase II study of intravenous Exatecan Mesylate (DX-8951F) administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer, ID00-411, 2001, \$179,183, Daiichi Pharmaceutical Corporation

Principal Investigator, An evaluation of the efficacy and safety of Peg-Camptothecin in the treatment of locally advanced and metastatic gastric adenocarcinoma which may involve the gastroesophageal junction, DM02-432, 2002, \$206,910, Enzon, Inc.

Principal Investigator, Phase I, open-label, dose escalation study of intravenously administered NS-9 in subjects with liver metastases from various primary cancers, ID02-349, 2002, \$289,354, NS Pharma, Inc.

Principal Investigator, Phase I/II correlative study of induction chemotherapy followed by preoperative chemoradiotherapy in patients with resectable esophageal and gastroesophageal adenocarcinoma, ID01-071, 2002, \$302,500, Pharmacia

Principal Investigator, Phase I/II correlative study of Taxotere, CPT-11, and Carboplatin in patients with advanced gastric and gastroesophageal adenocarcinoma, ID01-069, 2002, \$220,000, Pharmacia

Principal Investigator, A study to assess symptom burden in subjects with nonmyeloid malignancies receiving chemotherapy and Aranesp™, ID03-0082, 2003, \$10,000, Amgen, Inc.

Principal Investigator, An evaluation of efficacy and safety of Peg-Camptothecin for second line therapy of locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, 2003-0771, 2003, \$10,000, Enzon, Inc.

Principal Investigator, Genetic profiling of gastroesophageal adenocarcinoma and correlation with patient outcome: A lab protocol, LAB03-0067, 2003, UTMDACC

Principal Investigator, Phase I/II open-label, nonrandomized dose-finding safety, tolerance, pharmacokinetic, and efficacy study of orally administered S-1 in combination with Cisplatin in patients with advanced gastric cancer, ID02-694, 2003, \$580,882, Taiho Pharma U.S.A.

Principal Investigator, Phase II Study of Arsenic Trioxide in patients with advanced adenocarcinoma of the esophagus or gastroesophageal junction, DM02-172, 2003, National Cancer Institute (NCI)

Co-Principal Investigator, Phase II study of single agent OSI-7904L in patients with locally advanced metastatic adenocarcinoma of the stomach or gastroesophageal junction, 2003-0571, 2003, \$208,895, OSI Pharmaceuticals, Inc.

Principal Investigator, Phase II study of Tezacitabine with or without 5-Fluorouracil (5-FU) as second line therapy of advanced esophageal or gastric adenocarcinoma, ID02-629, 2003, \$478,397, Chiron Therapeutics

Principal Investigator, An Oxaliplatin-based Phase II correlative randomized study of induction chemotherapy followed by preoperative chemoradiotherapy or preoperative chemoradiotherapy in patients with resectable esophageal or gastroesophageal adenocarcinoma, 2004-0703, 2004-2008, \$412,935, Sanofi-Synthelabo Inc.

Principal Investigator, Phase I/II study of Docetaxel, 5-Fluorouracil, and Oxaliplatin (D-FOX) in patients with untreated metastatic adenocarcinoma of the stomach or gastroesophageal junction, Pending, 2004-0290, PI - Jaffer A. **Ajani**, MD, 2004-2010, \$249,435, Sanofi-Synthelabo Inc.

Principal Investigator, Molecular Epidemiology of Gastric Cancer, LAB03-1023, 2004, UTMDACC

Principal Investigator, Phase II trial of preoperative chemotherapy and chemoradiotherapy for potentially resectable adenocarcinoma of the stomach and gastroesophageal junction, 2003-0769, 2004, \$265,133, Sanofi-Synthelabo Inc.

Principal Investigator, An open-label, multi-center, randomized, Phase III study of S-1 in combination with Cisplatin compared against 5-FU in combination with Cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease., 2005-0056, 2005-2008, \$884,355, Taiho Pharma U.S.A.

Principal Investigator, An open-label, non-randomized, multi-center, two stage, phase II study of TAS-102 as second line therapy for patients with locally advanced or metastatic gastric cancer., 2005-0800, PI - Jaffer A. **Ajani**, MD, 2005-2008, \$753,145, Taiho Pharmaceutical Co., Ltd.

Principal Investigator, Phase I dose-escalation, sequential-cohort study of the safety, tolerability, and pharmacokinetics of intravenous AVE 0005 (VEGF Trap) in combination with intravenous docetaxel/cisplatin/5-fluorouracil administered every 3 weeks in subjects with advanced solid malignancies., 2005-0683, 2006-2008, \$372,760, Sanofi-Aventis

Principal Investigator, An open-Label, Single center, Phase I/II Study of Preoperative Chemoradiotherapy and AT-101 Followed by Surgery in Patients with Locally Advanced, Resectable Esophageal Cancer, 2006-1050, 2007-2010, \$526,297, Ascenta Therapeutics, Inc.

Principal Investigator, FDG-PET/CT and Biomarkers to Assess Pathologic Response in the Surgical Specimens of Patients with Localized Esophageal Cancer after Chemoradiation, 2008-0752, 2008, The University of Texas M.D. Anderson Cancer Center

Principal Investigator, A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric Cancer (TEL0805), 2009-0233, 2009-present, ACT Biotech



Principal Investigator, A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy (IMCL CP12-0715), 2009-0231, 2009-present, Imclone

Principal Investigator, A randomized, double-blind, multi-center phase III study comparing everolimus (RAD001) plus best supportive care versus placebo plus best supportive care in patients with advanced gastric cancer after progression on prior systemic chemotherapy (CRAD001R2301), 2009-0533, 2009-present, Novartis

Principal Investigator, A Phase Ib/II Study of MBP-426 in Patients with Second Line Gastric, Gastro-Esophageal, or Esophageal Adenocarcinoma (MBP-426 201), 2009-0252, 2009, Mebiopharm

Principal Investigator, Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First-Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas. (CA194004), 2009-0917, 2010-2015, Bristol Myers Squibb (BMS)

Principal Investigator, A Phase II study of tesetaxel administered at a flat dose once every 21 days as second-line therapy to subjects with advanced gastric cancer (TOG201), 2009-0995, 2010-2012, Genta

Study Chairman, A randomized, double-blind study of capecitabine plus tesetaxel versus capecitabine plus placebo as second-line therapy in subjects with gastric cancer (TOG301), 2011-0544, 2011-2012, Genta

Principal Investigator, An open-label, multicenter, randomized, phase 3 study of S-1 and cisplatin compared with 5-FU and cisplatin in patients with metastatic diffuse gastric cancer previously untreated with chemotherapy, 2010-0590, PI - Jaffer A. **Ajani**, MD, 2011-2015, \$1,269,936, Taiho Pharma USA Inc.

Principal Investigator, Phase I, Open-label, Multicenter, Dose Escalation, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors, 2011-0434, 2011, Bristol-Myers Oncology Division

Principal Investigator, A Randomized, Open-Label, Two-Arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab versus Best Supportive Care Following First-line Chemotherapy in Subjects with Unresectable Locally Advanced/Metastatic Gastric or Gastro-Esophageal Junction Cancer (CA184162), 2012-0526, 2012-2016, Bristol-Myers Squibb

Principal Investigator, An Open-Label, Single-Arm, Multi-Center Phase II Study to Evaluate the Efficacy and Safety of AUY922 in Combination with Trastuzumab Standard Therapy as Second-Line Treatment in Patients with HER2-positive Advanced Gastric Cancer (CAUY922A2205), 2011-0489, 2012, Novartis

Collaborator, A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors, 2013-0814, PI - Wu, 2013, MedImmune

Co-Principal Investigator, A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors (CA209032), 2013-0639, PI - Padmanee Sharma, MD, PhD, 2013, Bristol-Myers Squibb

Principal Investigator, A Phase I Study of LDE225 in Combination with Everolimus in Patients with Advanced Gastroesophageal Adenocarcinoma, 2013-0838, 2013, Novartis

Principal Investigator, A phase IB, multicenter, open-label dose escalation study of the PI3K inhibitor BYL719 in combination with the HSP90 inhibitor AUY922 in patients with advanced or metastatic gastric cancer carrying a molecular alteration of PIK3CA or an amplification of HER2, 2012-0872, 2013, Novartis

Collaborator, A Phase Ib/II, Open-Label Study of LJM716 in Combination with BYL719 Compared to Taxane or Irinotecan in Patients with Previously Treated Esophageal Squamous Cell Carcinoma (CLJM716X2103), 2013-0365, PI - Mariela Blum-Murphy, MD, 2013, Novartis

Principal Investigator, A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, an Inhibitor to AKT, in Combination with Fluoropyrimidine plus Oxaliplatin in Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GO28341), 2012-0867, 2013, Genentech, Inc

Principal Investigator, A Randomized, Multicenter, Adaptive Phase II/III study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine (T-DM1) Versus Taxane in Patients with Previously Treated Locally Advanced or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma of the Gastro Esophageal Junction, 2012-1062, 2014-2016, F. Hoffman-La Roche Ltd

Principal Investigator, A Phase I Study of Once-Daily Oral DFP-11207 in Patients with Solid Tumors (D13-11038), 2014-0203, 2015, Delta-Fly Pharma, Inc

Principal Investigator, A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors (FPA144-001), 2015-0187, 2015, Five Prime Therapeutics

Principal Investigator, A Phase 1B/2 Study of LY2940680 in Combination with Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction, 2014-0966, PI - Ajani, 2015, NCI/Lilly

Principal Investigator, A Phase I Study of Once-Daily Oral DFP-11207 in Patients with Solid Tumors (D13-11038), 2015-0203, PI - Ajani, 2015, Delta-Fly

Principal Investigator, Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma (I4T-MC-JVDB), 2015-0256, 2015, Eli Lilly

Principal Investigator, A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GS-US-296-1080), 2015-0976, 2016, Gilead Sciences

PI: Phase 3 Astellas. Anti-claudin 18.2 antibody. 2018-present

PI: Zymeworks Phase II trial of ZW25 plus chemotherapy: 2018-present

PI: Daiichi: Second line therapy of Her2 positive gastroesophageal cancers. 2019-present

PI: Prolinx Pharma. Phase I study pegylated SN38. 2015-present

PI: Merck Alliance study of pembrolizumab in second or later lines: 2015-2018

PI: DeltaFly Pharma: phase I study of novel fluoropyrimidine delivered orally. 2015-2018

PI: DeltaFly Pharma: Phase I study of pegylated nucleoside analogue. 2017-2021

#### **Unfunded**

P.I., Combination biochemotherapy for resectable gastric carcinoma, Schering-Plough

P.I., Phase II study of 4-epidoxorubicin in patients with advanced colorectal carcinoma, Adria Labs, Columbus, OH

P.I., Phase II study of ELF with GM-CSF in advanced gastric carcinoma, Bristol-Myers and Immunex

P.I., Phase II study of etoposide and alpha-interferon in patients with metastatic colorectal carcinoma, Schering-Plough and Bristol-Myers

P.I., Phase II study of oral Etoposide in patients with metastatic gastric or GE junction carcinoma, Bristol-Myers

P.I., Phase II study of oral Etoposide in patients with metastatic pancreatic carcinoma, Bristol-Myers

P.I., Phase II study of Sulfonylurea in patients with colorectal carcinoma, Eli-Lilly Company, IN

P.I., Phase II study of Tallysomyin in patients with advanced colorectal carcinoma, Bristol-Myers Company, CT

P.I., Characterization of both cancer associated-anemia and chemotherapy-induced anemia in patients with metastatic gastrointestinal, breast, and lung carcinoma, RCR03-0168, 2003, Amgen, Inc.

Principal Investigator, Collection of blood and tissue from patients with gastrointestinal malignancies: An endoscopic and laboratory protocol, LAB01-543, 2003, UTMDACC

Co-P.I., Phase II Study of Bevacizumab and PEG Interferon alpha-2b (PEG Intron) in patients with metastatic or unresectable carcinoid tumors, ID02-063, 2003, SAIC-Frederick, Inc. (NCI Subcontract)

### **Patents and Technology Licenses**

#### **Patents !**

999, Methods for reduction of difluoromethylornithine associated toxicity, United States, 4,859,452, 8/22/1989, Filed

999, Methods and improved formulation for the determination and treatment of malignant disease in patients, United States, 4,988,724, 1/29/1991, Filed

999, Methods and improved formulations for the determination and treatment of malignant disease in patients, United States, 5,162,373, 11/10/1992, Filed

999, Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions, United States, 5,189,025, 11/10/1992, Filed

#### **Technology Licenses**

N/A

### **Grant Reviewer/Service on Study Sections**

N/A

### **PUBLICATIONS**

#### **Peer-Reviewed Original Research Articles**

1. ! **Ajani** JA, Cabanillas FF, Bodey GP. Phase I trial of pentamethylmelamine. *Cancer Treat Rep* 66(5):1227-8, 5/1982. PMID: 6805950.
2. ! **Ajani** JA, Burgess MA. Multiple squamous cell carcinoma treated with intra-arterial cisplatin in a patient with rheumatoid arthritis. *Cancer Treat Rep* 66(11):1987-9, 11/1982. PMID: 6890408.
3. ! Legha SS, **Ajani** JA, Bodey GP. Phase I study of spirogermanium given daily. *J Clin Oncol* 1(5):331-6, 5/1983. PMID: 6668504.
4. ! Kanojia M, Kantarjian H, **Ajani** J, Barlogie B. High-dose cytosine arabinoside (Ara-C) in colorectal cancer. *British J Cancer* 48:869-871, 1983.
5. ! Legha SS, **Ajani** JA, Blumenschein GR, Hortobagyi GN, Buzdar AU. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. *Cancer* 53(9):1836-40, 5/1984. PMID: 6231092.
6. ! **Ajani** JA, Kalter S, Rios A. *Oncologic Emergencies: A guide for the practicing physician. Part I Drug Therapy:15-36, 8/1984.*
7. ! Feun LG, Savaraj N, Bodey GP, Lu K, Yap BS, **Ajani** JA, Burgess MA, Benjamin RS, McKelvey E, Krakoff I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. *Cancer Res* 44(8):3608-12, 8/1984. PMID: 6744283.

8. ! Legha SS, Keating M, Picket S, **Ajani** JA, Ewer M, Bodey GP. Phase I clinical investigation ! of homoharringtonine. *Cancer Treat Rep* 68(9):1085-91, 9/1984. PMID: 6478448. !
9. ! **Ajani** JA, Kanojia MD, Bodey GP. Phase II evaluation of 4'-epi-doxorubicin in patients with metastatic colorectal carcinoma. *Cancer Treat Rep* 68(12):1507-8, 12/1984. PMID: 6595058.
10. ! **Ajani** JA, Kalter S, Rios A. *Oncologic Emergencies: A guide for the practicing physician. Part II Drug Therapy*:54-63, 1984.
11. ! **Ajani** JA, Kanojia MD, Bedikian AY, Korinek JK, Stein SH, Espinoza EG, Bodey GP. Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma. *Am J Clin Oncol* 8(1):69-71, 2/1985. PMID: 3993626.
12. ! Singletary SE, Umbach GE, Spitzer G, Drewinko B, Tomasovic B, **Ajani** J, Hug V, Blumenschein G. The human tumor stem cell assay revisited. *Int J Cell Cloning* 3(2):116-28, 3/1985. PMID: 3998518.
13. ! Harris WB, Grossie VB, Ota DM, Nishioka K, **Ajani** JA, Chang T, Patenia D. Effect of difluoromethylornithine on host and tumor polyamine metabolism during total parenteral nutrition. *J Surg Res* 38(6):592-8, 6/1985. PMID: 3925242.
14. ! Gojobori T, Yokoyama S. Rates of evolution of the retroviral oncogene of Moloney murine sarcoma virus and of its cellular homologues. *Proc Natl Acad Sci U S A* 82(12):4198-201, 6/1985. PMID: 397963.
15. ! Feldman LD, **Ajani** JA. Fluorouracil-associated dermatitis of the hands and feet. *Jama* 254(24):3479, 12/1985. PMID: 2933539.
16. ! Kantarjian H, **Ajani** JA, Karlin DA. Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. *Oncology* 42(2):69-71, 1985. PMID: 3921891.
17. ! **Ajani** JA, Blaauw AA, Spitzer G, Baker FL, Tomasovic B, Umbach G, Thielvoldt D, Zander AR, Dicke KA. Differential cytotoxic activity of chemotherapy agents on colony-forming cells from human tumors and normal bone marrow in vitro. *Exp Hematol* 13 Suppl 16:95-100, 1985. PMID: 2580731.
18. ! Umbach G, Hug V, Spitzer G, Tomasovic G, Thames H, **Ajani** JA, Drewinko B. Responses of human bone marrow progenitor cells to fluoro-ARA-AMP, homoharringtonine, and elliptinium. *Invest New Drugs* 2:263-265, 1985.
19. ! Umbach GE, Hug V, Spitzer G, Tomasovic B, Thames H, **Ajani** JA, Drewinko B. Survival of human bone marrow cells after in vitro treatment with 12 anticancer drugs and implications for tumor drug sensitivity assays. *J Cancer Res Clin Oncol* 109(2):130-4, 1985. PMID: 3980561.
20. ! Baker FL, Spitzer G, **Ajani** JA, Brock WA, Lukeman J, Pathak S, Tomasovic B, Thielvoldt D, Williams M, Vines C, et al. Drug and radiation sensitivity measurements of successful primary monolayer culturing of human tumor cells using cell-adhesive matrix and supplemented medium. *Cancer Res* 46(3):1263-74, 3/1986. PMID: 3484678.
21. ! **Ajani** JA, Dimery I, Chawla SP, Pinnamaneni K, Benjamin RS, Legha SS, Krakoff IH. Phase II studies of homoharringtonine in patients with advanced malignant melanoma; sarcoma; and head and neck, breast, and colorectal carcinomas. *Cancer Treat Rep* 70(3):375-9, 3/1986. PMID: 3955548.
22. ! Adolphson CC, **Ajani** JA, Stroehlein JR, Barlogie B, Bodey GP, Korinek J, Bedikian AY. Phase II trial of acivicin in patients with advanced colorectal carcinoma. *Am J Clin Oncol* 9(3):189-91, 6/1986. PMID: 3728371.
23. ! Carrasco CH, Charnsangavej C, **Ajani** J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. *AJR Am J Roentgenol* 147(1):149-54, 7/1986. PMID: 2424291.
24. ! Ota DM, Grossie VB, Jr, **Ajani** JA, Stephens LC, Nishioka K. Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. *Int J Cancer* 38(2):245-9, 8/1986. PMID: 3089944.
25. ! Patt YZ, Boddie AW, Jr, Charnsangavej C, **Ajani** JA, Wallace S, Soski M, Claghorn L, Mavligit GM. Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. *J Clin Oncol* 4(9):1356-64, 9/1986. PMID: 2943876.

26. ! Odaimi M, **Ajani** JA. Brain metastases and elevated alpha-fetoprotein level in a patient with esophageal carcinoma. *South Med J* 79(10):1304-6, 10/1986. PMID: 2429372.
27. ! **Ajani** JA, Spitzer G, Tomasovic B, Drewinko B, Hug VM, Dicke K. In vitro cytotoxicity patterns of standard and investigational agents on human bone marrow granulocyte-macrophage progenitor cells. *Br J Cancer* 54(4):607-13, 10/1986. PMID: 3778805.
28. ! **Ajani** JA, Tomasovic B, Spitzer G, Kavanagh JJ, Thielvoldt D, Baker FL, Gershenson D. Activity of 2-fluoro-Ara AMP against gynecologic tumors in the soft agar assay. *Invest New Drugs* 4(2):141-8, 1986. PMID: 2426218.
29. ! Grossie VB, Nishioka K, Ota DM, **Ajani** JA, Chang TH. Ornithine decarboxylase activity of normal tissue from tumor-bearing rats. *J Nutr Growth Cancer* 3:13-18, 1986.
30. ! Hortobagyi G, Papadoupoulos N, Frye D, **Ajani** J, Reuben JM. Phase I clinical studies of Nafazatrom. *Invest N Drugs* 4:251-255, 1986.
31. ! **Ajani** JA, Faintuch JS, McClure RK, Levin B, Boman BM, Krakoff IH. Phase II study of spirogermanium in patients with advanced colorectal carcinoma. *Invest New Drugs* 4(4):383-5, 1986. PMID: 3583645.
32. ! Umbach GE, Spitzer G, **Ajani** JA, Hug V, Thames H, Rudolph FB, Drewinko B. Role of culture conditions and exposure duration in determining sensitivity of human bone marrow progenitor cells to methotrexate. *J Cancer Res Clin Oncol* 111(3):273-6, 1986. PMID: 3733857.
33. ! Grossie VB, Nishioka K, **Ajani** JA, Ota DM, Chang T, Patenia, D. The effect of spontaneous and induced cachexia on hepatic and tumor polyamine metabolism. *J Nutrit Growth Cancer* 3:143-150, 1986.
34. ! Singletary SE, Baker FL, Spitzer G, Tucker SL, Tomasovic B, Brock WA, **Ajani** JA, Kelly AM. Biological effect of epidermal growth factor on the in vitro growth of human tumors. *Cancer Res* 47(2):403-6, 1/1987. PMID: 3491676.
35. ! **Ajani** JA, Hortobagyi GN, Frye D, Levin B, Boman BM, Faintuch JS. A randomized study of two schedules of copovithane in patients with advanced colorectal carcinoma. *Am J Clin Oncol* 10(2):139-40, 4/1987. PMID: 3551577.
36. ! Grossie VB, Jr, Ota DM, **Ajani** JA, Nishioka K. Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. *Cancer Res* 47(7):1836-40, 4/1987. PMID: 3102050.
37. ! Odaimi M, **Ajani** J. High-dose chemotherapy. Concepts and strategies. *Am J Clin Oncol* 10(2):123-32, 4/1987. PMID: 3551575.
38. ! Fan D, **Ajani** JA, Baker FL, Tomasovic B, Brock WA, Spitzer G. Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs. *Eur J Cancer Clin Oncol* 23(10):1469-76, 10/1987. PMID: 2890527.
39. ! **Ajani** JA, Baker FL, Spitzer G, Kelly A, Brock W, Tomasovic B, Singletary SE, McMurtrey M, Plager C. Comparison between clinical response and in vitro drug sensitivity of primary human tumors in the adhesive tumor cell culture system. *J Clin Oncol* 5(12):1912-21, 12/1987. PMID: 3681375.
40. ! Baker FL, **Ajani** J, Spitzer G, Tomasovic BJ, Williams M, Finders M, Brock WA. High colony-forming efficiency of primary human tumor cells cultured in the adhesive-tumor-cell culture system: improvements with medium and serum alterations. *Int J Cell Cloning* 6(2):95-105, 3/1988. PMID: 3373036.
41. ! **Ajani** JA, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. *Ann Intern Med* 108(3):340-4, 3/1988. PMID: 2449109.
42. ! **Ajani** JA, Abbruzzese JL, Faintuch JS, Blackburn R, Levin B, Boman BM. Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. *Invest New Drugs* 6(1):47-50, 4/1988. PMID: 2457566.
43. ! Fan D, Baker FL, Khokhar AR, **Ajani** JA, Tomasovic B, Newman RA, Brock WA, Tueni E, Spitzer G. Antitumor activity against human tumor samples of cis-diamminedichloroplatinum(II) and analogues at equivalent in vitro myelotoxic concentrations. *Cancer Res* 48(11):3135-9, 6/1988. PMID: 3365698.

44. ! **Ajani** JA, Baker FL, Spitzer G. In vitro activity of amonafide against primary human tumors compared with the activity of standard agents. *Invest New Drugs* 6(2):79-85, 6/1988. PMID: 3170133.
45. ! Grossie VB, Jr, Ota DM, **Ajani** JA, Chang TH, Patenia D, Nishioka K. Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. *JPEN J Parenter Enteral Nutr* 12(5):441-4, 9/1988. PMID: 3141639.
46. ! Boman BM, Gagen MM, Bonnem E, **Ajani** JA, Schmidt S, Dimery IW, Golando J, Neidhart J. Phase I study of recombinant gamma-interferon (rIFN-gamma). *J Biol Response Mod* 7(5):438-46, 10/1988. PMID: 3141591.
47. ! **Ajani** JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, Levin B. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. *J Clin Oncol* 6(11):1703-7, 11/1988. PMID: 3141592.
48. ! Nishioka K, Grossie VB, Jr, **Ajani** JA, Patenia D, Chang TH, Ota DM. Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. *Int J Cancer* 42(5):744-7, 11/1988. PMID: 3141298.
49. ! Baker FL, Spitzer G, **Ajani** JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system (ATCCS). *Prog Clin Biol Res* 276:105-17, 1988. PMID: 3174675.
50. ! Tueni EA, Newman RA, Baker FL, **Ajani** JA, Fan D, Spitzer G. In vitro activity of bleomycin, tallysomyin S10b, and liblomycin against fresh human tumor cells. *Cancer Res* 49(5):1099-102, 3/1989. PMID: 2465080.
51. ! **Ajani** JA, Rios AA, Ende K, Abbruzzese JL, Edwards C, Faintuch JS, Saks S, Gutterman JU, Levin B. Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. *J Biol Response Mod* 8(2):140-6, 4/1989. PMID: 2499663.
52. ! Abbruzzese JL, Levin B, **Ajani** JA, Faintuch JS, Saks S, Patt YZ, Edwards C, Ende K, Gutterman JU. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. *Cancer Res* 49(14):4057-61, 7/1989. PMID: 2500234.
53. ! **Ajani** JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. *Am J Med* 87(2):221-4, 8/1989. PMID: 2527006.
54. ! **Ajani** JA, Kanojia MD, Bedikian AY. High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. *Am J Clin Oncol* 12(4):335-8, 8/1989. PMID: 2667325.
55. ! Grossie VB, Jr, Ota DM, **Ajani** JA, Chang TH, Patenia D, Nishioka K. Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. *Cancer Res* 49(15):4159-62, 8/1989. PMID: 2501023.
56. ! **Ajani** JA, Ota DM, Grossie VB, Jr, Levin B, Nishioka K. Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. *Cancer Res* 49(20):5761-5, 10/1989. PMID: 2507135.
57. ! Grossie VB, Jr, Nishioka K, Chang TH, Patenia D, Benitez MM, **Ajani** JA, Ota DM. Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. *JPEN J Parenter Enteral Nutr* 13(6):590-5, 11/1989. PMID: 2515305.
58. ! Hughes LL, Rich TA, Delclos L, **Ajani** JA, Martin RG. Radiotherapy for anal cancer: experience from 1979-1987. *Int J Radiat Oncol Biol Phys* 17(6):1153-60, 12/1989. PMID: 2599903.
59. ! **Ajani** JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. *Gastroenterol Clin North Am* 18(4):923-30, 12/1989. PMID: 2559037.
60. ! **Ajani** JA, Goudeau P, Levin B, Faintuch JS, Abbruzzese JL, Boman BM, Kanojia MD. Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. *Cancer Chemother Pharmacol* 24(1):41-4, 1989. PMID: 2720890.
61. ! Venkatesh S, Ordonez NG, **Ajani** J, Schultz PN, Hickey RC, Johnston DA, Samaan NA. Islet cell carcinoma of the pancreas. A study of 98 patients. *Cancer* 65(2):354-7, 1/1990. PMID: 2153046.

62. ! **Ajani** JA, Roth JA, Ryan B, McMurtrey M, Rich TA, Jackson DE, Abbruzzese JL, Levin B, DeCaro L, Mountain C. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. *J Clin Oncol* 8(7):1231-8, 7/1990. PMID: 2358838.
63. ! Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, **Ajani** JA, Levin B, Merchant B, Halverson C, Murray JL. Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases. *J Clin Oncol* 8(7):1246-54, 7/1990. PMID: 2193120.
64. ! Abbruzzese JL, Levin B, **Ajani** JA, Faintuch JS, Pazdur R, Saks S, Edwards C, Gutterman JU. A phase II trial of recombinant human interferon-gamma and recombinant tumor necrosis factor in patients with advanced gastrointestinal malignancies: results of a trial terminated by excessive toxicity. *J Biol Response Mod* 9(5):522-7, 10/1990. PMID: 2123922.
65. ! Pazdur R, **Ajani** JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintuch J, et al. Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. *J Clin Oncol* 8(12):2027-31, 12/1990. PMID: 2230894.
66. ! **Ajani** JA, Abbruzzese JL, Faintuch JS, Patt YZ, Boman BM, Jackson DE, Levin B, Krakoff IH. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. *Cancer Invest* 8(6):619-21, 1990. PMID: 2149834.
67. ! **Ajani** JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. *Cancer Invest* 8(2):147-59, 1990. PMID: 2400936.
68. ! **Ajani** JA, Ota DM, Grossie VB, Jr, Abbruzzese JL, Faintuch JS, Patt YZ, Jackson DE, Levin B, Nishioka K. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. *Cancer Chemother Pharmacol* 26(3):223-6, 1990. PMID: 2113439.
69. ! Roth JA, **Ajani** JA, Rich TA. Multidisciplinary therapy for esophageal cancer. *Adv Surg* 23:239-60, 1990. PMID: 2403459.
70. ! Nicaise C, **Ajani** J, Goudeau P, Rozenzweig M, Levin B, Krakoff I. Phase II study of tallysomycin S10b in patients with advanced colorectal cancer. *Cancer Chemother Pharmacol* 26(3):221-2, 1990. PMID: 1694112.
71. ! **Ajani** JA, Carrasco CH, Samaan NA, Wallace S. Therapeutic options for patients with advanced islet cell and carcinoid tumors. *Regional Cancer Treatment* 3:235-242, 1990.
72. ! Dhingra K, Talpaz M, Dhingra HM, **Ajani** JA, Rothberg JM, Gutterman JU. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatin. *Invest New Drugs* 9(1):37-9, 2/1991. PMID: 1851142.
73. ! Ellerbroek NA, Fossella FV, Rich TA, **Ajani** JA, Komaki R, Roth JA, Holoye PY. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. *Int J Radiat Oncol Biol Phys* 20(2):351-5, 2/1991. PMID: 1846848.
74. ! Nishioka K, Grossie VB, Chang TH, **Ajani** JA, Ota DM. Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. *J Surg Oncol* 47(2):117-20, 6/1991. PMID: 2062082.
75. ! Robey-Cafferty SS, **Ajani** JA, Ota DM, Roth JA, Bruner JM. Histologic observations and P-glycoprotein expression in gastric and esophageal adenocarcinomas treated with preoperative chemotherapy. *Arch Pathol Lab Med* 115(8):807-12, 8/1991. PMID: 1713759.
76. ! **Ajani** JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Wiseman C, Lenado-Lee MA, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. *Invest New Drugs* 9(3):257-9, 8/1991. PMID: 1783525.
77. ! **Ajani** JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. *Cancer* 68(7):1501-6, 10/1991. PMID: 1893349.
78. ! Grossie VB, Jr, Ota DM, **Ajani** JA, Nishioka K. Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. *Invest New Drugs* 9(4):321-6, 11/1991. PMID: 1804805.

79. ! Linke K, Pazdur R, Abbruzzese JL, **Ajani** JA, Winn R, Bradof JE, Daugherty K, Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. *Invest New Drugs* 9(4):353-6, 11/1991. PMID: 1804812.
80. ! **Ajani** JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. *Invest New Drugs* 9(4):369-71, 11/1991. PMID: 1804816.
81. ! Pazdur R, **Ajani** JA, Winn R, Bearden J, Belt RJ, Pilat S, Hallinan R, Levin B. A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma. *Cancer* 69(4):878-82, 2/1992. PMID: 1735078.
82. ! Hubbard KP, Daugherty K, **Ajani** JA, Pazdur R, Levin B, Abbruzzese JL. Phase II trial of fazarabine in advanced colorectal carcinoma. *Invest New Drugs* 10(1):39-42, 4/1992. PMID: 1376722.
83. ! Grossie VB, Jr, Nishioka K, **Ajani** JA, Ota DM. Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. *J Surg Oncol* 50(3):161-7, 7/1992. PMID: 1619938.
84. ! Jones DV, Jr, **Ajani** JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. *Invest New Drugs* 10(3):211-3, 8/1992. PMID: 1428730.
85. ! Jones DV, Jr, Samaan NA, Sellin RV, **Ajani** JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. *Am J Med* 93(3):348-9, 9/1992. PMID: 1524091.
86. ! Pazdur R, **Ajani** JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, Graham S, Pilat S, Winn R, Levin B. Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. *Cancer* 70(8):2073-6, 10/1992. PMID: 1394037.
87. ! **Ajani** JA, Dumas P. Evaluation of oral etoposide in patients with metastatic gastric carcinoma: a preliminary report. *Semin Oncol* 19(6 Suppl 14):45-7, 12/1992. PMID: 1488653.
88. ! Hubbard KP, Pazdur R, **Ajani** JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. *Am J Clin Oncol* 15(6):524-7, 12/1992. PMID: 1449117.
89. ! Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WKA, Moser RP, **Ajani** JA. Differentiation of residual or recurrent tumors from post-treatment changes with PET using 18F-FDG. *Radiographics* 12:269-275, 1992.
90. ! **Ajani** JA, Ryan B, Rich TA, McMurtrey M, Roth JA, DeCaro L, Levin B, Mountain C. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. *Eur J Cancer* 28A(4-5):880-4, 1992. PMID: 1524915.
91. ! Pazdur R, **Ajani** JA, Patt YZ, Gomez J, Bready B, Levin B. Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. *Cancer* 71(4):1214-8, 2/1993. PMID: 8435795.
92. ! **Ajani** JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. *Invest New Drugs* 11(1):67-9, 2/1993. PMID: 8349439.
93. ! Rich TA, **Ajani** JA, Morrison WH, Ota D, Levin B. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. *Radiother Oncol* 27(3):209-15, 6/1993. PMID: 8210457.
94. ! Shumate CR, Rich TA, Skibber JM, **Ajani** JA, Ota DM. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. *Cancer* 71(11):3690-6, 6/1993. PMID: 8490919.
95. ! Jones DV, Jr, Patt YZ, **Ajani** JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. *Cancer* 72(9):2560-3, 11/1993. PMID: 8402476.
96. ! Rouben LD, DuBrow R, David C, Lynch P, Fornage B, **Ajani** J, Roth J, Levin B. Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction. *Endoscopy* 25(9):587-91, 11/1993. PMID: 8119209.



97. ! **Ajani** JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, Sugarbaker DJ, Dumas P, Gray C, Vena DA, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. *J Natl Cancer Inst* 85(22):1839-44, 11/1993. PMID: 8230264.
98. ! Evans DB, Skibber JM, Lee JE, Cleary KR, **Ajani** JA, Gagel RF, Sellin RV, Fenoglio CJ, ! Merrell RC, Hickey RC. Nonfunctioning islet cell carcinoma of the pancreas. *Surgery* ! 114(6):1175-81; discussion 1181-2, 12/1993. PMID: 7903005. !
99. ! Jones DV, Jr, **Ajani** JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of ! merbarone in patients with adenocarcinoma of the pancreas. *Cancer Invest* 11(6):667-9, ! 1993. PMID: 8221199. !
100. ! **Ajani** JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M. Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction. *J Clin Oncol* 11(1):22-8, 1993. PMID: 8418237.
101. ! **Ajani** JA, Chesnut JR. Response to increasing doses of octreotide in a patient with carcinoid syndrome. *Eur J Cancer* 29A(16):2332-3, 1993. PMID: 7509166.
102. ! **Ajani** JA, Dodd LG, Daugherty K, Warkentin D, Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. *J Natl Cancer Inst* 86(1):51-3, 1/1994. PMID: 7903699.
103. ! Meterissian S, Skibber J, Rich T, Rouben L, **Ajani** J, Cleary K, Ota DM. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. *Ann Surg Oncol* 1(2):111-6, 3/1994. PMID: 7834435.
104. ! Moore DF, Jr, Pazdur R, Abbruzzese JL, **Ajani** JA, Dubovsky DW, Wade JL, 3rd, Belt RJ, Mangold C, Bready B, Winn RJ. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. *Ann Oncol* 5(3):286-7, 3/1994. PMID: 8186177.
105. ! Pazdur R, Lassere Y, Soh LT, **Ajani** JA, Bready B, Soo E, Sugarman S, Patt Y, Abbruzzese JL, Levin B. Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. *Ann Oncol* 5(5):468-70, 5/1994. PMID: 7915537.
106. ! **Ajani** JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. *J Natl Cancer Inst* 86(14):1086-91, 7/1994. PMID: 7912736.
107. ! Philip PA, **Ajani** JA. Has combined modality therapy improved the outlook in carcinoma of the esophagus? *Oncology (Williston Park)* 8(9):37-42; discussion 44-5, 50-2, 61, 9/1994. PMID: 7527642.
108. ! Pazdur R, Lassere Y, Rhodes V, **Ajani** JA, Sugarman SM, Patt YZ, Jones DV, Jr, Markowitz AB, Abbruzzese JL, Bready B, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. *J Clin Oncol* 12(11):2296-300, 11/1994. PMID: 7964943.
109. ! Rich TA, Evans DB, Curley SA, **Ajani** JA. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. *Ann Oncol* 5 Suppl 3:75-80, 1994. PMID: 8204533.
110. ! Rich TA, **Ajani** JA. High dose external beam radiation therapy with or without concomitant chemotherapy for esophageal carcinoma. *Ann Oncol* 5 Suppl 3:9-15, 1994. PMID: 8204536.
111. ! **Ajani** JA, Winn R, Baez L, Pollock T, Maher T, Hallinan-Fueger B, Newman J. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. *Cancer Invest* 12(5):488-90, 1994. PMID: 7922705.
112. ! Kim YH, **Ajani** JA, Ota DM, Lynch P, Roth JA. Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. *Cancer* 75(2):451-6, 1/1995. PMID: 7812915.
113. ! **Ajani** JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. *World J Surg* 19(2):216-20, 3/1995. PMID: 7754626.
114. ! Weinstein GD, Rich TA, Shumate CR, Skibber JM, Cleary KR, **Ajani** JA, Ota DM. Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. *Int J Radiat Oncol Biol Phys* 32(1):197-204, 4/1995. PMID: 7721616.

115. ! Rich TA, Skibber JM, **Ajani** JA, Buchholz DJ, Cleary KR, Dubrow RA, Levin B, Lynch PM, Meterissian SH, Roubein LD, et al. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. *Int J Radiat Oncol Biol Phys* 32(4):1025-9, 7/1995. PMID: 7607922.
116. ! Pazdur R, Bready B, **Ajani** JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. *Am J Clin Oncol* 18(5):436-8, 10/1995. PMID: 7572763.
117. ! **Ajani** JA, Roth JA, Putnam JB, Walsh G, Lynch PM, Roubein LD, Ryan MB, Natrajan G, Gould P. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastroesophageal junction. *Eur J Cancer* 31A(5):665-70, 1995. PMID: 7640036.
118. ! Wallace S, **Ajani** JA, Charnsangavej C, DuBrow R, Yang DJ, Chuang VP, Carrasco CH, Dodd GD, Jr. Carcinoid tumors: imaging procedures and interventional radiology. *World J Surg* 20(2):147-56, 2/1996. PMID: 8661810.
119. ! Lowy AM, Mansfield PF, Leach SD, **Ajani** J. Laparoscopic staging for gastric cancer. *Surgery* 119(6):611-4, 6/1996. PMID: 8650600.
120. ! Jeon HM, Lynch PM, Howard L, **Ajani** J, Levin B, Frazier ML. Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. *Hum Mutat* 7(4):327-33, 1996. PMID: 8723682.
121. ! Pazdur R, Meyers C, Diaz-Canton E, Abbruzzese JL, Patt Y, Grove W, **Ajani** J. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. *Am J Clin Oncol* 20(6):573-6, 12/1997. PMID: 9391543.
122. ! Rivera E **Ajani** JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. *Am J Clin Oncol* 21(1):36-8, 2/1998. PMID: 9499254.
123. ! Diamandidou E, **Ajani** JA, Yang DJ, Chuang VP, Brown CA, Carrasco HC, Lawrence DD, Wallace S. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors. *AJR Am J Roentgenol* 170(2):339-44, 2/1998. PMID: 9456942.
124. ! Ilson DH, **Ajani** J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. *J Clin Oncol* 16(5):1826-34, 5/1998. PMID: 9586897.
125. ! **Ajani** JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. *Cancer J Sci Am* 4(4):269-74, 7/1998. PMID: 9689986.
126. ! Rajjman I, Siddique I, **Ajani** J, Lynch P. Palliation of malignant dysphagia and fistulae with coated expandable metal stents: experience with 101 patients. *Gastrointest Endosc* 48(2):172-9, 8/1998. PMID: 9717783.
127. ! Takiuchi H, **Ajani** JA. Uracil-tegafur in gastric carcinoma: a comprehensive review. *J Clin Oncol* 16(8):2877-85, 8/1998. PMID: 9704742.
128. ! Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, **Ajani** J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. *N Engl J Med* 339(27):1979-84, 12/1998. PMID: 9869669.
129. ! **Ajani** JA et al. NCCN Practice guidelines for upper gastrointestinal carcinomas. *Oncology (USA)* 12(11A):179-213, 1998.
130. ! Thomas E, Dumas P, **Ajani** JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. *Invest New Drugs* 16(4):333-5, 1998. PMID: 10426667.
131. ! **Ajani** JA, Pazdur R, Dumas P, Fairweather J. Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. *Invest New Drugs* 16(2):175-7, 1998. PMID: 9848582.
132. ! Rubin J, **Ajani** J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. *J Clin Oncol* 17(2):600-6, 2/1999. PMID: 10080605.
133. ! **Ajani** JA, Mansfield PF, Dumas P. Oral etoposide for patients with metastatic gastric adenocarcinoma. *Cancer J Sci Am* 5(2):112-4, 3/1999. PMID: 10198733.

134. ! Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, **Ajani** JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. *Ann Surg* 229(3):303-8, 3/1999. PMID: 10077040.
135. ! Bold RJ, Ota DM, **Ajani** JA, Mansfield PF. Peritoneal and serum tumor markers predict recurrence and survival of patients with resectable gastric cancer. *Gastric Cancer* 2(1):1-7, 5/1999. PMID: 11957063.
136. ! Janjan NA, Abbruzzese J, Pazdur R, Khoo VS, Cleary K, Dubrow R, **Ajani** J, Rich TA, Goswitz MS, Evetts PA, Allen PK, Lynch PM, Skibber JM. Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. *Radiother Oncol* 51(2):153-60, 5/1999. PMID: 10435807.
137. ! Partyka S, Dumas P, **Ajani** J. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. *Cancer* 85(11):2336-9, 6/1999. PMID: 10357402.
138. ! **Ajani** JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Rajiman I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. *J Clin Oncol* 17(8):2403-11, 8/1999. PMID: 10561303.
139. ! Shimada K, **Ajani** JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. *Cancer* 86(9):1657-68, 11/1999. PMID: 10547537.
140. ! Yao JC, Shimada K, **Ajani** JA. Adjuvant therapy for gastric carcinoma: closing out the century. *Oncology (Williston Park)* 13(11):1485-94; discussion 1497-502 passim, 11/1999. PMID: 10581599.
141. ! York JE, Stringer J, **Ajani** JA, Wildrick DM, Gokaslan ZL. Gastric cancer and metastasis to the brain. *Ann Surg Oncol* 6(8):771-6, 12/1999. PMID: 10622506.
142. ! Thomas E, Dumas P, **Ajani** JA. Oral etoposide for patients with advanced adenocarcinoma of the pancreas. *Invet New Drugs* 16:333-335, 1999.
143. ! Kim YH, **Ajani** JA, Carrasco CH, Dumas P, Richli W, Lawrence D, Chuang V, Wallace S. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. *Cancer Invest* 17(7):474-8, 1999. PMID: 10518191.
144. ! Medgyesy CD, Wolff RA, Putnam JB, Jr, **Ajani** JA. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. *Cancer* 88(2):262-7, 1/2000. PMID: 10640955.
145. ! **Ajani** JA, Kelsen DP, Haller D, Hargraves K, Healey D. A multi-institutional phase II study of BMS-182248-01 (BR96-doxorubicin conjugate) administered every 21 days in patients with advanced gastric adenocarcinoma. *Cancer J* 6(2):78-81, 3/2000. PMID: 11069223.
146. ! **Ajani** JA, Yao JC. Preoperative therapy for local-regional gastric cancer: rationale and review of trials. *Gan To Kagaku Ryoho* 27 Suppl 2:392-4, 5/2000. PMID: 10895184.
147. ! Swisher SG, Deford L, Merriman KW, Walsh GL, Smythe R, Vaporicyan A, **Ajani** JA, Brown T, Komaki R, Roth JA, Putnam JB. Effect of operative volume on morbidity, mortality, and hospital use after esophagectomy for cancer. *J Thorac Cardiovasc Surg* 119(6):1126-32, 6/2000. PMID: 10838528.
148. ! **Ajani** JA. [Strategies for preoperative therapy of locoregional cancers: an opportunity for expanding current concepts]. *Chirurg* 71(12):1431-2, 12/2000. PMID: 11195060.
149. ! Komaki R, Janjan NA, **Ajani** JA, Lynch PM, Fairweather JS, Rajiman I, Blumenshein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. *Oncology (Williston Park)* 14(12 Suppl 14):34-7, 12/2000. PMID: 11200147.
150. ! **Ajani** JA. The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction. *Oncology (Williston Park)* 14(12 Suppl 14):17-8, 12/2000. PMID: 11200142.
151. ! Schnirer, II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, Roth JA, **Ajani** JA. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. *Am J Clin Oncol* 24(1):91-5, 2/2001. PMID: 11232959.
152. ! Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, **Ajani** JA, Mansfield PF. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. *Ann Surg Oncol* 8(6):519-24, 7/2001. PMID: 11456051.

153. ! **Ajani** JA, Komaki R, Putnam JB, Walsh G, Nesbitt J, Pisters PW, Lynch PM, Vaporciyan A, Smythe R, Lahoti S, Rajiman I, Swisher S, Martin FD, Roth JA. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. *Cancer* 92(2):279-86, 7/2001. PMID: 11466680.
154. ! Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, **Ajani** JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med* 345(10):725-30, 9/2001. PMID: 11547741.
155. ! Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, Gagel RF, **Ajani** JA, Wolff RA, Evans DB. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. *Surgery* 130(6):1078-85, 12/2001. PMID: 11742342.
156. ! Willett C, **Ajani** J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. *Int J Radiat Oncol Biol Phys* 51(3 Suppl 2):19-27, 2001. PMID: 11641011.
157. ! Pro B, Lozano R, **Ajani** JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. *Invest New Drugs* 19(4):341-3, 2001. PMID: 11561696.
158. ! **Ajani** JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. *Cancer* 94(3):641-6, 2/2002. PMID: 11857295.
159. ! **Ajani** JA. [Is neoadjuvant therapy for locally advanced stomach carcinoma standard?]. *Chirurg* 73(4):312-5, 4/2002. PMID: 12063914.
160. ! **Ajani** JA, Baker J, Pisters PW, Ho L, Mansfield PF, Feig BW, Charnsangavej C. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. *Oncology (Williston Park)* 16(5 Suppl 5):16-8, 5/2002. PMID: 12109800.
161. ! Kasakura Y, **Ajani** JA, Fujii M, Mochizuki F, Takayama T. Management of perforated gastric carcinoma: a report of 16 cases and review of world literature. *Am Surg* 68(5):434-40, 5/2002. PMID: 12013286.
162. ! Hasham-Jiwa N, Kasakura Y, **Ajani** JA. Brief review of advances in the treatment of gastric carcinoma in North America and Europe, 1995-2001. *Int J Clin Oncol* 7(4):219-24, 8/2002. PMID: 12202975.
163. ! Kasakura Y, **Ajani** JA, Mochizuki F, Morishita Y, Fujii M, Takayama T. Outcomes after emergency surgery for gastric perforation or severe bleeding in patients with gastric cancer. *J Surg Oncol* 80(4):181-5, 8/2002. PMID: 12210031.
164. ! Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Jr, **Ajani** JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Treatment outcomes of resected esophageal cancer. *Ann Surg* 236(3):376-84; discussion 384-5, 9/2002. PMID: 12192324.
165. ! Gunderson LL, Sargent DJ, Tepper JE, O'Connell MJ, Allmer C, Smalley SR, Martenson JA, Haller DG, Mayer RJ, Rich TA, **Ajani** JA, Macdonald JS, Goldberg RM. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. *Int J Radiat Oncol Biol Phys* 54(2):386-96, 10/2002. PMID: 12243812.
166. ! Windham TC, Termuhlen PM, **Ajani** JA, Mansfield PF. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. *J Surg Oncol* 81(3):118-24; discussion 124-5, 11/2002. PMID: 12407722.
167. ! Yao JC, Schnirer, II, Reddy S, Chiang S, Najam A, Yu C, Giacco G, Hess K, Rashid A, Xie K, Lynch P, **Ajani** JA. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. *Gastric Cancer* 5(4):208-12, 2002. PMID: 12491078.
168. ! Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, **Ajani** JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. *J Thorac Cardiovasc Surg* 123(1):175-83, 2002. PMID: 11782772.

169. ! Yao JC **Ajani** JA. Therapy of localized gastric cancer: preoperative and postoperative approaches. *Ann Oncol* 13 Suppl 4:7-12, 2002. PMID: 12401660.
170. ! Hung A, Crane C, Delclos M, Ballo M, **Ajani** J, Lin E, Feig B, Skibber J, Janjan N. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. *Cancer* 97(5):1195-202, 3/2003. PMID: 12599225.
171. ! Lisenko Y, Kumar AJ, Yao J, **Ajani** J, Ho L. Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. *Am J Clin Oncol* 26(2):165-70, 4/2003. PMID: 12714889.
172. ! Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, **Ajani** JA. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. *Cancer J* 9(4):261-7, 7/2003. PMID: 12967136.
173. ! Xiong HQ, Gunderson LL, Yao J, **Ajani** JA. Chemoradiation for resectable gastric cancer. *Lancet Oncol* 4(8):498-505, 8/2003. PMID: 12901965.
174. ! Swisher SG, **Ajani** JA, Komaki R, Nesbitt JC, Correa AM, Cox JD, Lahoti S, Martin F, Putnam JB, Smythe WR, Vaporciyan AA, Walsh GL, Roth JA. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. *Int J Radiat Oncol Biol Phys* 57(1):120-7, 9/2003. PMID: 12909224.
175. ! Higuchi K, Phan A, **Ajani** JA. Gastric cancer: advances in adjuvant and adjunct therapy. *Curr Treat Options Oncol* 4(5):413-9, 10/2003. PMID: 12941201.
176. ! Lee HK, Vaporciyan AA, Cox JD, Tucker SL, Putnam JB, Jr, **Ajani** JA, Liao Z, Swisher SG, Roth JA, Smythe WR, Walsh GL, Mohan R, Liu HH, Mooring D, Komaki R. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. *Int J Radiat Oncol Biol Phys* 57(5):1317-22, 12/2003. PMID: 14630268.
177. ! Wang L, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, **Ajani** J, Xie K. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. *Clin Cancer Res* 9(17):6371-80, 12/2003. PMID: 14695137.
178. ! Schnirer, II, Yao JC, **Ajani** JA. Carcinoid--a comprehensive review. *Acta Oncol* 42(7):672-92, 2003. PMID: 14690153.
179. ! Roth AD, **Ajani** J. Docetaxel-based chemotherapy in the treatment of gastric cancer. *Ann Oncol* 14 Suppl 2:ii41-4, 2003. PMID: 12810457.
180. ! Wang L, Gong W, Wei D, Peng Z, Wu T-T, **Ajani** JA, Xie K. Expression of Transcription Factor Sp1 Predicts the Microvessel Density of Human Gastric Cancer: Contribution of Increased VEGF Expression. *Clinical Cancer Res*, 2003.
181. ! Zheng L, Wang L, **Ajani** JA, K Xie. Molecular Basis of Gastric Cancer Development and progression. *Gastric Cancer*, 2003.
182. ! Hoff PM, Saad ED, **Ajani** JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. *Clin Cancer Res* 9(1):134-42, 2003. PMID: 12538461.
183. ! Gunderson LL, Sargent DJ, Tepper JE, Wolmark N, O'Connell MJ, Begovic M, Allmer C, Colangelo L, Smalley SR, Haller DG, Martenson JA, Mayer RJ, Rich TA, **Ajani** JA, MacDonald JS, Willett CG, Goldberg RM. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. *J Clin Oncol* 22(10):1785-96, 5/2004. PMID: 15067027.
184. ! **Ajani** JA, Walsh G, Komaki R, Morris J, Swisher SG, Putnam JB, Jr, Lynch PM, Wu TT, Smythe R, Vaporciyan A, Faust J, Cohen DS, Nivers R, Roth JA. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. *Cancer* 100(11):2347-54, 6/2004. PMID: 15160337.
185. ! **Ajani** JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, Feig B, Myerson R, Nivers R, Cohen DS, Gunderson LL. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. *J Clin Oncol* 22(14):2774-80, 7/2004. PMID: 15254045.
186. ! Benson AB, 3rd, **Ajani** JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, Jr, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for

- the treatment of cancer treatment-induced diarrhea. *J Clin Oncol* 22(14):2918-26, 7/2004. PMID: 15254061.
187. ! Dabaja BS, Suki D, Pro B, Bonnen M, **Ajani** J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. *Cancer* 101(3):518-26, 8/2004. PMID: 15274064.
  188. ! Whiting J, Sano T, Sasako M, **Ajani** JA. Report of the Seventeenth International Symposium of the Foundation for Promotion of Cancer Research: Recent Advances in Gastric Cancer. *Jpn J Clin Oncol* 34(8):481-8, 8/2004. PMID: 15371468.
  189. ! Harting MT, Blakely ML, Herzog CE, Lally KP, **Ajani** JA, Andrassy RJ. Treatment issues in pediatric gastric adenocarcinoma. *J Pediatr Surg* 39(8):e8-10, 8/2004. PMID: 15300556.
  190. ! Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, **Ajani** JA, Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB, Jr, Rice DC, Smythe WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. *Cancer* 101(8):1776-85, 10/2004. PMID: 15386332.
  191. ! Swisher SG, Maish M, Erasmus JJ, Correa AM, **Ajani** JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. *Ann Thorac Surg* 78(4):1152-60; discussion 1152-60, 10/2004. PMID: 15464463.
  192. ! Liao Z, Zhang Z, Jin J, **Ajani** JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Jr, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. *Int J Radiat Oncol Biol Phys* 60(5):1484-93, 12/2004. PMID: 15590179.
  193. ! Kouvaraki MA, **Ajani** JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. *J Clin Oncol* 22(23):4762-71, 12/2004. PMID: 15570077.
  194. ! **Ajani** JA. Irinotecan and other agents in the management of multiple tumor types: highlights from the 6th University of Texas M. D. Anderson Cancer Center Investigators' Workshop. *Oncology (Huntingt)*. 18(14 Suppl 14):7-9, 12/2004.
  195. ! Higuchi K, Koizumi W, Tanabe S, Saigenji K, **Ajani** JA. Chemotherapy is more active against proximal than distal gastric carcinoma. *Oncology* 66(4):269-74, 2004. PMID: 15218293.
  196. ! Yang Q, Cleary KR, Yao JC, Swisher SG, Roth JA, Lynch PM, Komaki R, **Ajani** JA, Rashid A, Hamilton SR, Wu TT. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. *Dis Esophagus* 17(1):38-43, 2004. PMID: 15209739.
  197. ! An C, Choi IS, Yao JC, Worah S, Xie K, Mansfield PF, **Ajani** JA, Rashid A, Hamilton SR, Wu TT. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. *Clin Cancer Res* 11(2 Pt 1):656-63, 1/2005. PMID: 15701853.
  198. ! Gong W, Wang L, Yao JC, **Ajani** JA, Wei D, Aldape KD, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. *Clin Cancer Res* 11(4):1386-93, 2/2005. PMID: 15746037.
  199. ! Varadhachary G, **Ajani** JA. Gastric cancer. *Clin Adv Hematol Oncol* 3(2):118-24, 2/2005. PMID: 16166979.
  200. ! **Ajani** JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. *J Clin Oncol* 23(6):1237-44, 2/2005. PMID: 15718321.
  201. ! Rice DC, Correa AM, Vaporciyan AA, Sodhi N, Smythe WR, Swisher SG, Walsh GL, Putnam JB, Jr, Komaki R, **Ajani** JA, Roth JA. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. *Ann Thorac Surg* 79(2):391-7; discussion 391-7, 2/2005. PMID: 15680801.
  202. ! Zhang Z, Liao Z, Jin J, **Ajani** J, Chang JY, Jeter M, Guerrero T, Stevens CW, Swisher S, Ho L, Yao J, Allen P, Cox JD, Komaki R. Dose-response relationship in locoregional control for

- patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. *Int J Radiat Oncol Biol Phys* 61(3):656-64, 3/2005. PMID: 15708243.
203. ! Chirieac LR, Swisher SG, Correa AM, **Ajani** JA, Komaki RR, Rashid A, Hamilton SR, Wu TT. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. *Clin Cancer Res* 11(6):2229-36, 3/2005. PMID: 15788671.
204. ! Hoque A, Lippman SM, Wu TT, Xu Y, Liang ZD, Swisher S, Zhang H, Cao L, **Ajani** JA, Xu XC. Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. *Carcinogenesis* 26(4):785-91, 4/2005. PMID: 15661803.
205. ! Xu XC, Lee JJ, Wu TT, Hoque A, **Ajani** JA, Lippman SM. Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 14(4):826-9, 4/2005. PMID: 15824151.
206. ! Chirieac LR, Swisher SG, **Ajani** JA, Komaki RR, Correa AM, Morris JS, Roth JA, Rashid A, Hamilton SR, Wu TT. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. *Cancer* 103(7):1347-55, 4/2005. PMID: 15719440.
207. ! Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer, II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, **Ajani** JA. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. *J Clin Oncol* 23(13):3094-103, 5/2005. PMID: 15860869.
208. ! Swisher SG, Hofstetter W, Wu TT, Correa AM, **Ajani** JA, Komaki RR, Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Roth JA. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). *Ann Surg* 241(5):810-7; discussion 817-20, 5/2005. PMID: 15849517.
209. ! **Ajani** JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *J Clin Oncol* 23(24):5660-7, 8/2005. PMID: 16110025.
210. ! Varadhachary G, **Ajani** JA. Preoperative and adjuvant therapies for upper gastrointestinal cancers. *Expert Rev Anticancer Ther* 5(4):719-25, 8/2005. PMID: 16111471.
211. ! Liu L, Hofstetter WL, Rashid A, Swisher SG, Correa AM, **Ajani** JA, Hamilton SR, Wu TT. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma. *Am J Surg Pathol* 29(8):1079-85, 8/2005. PMID: 16006804.
212. ! **Ajani** JA, Takimoto C, Becerra CR, Silva A, Baez L, Cohn A, Major P, Kamida M, Feit K, De Jager R. A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer. *Invest New Drugs* 23(5):479-84, 10/2005. PMID: 16133799.
213. ! Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh G, Vaporciyan A, Lynch PM, Rice DC, Roth JA, **Ajani** JA. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. *Cancer* 104(7):1349-55, 10/2005. PMID: 16130133.
214. ! Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, **Ajani** JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. *Cancer* 104(8):1590-602, 10/2005. PMID: 16134179.
215. ! **Ajani** JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. *J Clin Oncol* 23(28):6957-65, 10/2005. PMID: 16145066.
216. ! Hong D, Lunagomez S, Kim EE, Lee JH, Bresalier RS, Swisher SG, Wu TT, Morris J, Liao Z, Komaki R, **Ajani** JA. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. *Cancer* 104(8):1620-6, 10/2005. PMID: 16118804.

217. ! Rohatgi P, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Roth JA, **Ajani** JA. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. *Cancer* 104(11):2365-72, 12/2005. PMID: 16245310.
218. ! Das P, **Ajani** JA. Gastric and gastro-oesophageal cancer therapy. *Expert Opin Pharmacother* 6(16):2805-12, 12/2005. PMID: 16318431.
219. ! Izzo JG, Malhotra U, Wu TT, Ensor J, Babenko IM, Swisher SG, Correa A, Bresalier RS, Hittelman WN, **Ajani** JA. Impact of cyclin D1 A870G polymorphism in esophageal adenocarcinoma tumorigenesis. *Semin Oncol* 32(6 Suppl 9):S11-5, 12/2005. PMID: 16399423.
220. ! Song S, Lippman SM, Zou Y, Ye X, **Ajani** JA, Xu XC. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. *Oncogene* 24(56):8268-76, 12/2005. PMID: 16170369.
221. ! Wu X, Lu C, Chiang SS, **Ajani** JA. Pharmacogenetics in esophageal cancer. *Semin Oncol* 32(6 Suppl 9):S87-9, 12/2005. PMID: 16399440.
222. ! Shao L, Lin J, Huang M, **Ajani** JA, Wu X. Predictors of esophageal cancer risk: assessment of susceptibility to DNA damage using comet assay. *Genes Chromosomes Cancer* 44(4):415-22, 12/2005. PMID: 16114035.
223. ! Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, Vaporciyan AA, Rice DC, Fukami N, Roth JA, **Ajani** JA. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. *Int J Gastrointest Cancer* 36(2):69-76, 2005. PMID: 16648656.
224. ! **Ajani** JA. Evolving chemotherapy for advanced gastric cancer. *Oncologist* 10 Suppl 3:49-58, 2005. PMID: 16368871.
225. ! Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, **Ajani** JA, Huang S, Xie K. Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. *Gastric Cancer* 8(1):18-28, 2005. PMID: 15747170.
226. ! Tetzlaff ED, **Ajani** JA. Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. *Int J Gastrointest Cancer* 36(1):55-8, 2005. PMID: 16227636.
227. ! Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey J, Lee JH, Bresalier R, Rashid A, Swisher SG, **Ajani** JA. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. *J Clin Oncol* 24(2):259-67, 1/2006. PMID: 16344314.
228. ! Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, Swisher SG, Liao Z, Chao KS, Hittelman WN, Aggarwal BB, **Ajani** JA. Association of activated transcription factor nuclear factor kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. *J Clin Oncol* 24(5):748-54, 2/2006. PMID: 16401681.
229. ! Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Rice DC, Bresalier RS, Roth JA, **Ajani** JA. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. *Cancer* 106(3):552-8, 2/2006. PMID: 16353210.
230. ! **Ajani** JA, Lee FC, Singh DA, Haller DG, Lenz HJ, Benson AB, 3rd, Yanagihara R, Phan AT, Yao JC, Strumberg D. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. *J Clin Oncol* 24(4):663-7, 2/2006. PMID: 16446338.
231. ! Wang SL, Liao Z, Vaporciyan AA, Tucker SL, Liu H, Wei X, Swisher S, **Ajani** JA, Cox JD, Komaki R. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. *Int J Radiat Oncol Biol Phys* 64(3):692-9, 3/2006. PMID: 16242257.
232. ! Liao Z, Liu H, Swisher SG, Wang L, Wu TT, Correa AM, Roth JA, Cox JD, Komaki R, **Ajani** JA, Wei Q. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. *Int J Radiat Oncol Biol Phys* 64(3):700-8, 3/2006. PMID: 16242255.



233. ! Gu Y, Swisher SG, **Ajani** JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. *Cancer* 106(5):1017-25, 3/2006. PMID: 16456809.
234. ! **Ajani** JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatins-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. *Invest New Drugs*, 4/2006. PMID: 16628396.
235. ! Das P, Fukami N, **Ajani** JA. Combined modality therapy of localized gastric and esophageal cancers. *J Natl Compr Canc Netw* 4(4):375-82, 4/2006. PMID: 16569390.
236. ! Yasui W, **Ajani** JA, Nishiyama M, Ohtsu A, Tahara E. Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005. *Cancer Sci* 97(4):328-31, 4/2006. PMID: 16630126.
237. ! **Ajani** JA, Randolph Hecht J, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. *Cancer* 106(9):1908-16, 5/2006. PMID: 16568451.
238. ! **Ajani** JA. Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. *Gan To Kagaku Ryoho* 33 Suppl 1:117-20, 6/2006. PMID: 16897985.
239. ! **Ajani** JA, Jiang Y, Faust J, Chang BB, Ho L, Yao JC, Rousey S, Dakhil S, Cherny RC, Craig C, Bleyer A. A multi-center phase II study of sequential paclitaxel and bryostatins-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. *Invest New Drugs* 24:353-7, 7/2006. PMID: 16683077.
240. ! **Ajani** J. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. *Cancer* 107:221-31, 7/2006. PMID: 16770784.
241. ! **Ajani** JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. *Expert Opin Pharmacother* 7(12):1627-31, 8/2006. PMID: 16872265.
242. ! Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, **Ajani** JA. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. *Cancer* 107:676-85, 8/2006. PMID: 16847885.
243. ! Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, **Ajani** JA, Milas L, Gelovani JG, Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-<sup>3</sup>H-fluorothymidine using preclinical tumor models. *Clin Cancer Res* 12(15):4590-7, 8/2006. PMID: 16899606.
244. ! Wang KL, Wu TT, Resetskova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, **Ajani** JA, Rashid A, Hamilton SR, Albarracín CT. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. *Clin Cancer Res* 12(15):4598-604, 8/2006. PMID: 16899607.
245. ! Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, **Ajani** JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. *J Clin Oncol* 24(23):3789-98, 8/2006. PMID: 16785472.
246. ! Falk S, Anthony A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, **Ajani** J. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. *Br J Cancer* 95:450-6, 8/2006. PMID: 16880795.
247. ! **Ajani** JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *J Clin Oncol* 24(24):3953-8, 8/2006. PMID: 16921048.
248. ! **Ajani** JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, Burris HA, 3rd, Lebwohl D, Mullaney B. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. *Invest New Drugs* 24(5):441-6, 9/2006. PMID: 16586011.

249. ! Wang SL, Liao Z, Liu H, **Ajani** J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. *World J Gastroenterol* 12:5501-8, 9/2006. PMID: 17006988.
250. ! Malaisrie SC, Hofstetter WL, Correa AM, **Ajani** JA, Komaki RR, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Wu TT, Swisher SG. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. *Cancer* 107(5):967-74, 9/2006. PMID: 16874819.
251. ! Wang KL, Yang Q, Cleary KR, Swisher SG, Correa AM, Komaki R, **Ajani** JA, Rashid A, Hamilton SR, Wu TT. The significance of neuroendocrine differentiation in adenocarcinoma of the esophagus and esophagogastric junction after preoperative chemoradiation. *Cancer*, 9/2006. PMID: 16955509.
252. ! Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, **Ajani** JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. *Cancer* 107:1475-82, 10/2006. PMID: 16944539.
253. ! Sims-Mourtada J, Izzo JG, Apisarnthanarax S, Wu TT, Malhotra U, Luthra R, Liao Z, Komaki R, van der Kogel A, **Ajani** J, Chao KS. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. *Clin Cancer Res* 12:6565-72, 11/2006. PMID: 17085672.
254. ! Kanai M, Wei D, Li Q, Jia Z, **Ajani** J, Le X, Yao J, Xie K. Loss of Kruppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progression. *Clin Cancer Res* 12:6395-402, 11/2006. PMID: 17085651.
255. ! Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, **Ajani** JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol* 24:4991-7, 11/2006. PMID: 17075117.
256. ! Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, **Ajani** JA. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. *Mol Cancer Ther* 5:2844-50, 11/2006. PMID: 17121931.
257. ! Luthra R, Luthra MG, Izzo J, Wu TT, Lopez-Alvarez E, Malhotra U, Choi IS, Zhang L, **Ajani** JA. Biomarkers of response to preoperative chemoradiation in esophageal cancers. *Semin Oncol* 33 Suppl 11:2-5, 12/2006. PMID: 17178277.
258. ! Shao L, Hittelman WN, Lin J, Yang H, **Ajani** JA, Wu X. Deficiency of cell cycle checkpoints and DNA repair system predispose individuals to esophageal cancer. *Mutat Res* 602:143-50, 12/2006. PMID: 17011594.
259. ! **Ajani** JA. Introduction. *Semin Oncol* 33 Suppl 11:1, 12/2006. PMID: 17178276.
260. ! Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, **Ajani** JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. *Cancer* 107:2576-80, 12/2006. PMID: 17075877.
261. ! Malaisrie SC, Hofstetter WL, Correa AM, **Ajani** JA, Komaki RR, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh GL, Lahoti S, Lee JH, Bresalier R, Roth JA, Swisher SG. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. *J Thorac Cardiovasc Surg* 131(1):65-72, 2006. PMID: 16399296.
262. ! Rohatgi PR, Correa AM, Swisher SG, Wu TT, Liao Z, Komaki R, Walsh GL, Vaporciyan AA, Lee JH, Rice DC, Roth JA, **Ajani** JA. Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome. *Dis Esophagus* 19(3):152-7, 2006. PMID: 16722991.
263. ! Tetzlaff ED, Faust J, **Ajani** JA. Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatin. *Gastric Cancer* 9(2):140-3, 2006. PMID: 16767371.
264. ! Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, **Ajani** JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. *Clin Cancer Res* 13:234-40, 1/2007. PMID: 17200360.

265. ! Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi O, **Ajani** JA, Komaki RR, Fukami N, Erasmus JJ. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. *Cancer* 109:125-34, 1/2007. PMID: 17146785.
266. ! Ross WA, Alkassab F, Lynch PM, Ayers GD, **Ajani** J, Lee JH, Bismar M. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. *Gastrointest Endosc* 65:70-6, 1/2007. PMID: 17185082.
267. ! Wu TT, Chirieac LR, Abraham SC, Krasinskas AM, Wang H, Rashid A, Correa AM, Hofstetter WL, **Ajani** JA, Swisher SG. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. *Am J Surg Pathol* 31:58-64, 1/2007. PMID: 17197919.
268. ! Lenz HJ, Lee FC, Haller DG, Singh D, Benson AB, 3rd, Strumberg D, Yanagihara R, Yao JC, Phan AT, **Ajani** JA. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. *Cancer* 109:33-40, 1/2007. PMID: 17133415.
269. ! Fujitani K, **Ajani** JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. *Ann Surg Oncol*, 1/2007. PMID: 17253104.
270. ! Izzo JG, Wu TT, Wu X, Ensor J, Luthra R, Pan J, Correa A, Swisher SG, Chao CK, Hittelman WN, **Ajani** JA. Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. *J Clin Oncol* 25:698-707, 2/2007. PMID: 17308274.
271. ! Luthra MG, **Ajani** JA, Izzo J, Ensor J, Wu TT, Rashid A, Zhang L, Phan A, Fukami N, Luthra R. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. *Clin Cancer Res* 13:912-9, 2/2007. PMID: 17289885.
272. ! Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, **Ajani** JA, Rashid A, Albarracin CT. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. *Cancer* 109:658-67, 2/2007. PMID: 17211865.
273. ! Fujitani K, **Ajani** JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF. Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. *Ann Surg Oncol*, 3/2007. PMID: 17342569.
274. ! **Ajani** JA. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma: why bother? *J Clin Oncol* 25(7):906-7; author reply 908-9, 3/2007. PMID: 17327615.
275. ! Sims-Mourtada J, Izzo JG, **Ajani** J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. *Oncogene*, 3/2007. PMID: 17353904.
276. ! Tetzlaff ED, Correa AM, Baker J, Ensor J, **Ajani** JA. The impact on survival of thromboembolic phenomena occurring before and during protocol chemotherapy in patients with advanced gastroesophageal adenocarcinoma. *Cancer* 109(10):1989-95, 5/2007. PMID: 17397035.
277. ! Izzo JG, Malhotra U, Wu TT, Luthra R, Correa AM, Swisher SG, Hofstetter W, Chao KS, Hung MC, **Ajani** JA. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. *Cancer Epidemiol Biomarkers Prev* 16(6):1200-5, 6/2007. PMID: 17548685.
278. ! Das P, Crane CH, **Ajani** JA. Current treatment for localized anal carcinoma. *Curr Opin Oncol* 19(4):396-400, 7/2007. PMID: 17545807.
279. ! Das P, Bhatia S, Eng C, **Ajani** JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH. Predictors and patterns of recurrence after

- definitive chemoradiation for anal cancer. *Int J Radiat Oncol Biol Phys* 68(3):794-800, 7/2007. PMID: 17379452.
280. ! **Ajani** JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E, Van Cutsem E. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. *J Clin Oncol* 25(22):3205-9, 8/2007. PMID: 17664467.
281. ! Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, **Ajani** JA, Kocha W, Minsky BD, Roth JA, Willett CG, Willett CG, Willett CG. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. *J Clin Oncol* 25(24):3719-25, 8/2007. PMID: 17704421.
282. ! Hofstetter W, Correa AM, Bekele N, **Ajani** JA, Phan A, Komaki RR, Liao Z, Maru D, Wu TT, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Francis A, Blackmon S, Swisher SG. Proposed modification of nodal status in AJCC esophageal cancer staging system. *Ann Thorac Surg* 84(2):365-73; discussion 374-5, 8/2007. PMID: 17643602.
283. ! **Ajani** JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. *J Clin Oncol* 25(22):3210-6, 8/2007. PMID: 17664468.
284. ! Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, Mansfield PF, **Ajani** JA, Crane CH, Krishnan S. Clinical benefit of palliative radiation therapy in advanced gastric cancer. *Acta Oncol*:1-7, 9/2007. PMID: 17899453.
285. ! Patel PR, Mansfield PF, Crane CH, Wu TT, Lee JH, Lynch PM, Morris J, Pisters PW, Feig B, Sunder PK, Izzo JG, **Ajani** JA. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. *Cancer* 110(5):989-95, 9/2007. PMID: 17636525.
286. ! Abraham SC, Krasinskas AM, Correa AM, Hofstetter WL, **Ajani** JA, Swisher SG, Wu TT. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma. *Am J Surg Pathol* 31(11):1719-25, 11/2007. PMID: 18059229.
287. ! Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, **Ajani** JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. *Cancer* 110(10):2186-90, 11/2007. PMID: 17896785.
288. ! Cen P, **Ajani** JA. Medical treatment for advanced gastroesophageal adenocarcinoma. *Curr Opin Gastroenterol* 23(6):631-5, 11/2007. PMID: 17906439.
289. ! Izzo JG, **Ajani** JA. Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. *J Clin Oncol* 25(31):4865-7, 11/2007. PMID: 17971580.
290. ! **Ajani** JA. Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge! *Ann Surg Oncol* 14(12):3290-2, 12/2007. PMID: 17932722.
291. ! Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW, Pisters PW, **Ajani** JA, Crane CH. Incidence, Natural History, and Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated with Preoperative Chemoradiotherapy. *Int J Radiat Oncol Biol Phys*, 12/2007. PMID: 18164837.
292. ! **Ajani** JA. The area between the curves gets no respect: is it because of the median madness? *J Clin Oncol* 25(34):5531, 12/2007. PMID: 18048834.
293. ! Cen P, Hofstetter WL, Lee JH, Ross WA, Wu TT, Swisher SG, Davila M, Rashid A, Correa AM, **Ajani** JA. Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma. *Cancer* 112(3):503-10, 2/2008. PMID: 18072264.
294. ! Wang S, Liao Z, Wei X, Liu HH, Tucker SL, Hu C, **Ajani** JA, Phan A, Swisher SG, Mohan R, Cox JD, Komaki R. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. *J Thorac Oncol* 3(3):277-82, 3/2008. PMID: 18317071.

295. ! Tetzlaff ED, Cen P, **Ajani** JA. Emerging drugs in the treatment of advanced gastric cancer. *Expert Opin Emerg Drugs* 13(1):135-44, 3/2008. PMID: 18321153.
296. ! Cen P, Hofstetter WL, Correa AM, Wu TT, Lee JH, Ross WA, Davilla M, Swisher SG, Fukami N, Rashid A, Maru D, **Ajani** JA. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. *Cancer* 112(5):1020-7, 3/2008. PMID: 18205187.
297. ! Baker J, **Ajani** JA. Proactive nurse management guidelines for managing intensive chemotherapy regimens in patients with advanced gastric cancer. *Eur J Oncol Nurs*, 3/2008. PMID: 18329956.
298. ! Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, **Ajani** JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. *J Clin Oncol* 26(8):1316-23, 3/2008. PMID: 18323556.
299. ! Scott LC, Yao JC, Benson AB, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, **Ajani** JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. *Cancer Chemother Pharmacol*, 4/2008. PMID: 18398613.
300. ! **Ajani** JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA* 299(16):1914-21, 4/2008. PMID: 18430910.
301. ! **Ajani** JA, Schmoll HJ. Accomplishments in 2007 in the management of advanced gastroesophageal cancer. *Gastrointest Cancer Res.* 2(3 Suppl):S47-50, 5/2008.
302. ! Kim MM, Mansfield PF, Das P, Janjan NA, Badgwell BD, Phan AT, Delclos ME, Maru D, **Ajani** JA, Crane CH, Krishnan S. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. *Int J Radiat Oncol Biol Phys* 71(1):167-72, 5/2008. PMID: 18406886.
303. ! Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, **Ajani** JA. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. *Dis Esophagus*, 5/2008. PMID: 18459989.
304. ! Jiang Y, Kimchi ET, Montero AJ, Staveley-O'Carroll KF, **Ajani** JA. Upper gastrointestinal tumors: current status and future perspectives. *Expert Rev Anticancer Ther* 8(6):975-91, 6/2008. PMID: 18533807.
305. ! Baker J, **Ajani** J, Scott F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. *Eur J Oncol Nurs* 12(3):253-68, 7/2008. PMID: 18501674.
306. ! Javeri H, Arora R, Correa AM, Hofstetter WL, Lee JH, Liao Z, McAleer MF, Maru D, Bhutani MS, Swisher SG, Izzo JG, **Ajani** JA. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. *Cancer*, 7/2008. PMID: 18623381.
307. ! **Ajani** JA. Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer? *Nat Clin Pract Oncol*, 7/2008. PMID: 18628737.
308. ! **Ajani** JA. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. *Cancer*, 7/2008. PMID: 18623382.
309. ! Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, Komaki R, **Ajani** JA, Swisher SG, Hofstetter WL. Retrospective Study of Clinicopathologic Features and Prognosis of High-grade Neuroendocrine Carcinoma of the Esophagus. *Am J Surg Pathol*, 7/2008. PMID: 18670347.
310. ! **Ajani** J. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. *Onkologie* 31(7):360-1, 7/2008. PMID: 18596381.
311. ! **Ajani** JA. Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer? *Nat Clin Pract Gastroenterol Hepatol* 5(8):414-5, 8/2008. PMID: 18560397.
312. ! **Ajani** JA. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. *Br J Cancer* 99(7):1195; author reply 1196. e-Pub 9/2008. PMID: 18766183.

313. ! Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, **Ajani JA**, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. *Cancer* 113(8):2038-45, 10/2008. PMID: 18759326.
314. ! **Ajani JA**, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Ilson DH, Kleinberg LR, McAleer MF, Meropol NJ, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Swisher SG, Washington MK, Willett C, Wood DE, Wright CD, Yang G, Yang G. Esophageal cancer. *J Natl Compr Canc Netw* 6(9):818-49, 10/2008. PMID: 18926093.
315. ! **Ajani JA**. Gastroesophageal cancers: progress and problems. *J Natl Compr Canc Netw* 6(9):813-4, 10/2008. PMID: 18998257.
316. ! **Ajani JA**, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG. Phase II Randomized Trial of Two Nonoperative Regimens of Induction Chemotherapy Followed by Chemoradiation in Patients With Localized Carcinoma of the Esophagus: RTOG 0113. *J Clin Oncol* 26(28):4551-6, 10/2008. e-Pub 6/2008. PMID: 18574157.
317. ! Cen P, Correa AM, Le JH, Maru D, Anandasabapathy S, Liao Z, Hofstetter WL, Swisher SG, Komaki R, Ross WA, Vaporciyan A, **Ajani JA**. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. *Dis Esophagus*. e-Pub 11/2008. PMID: 19021684.
318. ! **Ajani JA**, Izzo JG, Lee JS. Chemotherapy and Radiotherapy Resistance: Complexity, Reality, and Promise. *J Clin Oncol*. e-Pub 12/2008. PMID: 19047300.
319. ! Chen G, Izzo J, Demizu Y, Wang F, Guha S, Wu X, Hung MC, **Ajani J**, Huang P. Different redox states in malignant and non-malignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol. *Antioxid Redox Signal*. e-Pub 1/2009. PMID: 19187006.
320. ! Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, **Ajani JA**, Wu X. Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. *J Clin Oncol*. e-Pub 1/2009. PMID: 19164214.
321. ! **Ajani JA**, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. US Intergroup Anal Carcinoma Trial: Tumor Diameter Predicts for Colostomy. *J Clin Oncol*. e-Pub 1/2009. PMID: 19139424.
322. ! Baker J, **Ajani J**, Scotté F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. *Eur J Oncol Nurs* 13(1):49-59. e-Pub 2/2009. PMID: 19201649.
323. ! Yendamuri S, Swisher SG, Correa AM, Hofstetter W, **Ajani JA**, Francis A, Maru D, Mehran RJ, Rice DC, Roth JA, Walsh GL, Vaporciyan AA. Esophageal tumor length is independently associated with long-term survival. *Cancer* 115(3):508-16, 2/2009. PMID: 19117343.
324. ! Javeri H, Xiao L, Rohren E, Komaki R, Hofstetter W, Lee JH, Maru D, Bhutani MS, Swisher SG, Wang X, **Ajani JA**. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. *Cancer* 115(3):624-30, 2/2009. PMID: 19130466.
325. ! Brücher BL, Swisher SG, Königsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, **Ajani JA**. Response to Preoperative Therapy in Upper Gastrointestinal Cancers. *Ann Surg Oncol*. e-Pub 2/2009. PMID: 19194759.
326. ! **Ajani JA**. Future developments in esophageal cancer research. *Gastroenterol Clin North Am* 38(1):183-8, x, 3/2009. PMID: 19327575.
327. ! Pan J, Lin J, Izzo JG, Liu Y, Xing J, Huang M, **Ajani JA**, Wu X. Genetic susceptibility to esophageal cancer: the role of the nucleotide excision repair pathway. *Carcinogenesis* 30(5):785-92. e-Pub 3/2009. PMID: 19327575.
328. ! Jiang Y, Kimchi E, **Ajani JA**. Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach? *Future Oncol* 5(2):157-61, 3/2009. PMID: 19284374.
329. ! Smith GL, Smith BD, Buchholz TA, Liao Z, Jeter M, Swisher SG, Hofstetter WL, **Ajani JA**, McAleer MF, Komaki R, Cox JD. Patterns of care and locoregional treatment outcomes in

- older esophageal cancer patients: The SEER-Medicare Cohort. *Int J Radiat Oncol Biol Phys* 74(2):482-9, e-Pub 3/2009. PMID: 19289262.
330. ! Maru DM, Luthra R, Correa AM, White-Cross J, Anandasabapathy S, Krishnan S, Guha S, Komaki R, Swisher SG, **Ajani** JA, Hofstetter WL, Rashid A. Frequent loss of heterozygosity of chromosome 1q in esophageal adenocarcinoma: loss of chromosome 1q21.3 is associated with shorter overall survival. *Cancer* 115(7):1576-85, 4/2009. e-Pub 1/2009. PMID: 19156915.
331. ! Xing J, **Ajani** JA, Chen M, Izzo J, Lin J, Chen Z, Gu J, Wu X. Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. *Cancer Prev Res (Phila Pa)* 2(5):459-65, 5/2009. PMID: 19401529.
332. ! Lagaly R, Horak A, Lee JH, Mansfield PF, **Ajani** JA. Patient with advanced gastric cancer responds twice to the same systemic therapy. *Gastrointest Cancer Res.* 3(3):115-7, 5/2009.
333. ! **Ajani** JA. Chemotherapy and radiation resistance: version 2.0. *J Clin Oncol* 27(16):2735-6; author reply 2737-8, 6/2009. PMID: 19398570.
334. ! McCurdy M, McAleer MF, Wei W, Ezhil M, Johnson V, Khan M, Baker J, Luo D, **Ajani** J, Guerrero T. Induction and Concurrent Taxanes Enhance both the Pulmonary Metabolic Radiation Response and the Radiation Pneumonitis Response in Patients with Esophagus Cancer. *Int J Radiat Oncol Biol Phys.* e-Pub 6/2009. PMID: 19525073.
335. ! Guan X, Zhao H, Niu J, Tan D, **Ajani** JA, Wei Q. Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer. *J Exp Clin Cancer Res* 28:94, 6/2009. PMID: 19566948.
336. ! Zhang Z, Chen Y, Chen Y, Jeter M, Hofstetter WL, **Ajani** J, Swisher SG, Chang JY, Allen PK, Cox JD, Komaki R, Liao ZX. Outcomes with Esophageal Cancer Radiation Therapy. *J Thorac Oncol* 4(7):880-8, 7/2009. e-Pub 5/2009. PMID: 19458557.
337. ! Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, **Ajani** JA. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. *Cancer* 115(16):3609-17, 8/2009. PMID: 19526592.
338. ! Javeri H, Xiao L, Rohren E, Lee JH, Liao Z, Hofstetter W, Maru D, Bhutani MS, Swisher SG, Macapinlac H, Wang X, **Ajani** JA. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. *Cancer*, 8/2009. e-Pub 8/2009. PMID: 19685531.
339. ! Al-Batran SE, **Ajani** JA. Accomplishments in 2008 in the management of advanced gastroesophageal cancer. *Gastrointest Cancer Res* 3(5 Supplement 2):S58-61, 9/2009.
340. ! **Ajani** JA. Accomplishments in gastrointestinal oncology in 2008: conclusion. *Gastrointest Cancer Res* 3(5 Supplement 2):S79, 9/2009. PMID: PMC2791378.
341. ! Yang H, Gu J, Wang KK, Zhang W, Xing J, Chen Z, **Ajani** JA, Wu X. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. *Clin Cancer Res* 15(18):5744-52, 9/2009. PMID: PMC2745487.
342. ! Braiteh F, Correa AM, Hofstetter WL, Rice DC, Vaporciyan AA, Walsh GL, Roth JA, Mehran RJ, Swisher SG, **Ajani** JA. Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapy. *Cancer* 115(19):4450-8, 10/2009. PMID: 19562780.
343. ! Bolton WD, Hofstetter WL, Francis AM, Correa AM, **Ajani** JA, Bhutani MS, Erasmus J, Komaki R, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. *J Thorac Cardiovasc Surg* 138(4):831-6, 10/2009. PMID: 19660349.
344. ! Goodarzi M, Correa AM, **Ajani** JA, Swisher SG, Hofstetter WL, Guha S, Deavers MT, Rashid A, Maru DM. Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. *Mod Pathol* 22(12):1612-21, 12/2009. PMID: 19734842.
345. ! Cox JD, Giralt SA, Veazie ML, **Ajani** JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience. *Oncology* 77(2):75-81, 2009. PMID: 19571599.

346. ! Guan X, Zhao H, Niu J, Tang D, **Ajani** JA, Wei Q. The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. *BMC Gastroenterol* 9:77, 2009. PMID: PMC2771032.
347. ! Izzo JG, Wu X, Wu TT, Huang P, Lee JS, Liao Z, Lee JH, Bhutani MS, Hofstetter W, Maru D, Hung MC, **Ajani** JA. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. *Dis Esophagus* 22(2):127-32, 2009. PMID: 19021681.
348. ! Jiang Y, Mackley H, Cheng H, **Ajani** JA. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? *J Natl Compr Canc Netw* 8(1):135-44, 1/2010. PMID: 20064295.
349. ! Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, **Ajani** J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. *Cancer*. e-Pub 1/2010. PMID: 20108336.
350. ! **Ajani** JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. *J Clin Oncol* 28(9):1547-53, 3/2010. e-Pub 2/2010. PMID: 20159816.
351. ! **Ajani** JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A. Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation. *Dig Dis Sci* 55(4):1098-105, 4/2010. e-Pub 4/2009. PMID: 19399614.
352. ! Das P, Jiang Y, Lee JH, Bhutani MS, Ross WA, Mansfield PF, **Ajani** JA. Multimodality approaches to localized gastric cancer. *J Natl Compr Canc Netw* 8(4):417-25, 4/2010. PMID: 20410334.
353. ! Zachariah B, Gwede CK, James J, **Ajani** J, Chin LJ, Donath D, Rosenthal SA, Kane BL, Rotman M, Berk L, Kachnic LA. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: randomized RTOG trial 0315. *J Natl Cancer Inst* 102(8):547-56, 4/2010. e-Pub 3/2010. PMID: PMC2857801.
354. ! **Ajani** JA, Correa AM, Walsh GL, Komaki R, Lee JH, Vaporciyan AA, Rice DC, Yao JC, Maru DM, Hofstetter WL, Phan AT, Swisher SG. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. *Cancer* 116(7):1656-63, 4/2010. e-Pub 2/2010. PMID: 20143431.
355. ! Shah MA, **Ajani** JA. Gastric cancer--an enigmatic and heterogeneous disease. *JAMA* 303(17):1753-4, 5/2010. PMID: 20442394.
356. ! **Ajani** JA. Resectable Esophageal Cancer: Surgery As Primary Therapy Is Not the Answer, but Then, What Is and Why? *J Clin Oncol* 28(15):e243-4, 5/2010. e-Pub 4/2010. PMID: 20368554.
357. ! Al-Batran SE, **Ajani** JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. *Cancer* 116(11):2511-8, 6/2010. PMID: 20301114.
358. ! Jiang Y, Mackley H, Cheng H, **Ajani** JA. Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. *Biomark Med* 4(4):535-41, 8/2010. PMID: 20701442.
359. ! Gu J, **Ajani** JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, Wang KK, Wu X. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. *Cancer Prev Res (Phila)* 3(9):1176-86, 9/2010. e-Pub 7/2010. PMID: 20651033.
360. ! Swisher SG, Hofstetter W, Komaki R, Correa AM, Erasmus J, Lee JH, Liao Z, Maru D, Mehran R, Patel S, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, **Ajani** JA. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. *Ann Thorac Surg* 90(3):892-8; discussion 898-9, 9/2010. PMID: 20732514.
361. ! Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, Walsh GL, **Ajani** JA, Maru DM, Chang JY, Marom EM, Macapinlac HA, Lee JH, Vaporciyan AA, Rice T, Swisher SG, Hofstetter WL. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. *Ann Thorac Surg* 90(3):884-90; discussion 890-1, 9/2010. PMID: 20732513.



362. ! **Ajani** JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). *Cancer* 116(17):4007-13, 9/2010. PMID: 20564111.
363. ! Patnana SV, Murthy SB, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, **Ajani** JA. Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. *Cancer* 116(19):4487-94, 10/2010. PMID: 20629031.
364. ! Jiang Y, **Ajani** JA. Multidisciplinary management of gastric cancer. *Curr Opin Gastroenterol* 26(6):640-6, 11/2010. PMID: 20827183.
365. ! Ben-Josef E, Moughan J, **Ajani** JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C. Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11. *J Clin Oncol* 28(34):5061-6, 12/2010. e-Pub 10/2010. PMCID: PMC3018356.
366. ! Hayashi Y, Correa AM, Hofstetter WL, Vaporciyan AA, Rice DC, Walsh GL, Mehran RJ, Lee JH, Bhutani MS, Dekovich A, Swisher SG, **Ajani** JA. The influence of high body mass index on the prognosis of patients with esophageal cancer after surgery as primary therapy. *Cancer* 116(24):5619-27, 12/2010. PMID: 21136578.
367. ! Correa MC, Deus HF, Vasconcelos AT, Hayashi Y, **Ajani** JA, Patnana SV, Almeida JS. AGUIA: autonomous graphical user interface assembly for clinical trials semantic data services. *BMC Med Inform Decis Mak* 10:65, 2010. e-Pub 10/2010. PMCID: PMC2987967.
368. ! **Ajani** JA. In the ring with a raging bull: unresectable localized esophageal carcinoma. *Onkologie* 33(5):220-1, 2010. e-Pub 4/2010. PMID: 20502055.
369. ! Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, **Ajani** JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. *PLoS One* 5(11):e15074, 2010. e-Pub 11/2010. PMCID: PMC2994829.
370. ! Murthy SB, Patnana SV, Xiao L, Rohren E, Hofstetter WL, Swisher SG, Liao Z, Lee JH, Bhutani MS, Macapinlac HA, Wang X, **Ajani** JA. The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. *Oncology* 78(5-6):316-22, 2010. e-Pub 8/2010. PMID: 20699623.
371. ! Hu Y, Correa AM, Hoque A, Guan B, Ye F, Huang J, Swisher SG, Wu TT, **Ajani** JA, Xu XC. Prognostic significance of differentially expressed miRNAs in esophageal cancer. *Int J Cancer* 128(1):132-43, 1/2011. e-Pub 3/2010. PMCID: PMC2937084.
372. ! Kountourakis P, Correa AM, Hofstetter WL, Lee JH, Bhutani MS, Rice DC, Komaki R, Maru DM, Ross WA, Vaporciyan A, Swisher SG, **Ajani** JA. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. *Cancer* 117(5):925-30, 3/2011. e-Pub 10/2010. PMCID: PMC3080168.
373. ! Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, Kim SB, Kim H, Hong SW, Park YN, Noh SH, Park ES, Chu IS, Hong WK, **Ajani** JA, Lee JS. Gene expression signature-based prognostic risk score in gastric cancer. *Clin Cancer Res* 17(7):1850-7, 4/2011. e-Pub 3/2011. PMCID: PMC3078023.
374. ! Khokhar NZ, Jiang Y, Benson AB, **Ajani** JA, Mulcahy MF. Refining docetaxel-containing therapy for gastric cancer. *Gastrointest Cancer Res* 4(3):96-105, 5/2011. PMCID: PMC3201643.
375. ! Blum M, Suzuki A, **Ajani** JA. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. *Future Oncol* 7(6):715-26, 6/2011. PMID: 21675835.
376. ! Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, **Ajani** JA. Update: modern approaches to the treatment of localized esophageal cancer. *Curr Oncol Rep* 13(3):157-67, 6/2011. PMID: 21365188.
377. ! Estrella JS, Hofstetter WL, Correa AM, Swisher SG, **Ajani** JA, Lee JH, Bhutani MS, Abraham SC, Rashid A, Maru DM. Duplicated Muscularis Mucosae Invasion has Similar Risk of Lymph

- Node Metastasis and Recurrence-free Survival as Intramucosal Esophageal Adenocarcinoma. *Am J Surg Pathol* 35(7):1045-53, 7/2011. e-Pub 5/2011. PMID: 21602659.
378. ! Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D, Holt L, Zelman D, **Ajani** JA, American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays. *J Clin Oncol* 29(24):3328-30, 8/2011. e-Pub 7/2011. PMID: 21788567.
379. ! **Ajani** JA, Barthel JS, Bentrem DJ, D'Amico TA, Das P, Denlinger CS, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. *J Natl Compr Canc Netw* 9(8):830-87, 8/2011. PMID: 21900218.
380. ! Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, **Ajani** JA, Lee JS, Tellez MS, Tan P. Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. *Gastroenterology* 141(2):476-485.e11, 8/2011. e-Pub 4/2011. PMCID: PMC3152688.
381. ! Glasgow RE, Ilson DH, Hayman JA, Gerdes H, Mulcahy MF, **Ajani** JA. Modern approaches to localized cancer of the esophagus. *J Natl Compr Canc Netw* 9(8):902-11, 8/2011. PMID: 21900220.
382. ! **Ajani** JA, Mangu PB, Burstein HJ. Peek before you treat? Is it a fantasy or reality? *J Oncol Pract* 7(5):338-9, 9/2011. PMCID: PMC3170070.
383. ! Suzuki A, Xiao L, Hayashi Y, Macapinlac HA, Welsh J, Lin SH, Lee JH, Bhutani MS, Maru DM, Hofstetter WL, Swisher SG, **Ajani** JA. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. *Cancer* 117(21):4823-33, 11/2011. e-Pub 3/2011. PMCID: PMC3144261.
384. ! Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, **Ajani** J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of Tumor Energy Pathway by 2-deoxy glucose and metformin Is Effective Against a Broad Spectrum of Preclinical Cancer Models. *Mol Cancer Ther* 10(12):2350-62, 12/2011. e-Pub 10/2011. PMCID: PMC3237863.
385. ! Welsh J, Gomez D, Palmer MB, Riley BA, Mayankkumar AV, Komaki R, Dong L, Zhu XR, Likhacheva A, Liao Z, Hofstetter WL, **Ajani** JA, Cox JD. Intensity-Modulated Proton Therapy Further Reduces Normal Tissue Exposure During Definitive Therapy for Locally Advanced Distal Esophageal Tumors: A Dosimetric Study. *Int J Radiat Oncol Biol Phys* 81(5):1336-42, 12/2011. e-Pub 4/2011. PMID: 21470796.
386. ! Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, **Ajani** JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL. Does the Timing of Esophagectomy After Chemoradiation Affect Outcome? *Ann Thorac Surg* 93(1):207-13, 1/2012. e-Pub 10/2011. PMID: 21962263.
387. ! Welsh J, Palmer MB, **Ajani** JA, Liao Z, Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva A, Cox JD, Komaki R. Esophageal Cancer Dose Escalation using a Simultaneous Integrated Boost Technique. *Int J Radiat Oncol Biol Phys* 82(1):468-74, 1/2012. e-Pub 12/2010. PMID: 21123005.
388. ! **Ajani** JA, Swisher SG. Preoperative Chemotherapy for Localized Squamous Cell Carcinoma of the Esophagus? We Should Go Back to the Drawing Board! *Ann Surg Oncol* 19(1):3-4, 1/2012. e-Pub 10/2011. PMID: 21989665.
389. ! Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, **Ajani** J, Swisher SG, Hofstetter WL, Guha S, Bhutani MS. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. *Gastrointest Endosc* 75(2):242-53, 2/2012. e-Pub 11/2011. PMID: 22115605.
390. ! Harvin JA, Lahat G, Correa AM, Lee J, Maru D, **Ajani** J, Marom EM, Welsh J, Bhutani MS, Walsh G, Roth J, Mehran R, Vaporciyan A, Rice D, Swisher S, Hofstetter W. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: Significance of

- microscopically positive circumferential radial margins. *J Thorac Cardiovasc Surg* 143(2):412-20, 2/2012. e-Pub 12/2011. PMID: 22172216.
391. ! Kountourakis P, **Ajani** JA, Davila M, Lee JH, Bhutani MS, Izzo JG. Barrett's Esophagus: A Review of Biology and Therapeutic Approaches. *Gastrointest Cancer Res* 5(2):49-57, 3/2012. PMID: PMC3369601.
392. ! **Ajani** JA, Blum MA, Estrella JS, Das P, Fournier KF. Gastric Cancer: Apples Will Always Be Apples. *J Clin Oncol* 30(9):1017-8; author reply 1019-20, 3/2012. e-Pub 2/2012. PMID: 22331947.
393. ! Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, **Ajani** J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. *Cancer Cell* 21(3):374-87, 3/2012. PMID: PMC3350095.
394. ! Swisher SG, Winter KA, Komaki RU, **Ajani** JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. A Phase II Study of a Paclitaxel-based Chemoradiation Regimen with Selective Surgical Salvage for Resectable Locoregionally Advanced Esophageal Cancer: Initial Reporting of RTOG 0246. *Int J Radiat Oncol Biol Phys* 82(5):1967-72, 4/2012. e-Pub 4/2011. PMID: 21507583.
395. ! Blum MA, **Ajani** JA. Therapy: Localized gastric cancer-a CLASSIC shift in the paradigm? *Nat Rev Gastroenterol Hepatol* 9(4):194-5, 4/2012. e-Pub 3/2012. PMID: 22392288.
396. ! Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, **Ajani** JA. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. *Cancer* 118(10):2632-40, 5/2012. e-Pub 10/2011. PMID: 22565611.
397. ! Amini A, Xiao L, Allen PK, Suzuki A, Hayashi Y, Liao Z, Hofstetter W, Crane C, Komaki R, Bhutani MS, Lee JH, **Ajani** JA, Welsh J. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. *Int J Radiat Oncol Biol Phys* 83(2):e231-9, 6/2012. e-Pub 3/2012. PMID: 22436793.
398. ! Chakravarty T, Crane CH, **Ajani** JA, Mansfield PF, Briere TM, Beddar AS, Mok H, Reed VK, Krishnan S, Delclos ME, Das P. Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma. *Int J Radiat Oncol Biol Phys* 83(2):581-6, 6/2012. e-Pub 12/2011. PMID: 22137021.
399. ! Jiang Y, **Ajani** JA. Anal margin cancer: current situation and ongoing trials. *Curr Opin Oncol* 24(4):448-53, 7/2012. PMID: 22581355.
400. ! Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, **Ajani** JA, Cox JD. Proton beam therapy and concurrent chemotherapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 83(3):e345-51, 7/2012. e-Pub 3/2012. PMID: 22417808.
401. ! Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, **Ajani** JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. *J Clin Oncol* 30(19):2327-33, 7/2012. e-Pub 5/2012. PMID: 22585691.
402. ! Blum MA, **Ajani** JA. Chemoradiation: Gastro-oesophageal cancer-is CROSSing over so hard to do? *Nat Rev Clin Oncol* 9(9):493-4, 8/2012. e-Pub 7/2012. PMID: 22825372.
403. ! Pan JY, **Ajani** JA, Gu J, Gong Y, Quin A, Hung M, Wu X, Izzo JG. Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. *Cancer* 118(17):4346-53, 9/2012. e-Pub 12/2011. PMID: 22213102.
404. ! Swisher S, **Ajani** J, Correa A, Komaki R, Hofstetter W. Minimally invasive versus open oesophagectomy for oesophageal cancer. *Lancet* 380(9845):883; author reply 885-6, 9/2012. PMID: 22959377.
405. ! Taketa T, Correa AM, Suzuki A, Blum MA, Chien P, Lee JH, Welsh J, Lin SH, Maru DM, Erasmus JJ, Bhutani MS, Weston B, Rice DC, Vaporciyan AA, Hofstetter WL, Swisher SG, **Ajani** JA. Outcome of Trimodality-Eligible Esophagogastric Cancer Patients Who Declined Surgery after Preoperative Chemoradiation. *Oncology* 83(5):300-304. e-Pub 9/2012. PMID: 22964903.

406. ! Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, Walsh G, Vaporciyan A, Erasmus J, Chang J, Maru D, Lee JH, Lee J, **Ajani** JA, Swisher SG. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. *Ann Thorac Surg* 94(4):1126-33, 10/2012. e-Pub 8/2012. PMID: 22921233.
407. ! Lutz MP, Zalcborg JR, Ducreux M, **Ajani** JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - Differential treatment strategies for subtypes of early gastroesophageal cancer. *Eur J Cancer* 48(16):2941-53, 11/2012. e-Pub 8/2012. PMID: 22921186.
408. ! Gunderson LL, Winter KA, **Ajani** JA, Pedersen JE, Moughan J, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Long-Term Update of US GI Intergroup RTOG 98-11 Phase III trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin. *J Clin Oncol*. e-Pub 11/2012. PMID: 23150707.
409. ! Thosani N, Lee JH, Hofstetter WL, **Ajani** JA, Guha S, Bhutani MS. Response. *Gastrointest Endosc* 76(5):1073-5, 11/2012. PMID: 23078931.
410. ! Hayashi Y, Xiao L, Suzuki A, Blum MA, Sabloff B, Taketa T, Maru DM, Welsh J, Lin SH, Weston B, Lee JH, Bhutani MS, Hofstetter WL, Swisher SG, **Ajani** JA. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. *Eur J Cancer* 48(18):3396-404, 12/2012. e-Pub 7/2012. PMID: 22853875.
411. ! Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, **Ajani** JA, Cox JD, Komaki R, Liao Z. Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. *Int J Radiat Oncol Biol Phys* 84(5):1078-85, 12/2012. e-Pub 8/2012. PMID: 22867894.
412. ! Hayashi Y, Blum MA, **Ajani** JA. Advanced gastroesophageal carcinoma: an update on the current therapeutic landscape. *Onkologie* 35(4):204-9, 2012. e-Pub 3/2012. PMID: 22488092.
413. ! Suzuki A, Xiao L, Taketa T, Blum MA, Matamoros A, Chien PL, Mansfield PF, Fournier KF, Weston B, Lee JH, Bhutani MS, Estrella JS, Delclos ME, Krishnan S, Das P, **Ajani** JA. Localized Gastric Cancer Treated with Chemoradation without Surgery: UTMD Anderson Cancer Center Experience. *Oncology* 82(6):347-351, 2012. e-Pub 6/2012. PMID: 22677933.
414. ! Suzuki A, Xiao L, Hayashi Y, Blum MA, Welsh JW, Lin SH, Lee JH, Bhutani MS, Weston B, Maru DM, Rice DC, Swisher SG, Hofstetter WL, Erasmus J, **Ajani** JA. Nomograms for Prognostication of Outcome in Patients with Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy. *Oncology* 82(2):108-113, 2012. PMID: 22328056.
415. ! Strong VE, D'Amico TA, Kleinberg L, **Ajani** J. Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. *J Natl Compr Canc Netw* 11(1):60-6, 1/2013. PMID: 23307982.
416. ! Murphy CC, Hofstetter WL, Correa AM, **Ajani** JA, Komaki RU, Swisher SG. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. *Dis Esophagus*. e-Pub 1/2013. PMID: 23350713.
417. ! Song S, **Ajani** JA. The role of microRNAs in cancers of the upper gastrointestinal tract. *Nat Rev Gastroenterol Hepatol* 10(2):109-18, 2/2013. e-Pub 11/2012. PMID: 23165235.
418. ! Blum MA, Takashi T, Suzuki A, **Ajani** JA. Management of localized gastric cancer. *J Surg Oncol* 107(3):265-70, 3/2013. e-Pub 1/2013. PMID: 23303654.
419. ! Wu X, **Ajani** JA, Gu J, Chang DW, Tan W, Hildebrandt MA, Huang M, Wang KK, Hawk E. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. *Cancer Prev Res (Phila)* 6(3):196-205, 3/2013. PMCID: PMC3608471.
420. ! Taketa T, Sudo K, Wadhawa R, Blum MM, **Ajani** JA. Adjuvant therapy in gastric cancer: what is the optimal approach? *Curr Oncol Rep* 15(2):146-51, 4/2013. PMID: 23355076.
421. ! Song S, Maru DM, **Ajani** JA, Chan CH, Honjo S, Lin HK, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L. Loss of TGF- $\beta$  adaptor  $\beta$ 2SP activates notch signaling and SOX9

- expression in esophageal adenocarcinoma. *Cancer Res* 73(7):2159-69, 4/2013. e-Pub 3/2013. PMID: 23536563.
422. ! Cheedella NK, Suzuki A, Xiao L, Hofstetter WL, Maru DM, Taketa T, Sudo K, Blum MA, Lin SH, Welch J, Lee JH, Bhutani MS, Rice DC, Vaporciyan AA, Swisher SG, **Ajani JA**. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. *Ann Oncol* 24(5):1262-6, 5/2013. e-Pub 12/2012. PMCID: PMC3629896.
423. ! **Ajani JA**, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Warren G, Washington MK, Willett C, Wright CD, McMillian NR, Sundar H. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. *J Natl Compr Canc Netw* 11(5):531-46, 5/2013. PMID: 23667204.
424. ! Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, **Ajani JA**, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. *Acta Oncol* 52(5):1002-9, 6/2013. e-Pub 9/2012. PMID: 22950385.
425. ! Wadhwa R, Taketa T, Sudo K, Blum MA, **Ajani JA**. Modern oncological approaches to gastric adenocarcinoma. *Gastroenterol Clin North Am* 42(2):359-69, 6/2013. e-Pub 3/2013. PMID: 23639645.
426. ! Wadhwa R, Taketa T, Sudo K, Blum-Murphy M, **Ajani JA**. Ramucirumab: a novel antiangiogenic agent. *Future Oncol* 9(6):789-95, 6/2013. PMID: 23718298.
427. ! Xu E, Sun W, Gu J, Chow WH, **Ajani JA**, Wu X. Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. *Carcinogenesis*. e-Pub 7/2013. PMID: 23803692.
428. ! **Ajani JA**. Challenges imposed by the complexity of cancer genome. *Lancet Oncol* 14(8):e291-2, 7/2013. PMID: 23816294.
429. ! **Ajani JA**, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. *Eur J Cancer*. e-Pub 7/2013. PMID: 23899532.
430. ! Taketa T, Xiao L, Sudo K, Suzuki A, Wadhwa R, Blum MA, Lee JH, Weston B, Bhutani MS, Skinner H, Komaki R, Maru DM, Rice DC, Swisher SG, Hofstetter WL, **Ajani JA**. Propensity-Based Matching between Esophagogastric Cancer Patients Who Had Surgery and Who Declined Surgery after Preoperative Chemoradiation. *Oncology* 85(2):95-99. e-Pub 7/2013. PMID: 23860252.
431. ! Wu Y, Grabsch H, Ivanova T, Tan IB, Murray J, Ooi CH, Wright AI, West NP, Hutchins GG, Wu J, Lee M, Lee J, Koo JH, Yeoh KG, van Grieken N, Ylstra B, Rha SY, **Ajani JA**, Cheong JH, Noh SH, Lim KH, Boussioutas A, Lee JS, Tan P. Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. *Gut* 62(8):1100-11, 8/2013. e-Pub 6/2012. PMID: 22735568.
432. ! Wang J, Wei C, Tucker SL, Myles B, Palmer M, Hofstetter WL, Swisher SG, **Ajani JA**, Cox JD, Komaki R, Liao Z, Lin SH. Predictors of postoperative complications after trimodality therapy for esophageal cancer. *Int J Radiat Oncol Biol Phys* 86(5):885-91, 8/2013. PMID: 23845841.
433. ! Murphy CC, Correa AM, **Ajani JA**, Komaki RU, Welsh JW, Swisher SG, Hofstetter WL. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. *J Gastrointest Surg* 17(8):1359-69, 8/2013. e-Pub 5/2013. PMID: 23715646.
434. ! **Ajani JA**, Xiao L, Roth JA, Hofstetter WL, Walsh G, Komaki R, Liao Z, Rice DC, Vaporciyan AA, Maru DM, Lee JH, Bhutani MS, Eid A, Yao JC, Phan AP, Halpin A, Suzuki A, Taketa T, Thall PF, Swisher SG. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. *Ann Oncol* 24(11):2844-9, 11/2013. e-Pub 8/2013. PMID: 23975663.

435. ! Gunderson LL, Moughan J, **Ajani** JA, Pedersen JE, Winter KA, Benson AB, Thomas CR, Mayer RJ, Haddock MG, Rich TA, Willett CG. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. *Int J Radiat Oncol Biol Phys* 87(4):638-45, 11/2013. e-Pub 9/2013. PMID: 24035327.
436. ! Blum MA, Taketa T, Sudo K, Wadhwa R, Skinner HD, **Ajani** JA. Chemoradiation for esophageal cancer. *Thorac Surg Clin* 23(4):551-8, 11/2013. PMID: 24199704.
437. ! Ohtsu A, **Ajani** JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. *J Clin Oncol* 31(31):3935-43, 11/2013. e-Pub 9/2013. PMID: 24043745.
438. ! Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, **Ajani** JA. Gastric cancer-molecular and clinical dimensions. *Nat Rev Clin Oncol* 10(11):643-55, 11/2013. e-Pub 9/2013. PMID: 24061039.
439. ! Suzuki A, Xiao L, Taketa T, Sudo K, Wadhwa R, Blum MA, Skinner H, Komaki R, Weston B, Lee JH, Bhutani MS, Rice DC, Maru DM, Erasmus J, Swisher SG, Hofstetter WL, **Ajani** JA. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. *Ann Oncol* 24(11):2854-9, 11/2013. e-Pub 8/2013. PMID: 23994746.
440. ! Sudo K, Taketa T, Correa AM, Campagna MC, Wadhwa R, Blum MA, Komaki R, Lee JH, Bhutani MS, Weston B, Skinner HD, Maru DM, Rice DC, Swisher SG, Hofstetter WL, **Ajani** JA. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. *J Clin Oncol* 31(34):4306-10, 12/2013. e-Pub 10/2013. PMID: PMC3837091.
441. ! Xu Y, Ma H, Yu H, Liu Z, Wang LE, Tan D, Muddasani R, Lu V, **Ajani** JA, Wang Y, Wei Q. The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. *PLoS One* 8(5):e64973, 2013. e-Pub 5/2013. PMID: PMC3665554.
442. ! Amini A, **Ajani** J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W, Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW. Factors Associated with Local-Regional Failure After Definitive Chemoradiation for Locally Advanced Esophageal Cancer. *Ann Surg Oncol* 21(1):306-14, 1/2014. e-Pub 11/2013. PMID: 24197760.
443. ! **Ajani** JA, Wang X, Song S, Suzuki A, Taketa T, Sudo K, Wadhwa R, Hofstetter WL, Komaki R, Maru DM, Lee JH, Bhutani MS, Weston B, Baladandayuthapani V, Yao Y, Honjo S, Scott AW, Skinner HD, Johnson RL, Berry D. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. *Mol Oncol* 8(1):142-9, 2/2014. e-Pub 10/2013. PMID: PMC3946849.
444. ! Wang J, Myles B, Wei C, Chang JY, Hofstetter WL, **Ajani** JA, Swisher SG, Cox JD, Komaki R, Liao Z, Lin SH. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma. *Dis Esophagus* 27(2):168-75, Feb-Mar, 2/2014. e-Pub 4/2013. PMID: PMC3740061.
445. ! Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, **Ajani** J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. *Oncotarget*. e-Pub 3/2014. PMID: 24742823.
446. ! Wadhwa R, Elimova E, Shiozaki H, Sudo K, Blum MA, Estrella JS, Chen Q, Song S, **Ajani** JA. Anti-angiogenic agent ramucirumab: meaningful or marginal? *Expert Rev Anticancer Ther* 14(4):367-79, 4/2014. e-Pub 3/2014. PMID: 24605771.
447. ! Shen R, Liu H, Wen J, Liu Z, Wang LE, Wang Q, Tan D, **Ajani** JA, Wei Q. Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. *Mol Carcinog*. e-Pub 4/2014. PMID: 24756984.
448. ! Sudo K, Elimova E, Skinner HD, Hofstetter WL, **Ajani** JA. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. *J Clin Oncol* 32(19):2112-3, 7/2014. e-Pub 5/2014. PMID: 24868018.

449. ! Cuellar SL, Carter BW, Macapinlac HA, **Ajani** JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL. Clinical Staging of Patients with Early Esophageal Adenocarcinoma: Does FDG-PET/CT Have a Role? *J Thorac Oncol* 9(8):1202-6, 8/2014. PMID: 25157774.
450. ! Song S, **Ajani** JA, Honjo S, Maru DM, Chen Q, Scott AW, Heallen TR, Xiao L, Hofstetter WL, Weston B, Lee JH, Wadhwa R, Sudo K, Stroehlein JR, Martin JF, Hung MC, Johnson RL. Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. *Cancer Res* 74(15):4170-82, 8/2014. e-Pub 6/2014. PMCID: PMC4136429.
451. ! Honjo S, **Ajani** JA, Scott AW, Chen Q, Skinner HD, Stroehlein J, Johnson RL, Song S. Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. *Int J Oncol* 45(2):567-74, 8/2014. e-Pub 5/2014. PMCID: PMC4091970.
452. ! Taketa T, Sudo K, Correa AM, Wadhwa R, Shiozaki H, Elimova E, Campagna MC, Blum MA, Skinner HD, Komaki RU, Lee JH, Bhutani MS, Weston BR, Rice DC, Swisher SG, Maru DM, Hofstetter WL, **Ajani** JA. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. *J Natl Compr Canc Netw* 12(8):1139-44, 8/2014. PMID: 25099446.
453. ! Li Y, Liu Z, Liu H, Wang LE, Onodera H, Suzuki A, Suzuki K, Wadhwa R, Elimova E, Sudo K, Shiozaki H, Estrella J, Lee JS, Song S, Tan D, **Ajani** JA, Wei Q. Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. *Carcinogenesis* 35(9):2031-8, 9/2014. e-Pub 7/2014. PMID: 24990617.
454. ! Patel VR, Hofstetter WL, Correa AM, Agarwal A, Rashid A, Bhutani MS, Lin SH, **Ajani** JA, Swisher SG, Maru DM. Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. *Ann Thorac Surg* 98(3):1064-71, 9/2014. e-Pub 7/2014. PMID: 25038008.
455. ! **Ajani** JA, Swisher SG. Three Angels are Dancing on the Head of the Esophageal Cancer Pin, but Shouldn't We Not Topple One or Two? *Ann Surg Oncol* 21(9):2815-6, 9/2014. e-Pub 4/2014. PMID: 24756809.
456. ! Sun Y, Gu J, **Ajani** JA, Chang DW, Wu X, Stroehlein JR. Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: A case-control study. *Cancer* 120(19):3040-8, 10/2014. e-Pub 6/2014. PMID: 24962126.
457. ! Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani MS, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, **Ajani** JA. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. *J Clin Oncol* 32(30):3400-5, 10/2014. e-Pub 9/2014. PMID: 25225435.
458. ! Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, **Ajani** JA. Medical management of gastric cancer: A 2014 update. *World J Gastroenterol* 20(38):13637-13647, 10/2014. PMCID: PMC4194548.
459. ! Skinner HD, Lee JH, Bhutani MS, Weston B, Hofstetter W, Komaki R, Shiozaki H, Wadhwa R, Sudo K, Elimova E, Song S, Ye Y, Huang M, **Ajani** J, Wu X. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. *Cancer* 120(23):3635-41, 12/2014. e-Pub 8/2014. PMCID: PMC4239178.
460. ! Shiozaki H, Sudo K, Xiao L, Wadhwa R, Elimova E, Hofstetter WL, Skinner HD, Lee JH, Weston B, Bhutani MS, Blum MA, Maru DM, **Ajani** JA. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. *Oncology* 86(5-6):336-9, 2014. e-Pub 6/2014. PMCID: PMC4105702.
461. ! **Ajani** JA. After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how? *J Natl Compr Canc Netw* 13(1):2-3, 1/2015. PMID: 25583763.
462. ! Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Prausová J, Van Laethem JL, Cascinu S, **Ajani** JA. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). *J Gastrointest Cancer*. e-Pub 2/2015. PMID: 25707610.

463. ! **Ajani** JA, D'Amico TA, Almhanna K, Bentrem DJ, Besh S, Chao J, Das P, Denlinger C, Fanta P, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Jaspersen K, Keswani RN, Kleinberg LR, Korn WM, Leong S, Lockhart AC, Mulcahy MF, Orringer MB, Posey JA, Poultsides GA, Sasson AR, Scott WJ, Strong VE, Varghese TK, Washington MK, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Esophageal and esophagogastric junction cancers, version 1.2015. *J Natl Compr Canc Netw* 13(2):194-227, 2/2015. PMID: 25691612.
464. ! Neishaboori N, Wadhwa R, Noguera-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, **Ajani** JA. Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. *Oncology*. e-Pub 3/2015. PMID: 25765719.
465. ! **Ajani** JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. *Semin Oncol* 42 Suppl 1:S3-17, 4/2015. e-Pub 1/2015. PMID: 25839664.
466. ! **Ajani** JA, Song S, Hochster HS, Steinberg IB. Introduction. *Semin Oncol* 42 Suppl 1:S1-2, 4/2015. e-Pub 2/2015. PMID: 25839663.
467. ! Elimova E, Wadhwa R, Shiozaki H, Sudo K, Estrella JS, Badgwell BD, Das P, Matamoros A, Song S, **Ajani** JA. Molecular biomarkers in gastric cancer. *J Natl Compr Canc Netw* 13(4):e19-29, 4/2015. PMID: 26052595.
468. ! Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, Fournier K, Mansfield P, **Ajani** J. Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. *J Am Coll Surg*. e-Pub 4/2015. PMID: 26002780.
469. ! Charalampakis N, Elimova E, Shimodaira Y, Shiozaki H, Wadhwa R, **Ajani** JA. Biologics in combination with chemotherapy for gastric cancer: is this the answer? *Expert Opin Pharmacother* 16(7):955-60, 5/2015. e-Pub 4/2015. PMID: 25850442.
470. ! Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, **Ajani** J. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. *J Surg Oncol* 111(7):875-81, 6/2015. e-Pub 4/2015. PMID: 25872485.
471. ! Badgwell B, **Ajani** J, Blum M, Ho L, Fournier K, Chiang YJ, Matamoros A, Das P, Mansfield P. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. *Ann Surg Oncol*. e-Pub 6/2015. PMID: 26059652.
472. ! Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracín CT, Wu TT, Johnson RL, Hung MC, **Ajani** JA. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemo-resistance in esophageal cancer. *Clin Cancer Res* 21(11):2580-90, 6/2015. e-Pub 3/2015. PMID: PMC4452384.
473. ! Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, **Ajani** JA. Early versus Delayed Therapy of Advanced Gastric Cancer Patients - Does It Make a Difference? *Oncology*. e-Pub 7/2015. PMID: 26159599.
474. ! Elimova E, **Ajani** JA. Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? *J Clin Oncol* 33(21):2410, 7/2015. e-Pub 6/2015. PMID: 26077236.
475. ! Pujara D, Mansfield P, **Ajani** J, Blum M, Elimova E, Chiang YJ, Das P, Badgwell B. Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. *J Surg Oncol*. e-Pub 10/2015. PMID: 26482869.
476. ! Sanchez-Espiridion B, Liang D, **Ajani** JA, Liang S, Ye Y, Hildebrandt MA, Gu J, Wu X. Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. *Clin Gastroenterol Hepatol* 13(10):1730-1737.e9, 10/2015. e-Pub 5/2015. PMID: PMC4596233.
477. ! Elimova E, **Ajani** JA. Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options? *J Clin Oncol* 33(28):3085-91, 10/2015. e-Pub 8/2015. PMID: 26324361.



478. ! Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, **Ajani** JA. 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. *Eur J Cancer* 51(17):2545-52, 11/2015. e-Pub 8/2015. PMID: PMC4663130.
479. ! Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, **Ajani** JA. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. *Oncology* 89(6):305-10, 11/2015. e-Pub 9/2015. PMID: PMC4659715.
480. ! Sharma P, Katzka DA, Gupta N, **Ajani** J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K. Quality Indicators for the Management of Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. *Gastroenterology* 149(6):1599-606, 11/2015. PMID: 26296479.
481. ! Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, Ylstra B, van Grieken N, Rha SY, Chung HC, Lee JS, Cheong JH, Noh SH, Aoyama T, Miyagi Y, Tsuburaya A, Yoshikawa T, **Ajani** JA, Boussioutas A, Yeoh KG, Yong WP, So J, Lee J, Kang WK, Kim S, Kameda Y, Arai T, Zur Hausen A, Speed TP, Grabsch HI, Tan P. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. *Gut* 64(11):1721-31, 11/2015. e-Pub 11/2014. PMID: PMC4680172.
482. ! Shiozaki H, Elimova E, Slack RS, Chen HC, Staerkel GA, Sneige N, Shimodaira Y, Sagebiel T, Lee JH, Bhutani MS, Das P, Mansfield PF, Estrella JS, Badgwell BD, **Ajani** JA. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. *J Surg Oncol* 113(1):29-35, 1/2016. e-Pub 11/2015. PMID: 26603684.
483. ! Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, **Ajani** JA. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. *J Natl Compr Canc Netw* 14(2):173-9, 2/2016. PMID: 26850487.
484. ! Blum Murphy MA, Elimova E, **Ajani** JA. Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. *Expert Rev Gastroenterol Hepatol* 10(3):1-10, 3/2016. e-Pub 12/2015. PMID: 26560689.
485. ! Sepesi B, Schmidt HE, Lada M, Correa AM, Walsh GL, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, **Ajani** JA, Watson TJ, Swisher SG, Low DE, Hofstetter WL. Survival in Patients with Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. *Ann Thorac Surg* 101(3):1075-81, 3/2016. e-Pub 12/2015. PMID: 26680311.
486. ! Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, **Ajani** JA. Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. *Oncology*. e-Pub 4/2016. PMID: 27120436.
487. ! Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P, Mansfield P, **Ajani** J. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. *Ann Surg Oncol* 23(6):1948-55, 6/2016. e-Pub 2/2016. PMID: 26868957.
488. ! Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, **Ajani** JA. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. *J Gastrointest Oncol* 7(4):499-505, 8/2016. PMID: PMC4963369.

489. ! Elimova E, Mizrak Kaya D, Harada K, **Ajani JA**. Potentially Curable Cancers of the Esophagus and Stomach. *Mayo Clin Proc* 91(9):1307-18, 9/2016. PMID: 27594190.
490. ! Fuchs CS, Taberero J, Tomášek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Emig M, Melemed SA, Hozak RR, Ferry D, Caldwell CW, **Ajani JA**. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. *Br J Cancer* 115(8):974-982, 10/2016. e-Pub 9/2016. PMID: 275061911.
491. ! **Ajani JA**, D'Amico TA, Almanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 14(10):1286-1312, 10/2016. PMID: 27697982.
492. ! Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D, Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X, Chen M, Vidhu F, Bartholomeusz GA, Toiyama Y, Kusunoki M, Doki Y, Mori M, Song S, Gunther JR, Krishnan S, Slaby O, Goel A, **Ajani JA**, Radovich M, Calin GA. H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8- $\beta$ -Catenin Signaling in Colorectal Cancer. *EBioMedicine*. e-Pub 10/2016. PMID: 27789274.
493. ! Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, **Ajani JA**. Proteomics approach to identify biomarkers for upper gastrointestinal cancer. *Expert Rev Proteomics*. e-Pub 10/2016. PMID: 27718753.
494. ! Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, **Ajani JA**, Badgwell BD. Survival rates in T1 and T2 gastric cancer: A Western report. *J Surg Oncol* 114(5):602-606, 10/2016. e-Pub 7/2016. PMID: 27439746.
495. ! Elimova E, Song S, Shimodaira Y, Lin Q, **Ajani JA**. Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. *Ann Surg Oncol* 23(12):3786-3791, 11/2016. e-Pub 8/2016. PMID: 27503493.
496. ! Yi J, Lu L, Yanger K, Wang W, Sohn BH, Stanger BZ, Zhang M, Martin JF, **Ajani JA**, Chen J, Lee JS, Song S, Johnson RL. LATS1 and LATS2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. *Hepatology* 64(5):1757-1772, 11/2016. e-Pub 9/2016. PMID: 27531557.
497. ! Lee KW, Lee SS, Hwang JE, Jang HJ, Lee HS, Oh SC, Lee SH, Sohn BH, Kim SB, Shim JJ, Jeong W, Cha M, Cheong JH, Cho JY, Lim JY, Park ES, Kim SC, Kang YK, Noh SH, **Ajani JA**, Lee JS. Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. *Clin Cancer Res* 22(24):6228-6235, 12/2016. e-Pub 9/2016. PMID: 27654712.
498. ! Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, **Ajani JA**. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. *Am J Clin Pathol* 146(6):647-669, 12/2016. e-Pub 11/2016. PMID: 28077399.
499. ! Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, **Ajani JA**. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. *Arch Pathol Lab Med* 140(12):1345-1363, 12/2016. e-Pub 11/2016. PMID: 27841667.
500. ! Mizrak Kaya D, Harada K, **Ajani JA**. Is targeted therapy possible for patients with gastric adenocarcinoma? *Expert Opin Pharmacother* 17(18):1-4, 12/2016. e-Pub 9/2016. PMID: 27652930.
501. ! Ikoma N, Blum M, Chiang YJ, Estrella JS, Roy-Chowdhuri S, Fournier K, Mansfield P, **Ajani JA**, Badgwell BD. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. *Ann Surg Oncol* 23(13):4332-4337, 12/2016. e-Pub 7/2016. PMID: 27384751.

502. ! Shiozaki H, Shimodaira Y, Elimova E, Wadhwa R, Sudo K, Harada K, Estrella JS, Das P, Badgwell B, **Ajani** JA. Evolution of gastric surgery techniques and outcomes. *Chin J Cancer* 35(1):69, 2016. e-Pub 7/2016. PMID: PMC4962398.
503. ! Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, **Ajani** JA. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. *Oncology* 90(1):10-20, 2016. e-Pub 10/2015. PMID: 26492090.
504. ! Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, **Ajani** JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. *Oncology* 90(5):239-47, 2016. e-Pub 4/2016. PMID: PMC4870109.
505. ! Gu J, Liang D, Pierzynski JA, Zheng L, Ye Y, Zhang J, **Ajani** JA, Wu X. D-mannose: a Novel Prognostic Biomarker for Patients with Esophageal Adenocarcinoma. *Carcinogenesis*. e-Pub 1/2017. PMID: 28062409.
506. ! Bartley AN, Washington MK, Ismaila N, **Ajani** JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. *J Oncol Pract* 13(1):53-57, 1/2017. e-Pub 11/2016. PMID: 27907277.
507. ! Swisher SG, Moughan J, Komaki RU, **Ajani** JA, Wu TT, Hofstetter WL, Konski AA, Willett CG. Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. *J Thorac Oncol* 12(2):368-374, 2/2017. e-Pub 10/2016. PMID: PMC5263046.
508. ! Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, **Ajani** JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. *J Clin Oncol* 35(4):446-464, 2/2017. e-Pub 11/2016. PMID: 28129524.
509. ! Elimova E, Janjigian YY, Mulcahy M, Catenacci DV, Blum MA, Almhanna K, Hecht JR, **Ajani** JA. It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. *J Clin Oncol* 35(4):475-477, 2/2017. e-Pub 10/2016. PMID: 28129519.
510. ! Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, **Ajani** JA, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Nguyen QN, Minsky BD, Erasmus JJ, Lee JH, Bhutani M, Komaki RU. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. *J Thorac Oncol* 12(2):375-382, 2/2017. e-Pub 10/2016. PMID: 27794500.
511. ! Mizrak Kaya D, Harada K, Shimodaira Y, Amlashi FG, Lin Q, **Ajani** JA. Advanced gastric adenocarcinoma: optimizing therapy options. *Expert Rev Clin Pharmacol* 10(3):1-9, 3/2017. e-Pub 2/2017. PMID: 28094573.
512. ! Betancourt Cuellar SL, Sabloff B, Carter BW, Benveniste MF, Correa AM, Maru DM, **Ajani** JA, Erasmus JJ, Hofstetter WL. Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved? *Eur J Radiol* 88:56-60, 3/2017. e-Pub 1/2017. PMID: 28189209.
513. ! Harada K, Mizrak Kaya D, Shimodaira Y, **Ajani** JA. Global chemotherapy development for gastric cancer. *Gastric Cancer* 20(Suppl 1):92-101, 3/2017. e-Pub 10/2016. PMID: 27718136.
514. ! Harada K, Mizrak Kaya D, Shimodaira Y, Song S, Baba H, **Ajani** JA. Translating genomic profiling to gastrointestinal cancer treatment. *Future Oncol* 13(10):919-934, 4/2017. e-Pub 1/2017. PMID: PMC5348722.
515. ! Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, **Ajani** JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma

- (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. *Lancet Oncol* 18(5):640-653, 5/2017. e-Pub 3/2017. PMID: 28343975.
516. ! Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerckel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, **Ajani JA**. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. *Oncotarget*. e-Pub 5/2017. PMID: 28611281.
517. ! **Ajani JA**, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. *Nat Rev Dis Primers* 3:17036, 6/2017. e-Pub 6/2017. PMID: 28569272.
518. ! Xi M, Hallemeier CL, Merrell KW, Liao Z, Murphy MAB, Ho L, Hofstetter WL, Mehran R, Lee JH, Bhutani MS, Weston B, Maru DM, Komaki R, **Ajani JA**, Lin SH. Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. *Ann Surg*. e-Pub 6/2017. PMID: 28628563.
519. ! Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, **Ajani JA**. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. *Oncology*. e-Pub 7/2017. PMID: 28683449.
520. ! Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, Lee KW, Kim EH, Yim SY, Lee SH, Cheong JH, Jeong W, Cho JY, Kim J, Chae J, Lee J, Kang WK, Kim S, Noh SH, **Ajani JA**, Lee JS. Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. *Clin Cancer Res*. e-Pub 7/2017. PMID: 28747339.
521. ! Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A, Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, **Ajani JA**. Comorbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. *Ann Surg Oncol* 24(8):2291-2301, 8/2017. e-Pub 10/2016. PMID: 27770339.
522. ! Elimova E, Lin Q, Song S, **Ajani JA**. Current status of ramucirumab in gastroesophageal adenocarcinoma. *Future Oncol* 13(18):1585-1592, 8/2017. e-Pub 4/2017. PMID: 28436242.
523. ! Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, **Ajani JA**. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. *Br J Cancer* 117(5):648-655, 8/2017. e-Pub 7/2017. PMID: PMC5572179.
524. ! Mizrak Kaya D, Dong X, Nogueras-González GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, **Ajani JA**. Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. *Med Oncol* 34(8):135, 8/2017. e-Pub 7/2017. PMID: 28685276.
525. ! Badgwell B, Das P, **Ajani J**. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. *J Hematol Oncol* 10(1):149, 8/2017. e-Pub 8/2017. PMID: PMC5558742.
526. ! **Ajani JA**, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G, DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. *Ann Oncol* 28(9):2142-2148, 9/2017. PMID: 28911091. **Impact Factor 13.930**
527. ! Ikoma N, Chen HC, Wang X, Blum M, Estrella JS, Fournier K, Mansfield P, **Ajani J**, Badgwell BD. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. *Ann Surg Oncol* 24(9):2679-2687, 9/2017. e-Pub 3/2017. PMID: 28332034. **Impact Factor 3.857**
528. ! Bang YJ, Cho JY, Kim YH, Kim JW, Di Bartolomeo M, **Ajani JA**, Yamaguchi K, Balogh A, Sanchez T, Moehler M. Efficacy of Sequential Ipilimumab Monotherapy vs Best Supportive

- Care For Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. *Clin Cancer Res* 23(19):5671-5678, 10/2017. e-Pub 6/2017. PMID: 28655793. **Impact Factor 10.199**
529. ! Taberero J, Ohtsu A, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, **Ajani JA**, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan A, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-Line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. *Mol Cancer Ther* 16(10):2215-2222, 10/2017. e-Pub 7/2017. PMID: 28716815. **Impact Factor 5.365**
530. ! Ikoma N, Blum M, Estrella JS, Wang X, Fournier KF, Mansfield PF, **Ajani JA**, Badgwell BD. Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. *J Gastrointest Surg* 21(10):1563-1570, 10/2017. e-Pub 8/2017. PMID: 28819789. **Impact Factor 2.813**
531. ! Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, **Ajani JA**. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. *Oncotarget* 8(46):81430-81440, 10/2017. e-Pub 7/2017. PMID: PMC5655297. **Impact Factor 2.656**
532. ! Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, **Ajani J**. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. *Ann Surg Oncol* 24(11):3338-3344, 10/2017. e-Pub 8/2017. PMID: 28799004. **Impact Factor 3.857**
533. ! Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerckel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, **Ajani JA**. Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. *Oncotarget* 8(45):79356-79365, 10/2017. e-Pub 5/2017. PMID: PMC5668047. **Impact Factor 2.656**
534. ! Blum Murphy M, Xiao L, Patel VR, Maru DM, Correa AM, G Amlashi F, Liao Z, Komaki R, Lin SH, Skinner HD, Vaporciyan A, Walsh GL, Swisher SG, Sepesi B, Lee JH, Bhutani MS, Weston B, Hofstetter WL, **Ajani JA**. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. *Cancer* 123(21):4106-4113, 11/2017. e-Pub 9/2017. PMID: 28885712. **Impact Factor 6.537**
535. ! In H, Solsky I, Palis B, Langdon-Embry M, **Ajani J**, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. *Ann Surg Oncol* 24(12):3683-3691, 11/2017. e-Pub 9/2017. PMID: 28895113. **Impact Factor 3.857**
536. ! Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A, Fournier K, Mansfield P, **Ajani JA**, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. *J Gastrointest Oncol* 8(6):1009-1017, 12/2017. PMID: PMC5750173. **Impact Factor 2.813**
537. ! Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, **Ajani JA**, Komaki R, Minsky B, Mohan R, Hsu CC, Hobbs BP, Lin SH. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. *Radiother Oncol*. e-Pub 12/2017. PMID: 29248170. **Impact Factor 4.942**
538. ! Harada K, Mizrak Kaya D, Baba H, **Ajani JA**. Recent advances in preoperative management of esophageal adenocarcinoma. *F1000Res* 6:501, 2017. e-Pub 4/2017. PMID: PMC5399958.
539. ! Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, **Ajani JA**, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging

- system for gastric cancer patients after preoperative therapy. *Gastric Cancer* 21(1):74-83, 1/2018. e-Pub 6/2017. PMID: 28643144. **Impact Factor 5.045**
540. ! **Ajani** JA, Estrella JS, Chen Q, Correa AM, Ma L, Scott AW, Jin J, Liu B, Xie M, Sudo K, Shiozaki H, Badgwell B, Weston B, Lee JH, Bhutani MS, Onodera H, Suzuki K, Suzuki A, Ding S, Hofstetter WL, Johnson RL, Bresalier RS, Song S. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. *Br J Cancer* 118(1):52-61, 1/2018. e-Pub 11/2017. PMID: PMC5765229. **Impact Factor 5.922**
541. ! Badgwell B, Blum M, Das P, Estrella J, Wang X, Fournier K, Royal R, Mansfield P, **Ajani** J. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. *Surg Endosc* 32(1):512, 1/2018. e-Pub 6/2017. PMID: 28643069. **Impact Factor 3.117**
542. ! Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, **Ajani** JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? *Expert Rev Anticancer Ther* 18(1):1-20, 1/2018. e-Pub 12/2017. PMID: 29202614. **Impact Factor 2.347**
543. ! Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, **Ajani** JA, Psyrri A. Medical management of gastric cancer: a 2017 update. *Cancer Med* 7(1):123-133, 1/2018. e-Pub 12/2017. PMID: PMC5773977. **Impact Factor 3.202**
544. ! Vali Pasha K, Ratnavathi CV, **Ajani** J, Raju D, Manoj Kumar S, Beedu SR. Proximate, mineral composition and antioxidant activity of traditional small millets cultivated and consumed in Rayalaseema region of south India. *J Sci Food Agric* 98(2):652-660, 1/2018. e-Pub 8/2017. PMID: 28665516. **Impact Factor 2.379**
545. ! In H, Ravetch E, Langdon-Embry M, Palis B, **Ajani** JA, Hofstetter WL, Kelsen DP, Sano T. The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. *Gastric Cancer* 21(1):1-9, 1/2018. e-Pub 9/2017. PMID: 28948368. **Impact Factor 5.045**
546. ! Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, Sudo K, Onodera H, Suzuki K, Suzuki A, Johnson RL, Wang Z, Song S, **Ajani** JA. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. *Gastric Cancer* 21(1):31-40, 1/2018. e-Pub 8/2017. PMID: 28801853. **Impact Factor 5.045**
547. ! Song S, Xie M, Scott AW, Jin J, Ma L, Dong X, Skinner HD, Johnson RL, Ding S, **Ajani** JA. A Novel YAP1 Inhibitor targets CSCs-enriched Radiation Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. *Mol Cancer Ther* 17(2):443-454, 2/2018. e-Pub 11/2017. PMID: PMC5805581. **Impact Factor 5.365**
548. ! Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, **Ajani** JA. Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. *Target Oncol* 13(1):99-106, 2/2018. e-Pub 12/2017. PMID: PMC5826863. **Impact Factor 3.877**
549. ! Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, **Ajani** JA. Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. *Br J Cancer* 118(3):331-337, 2/2018. e-Pub 12/2017. PMID: PMC5808035. **Impact Factor 5.922**
550. ! Ikoma N, Cloyd J, Badgwell BD, Agnes A, Rodriguez-Bigas M, **Ajani** JA, You YN. Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. *J Surg Oncol* 117(4):707-709, 3/2018. e-Pub 12/2017. PMID: 29228462. **Impact Factor 2.886**
551. ! Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, **Ajani** JA, Watanabe M, Baba H. Pyloroplasty may reduce weight loss 1 year after esophagectomy. *Dis Esophagus* 31(3), 3/2018. PMID: 29579257. **Impact Factor 2.702**
552. ! Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, **Ajani** JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD. Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National



- Cancer Data Base, 2006-2014. Cancer 124(5):998-1007, 3/2018. e-Pub 2/2018. PMID: 29393964. **Impact Factor 6.537**
553. ! Mizrak Kaya D, Nogueras-González GM, Harada K, Amlashi FG, Roy-Chowdhuri S, Estrella JS, Das P, Lee JH, Weston B, Bhutani MS, Matamoros A, Thomas I, Lin Q, Badgwell BD, **Ajani JA**. Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. J Surg Oncol 117(4):678-684, 3/2018. e-Pub 12/2017. PMID: PMC5878692. **Impact Factor 2.866**
554. ! Blum Murphy MA, Qiao W, Mewada N, Wadhwa R, Elimova E, Takashi T, Ho L, Phan A, Baker J, **Ajani J**. A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. Am J Clin Oncol 41(4):321-325, 4/2018. PMID: 26908161. **Impact Factor 3.424**
555. ! Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, **Ajani JA**. Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94(6):345-353. e-Pub 4/2018. PMID: 29705797. **Impact Factor 3.143**
556. ! Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, **Ajani J**, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg. e-Pub 4/2018. PMID: 29679346. **Impact Factor 2.813**
557. ! Zhao W, **Ajani JA**, Sushovan G, Ochi N, Hwang R, Hafley M, Johnson RL, Bresalier RS, Logsdon CD, Zhang Z, Song S. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling. Gastroenterology 154(5):1524-1537.e6, 4/2018. e-Pub 12/2017. PMID: 29274868. **Impact Factor 20.773**
558. ! Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, **Ajani JA**, Li GM, Liang H, Shen X, Mills GB, Peng G. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. e-Pub 5/2018. PMID: 29736026. **Impact Factor 39.235**
559. ! Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, **Ajani JA**. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology:1-10. e-Pub 5/2018. PMID: 29843157. **Impact Factor 3.143**
560. ! Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, **Ajani JA**, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 9(1):1777, 5/2018. e-Pub 5/2018. PMID: PMC5934392. **Impact Factor 12.353**
561. ! Taieb J, Moehler M, Boku N, **Ajani JA**, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev 66:104-113, 5/2018. e-Pub 4/2018. PMID: 29730461. **Impact Factor 8.122**
562. ! Thiels CA, Ikoma N, Fournier K, Das P, Blum M, Estrella JS, Minsky BD, **Ajani J**, Mansfield P, Badgwell BD. Repeat staging laparoscopy for gastric cancer after preoperative therapy. J Surg Oncol. e-Pub 6/2018. PMID: 29878364. **Impact Factor 2.886**
563. ! Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, **Ajani JA**, Badgwell BD. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol. e-Pub 6/2018. PMID: 29949666. **Impact Factor 2.886**
564. ! Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, **Ajani JA**, Fournier KF, Mansfield P, Badgwell BD. Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. Ann Surg Oncol 25(7):2012-2017, 7/2018. e-Pub 5/2018. PMID: 29748883. **Impact Factor 3.857**

565. ! Nelson DB, Dhupar R, Katkhuda R, Correa A, Goltsov A, Maru D, Sepesi B, Antonoff MB, Mehran RJ, Rice DC, Vaporciyan AA, Davila M, Davila R, Betancourt S, **Ajani J**, Hofstetter WL. Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. *J Thorac Cardiovasc Surg* 156(1):406-413.e3, 7/2018. e-Pub 3/2018. PMID: 29605441. **Impact Factor 4.880**
566. ! Mizrak Kaya D, Nogueras-González GM, Harada K, Amlashi FG, Thomas I, Rogers JE, ! Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, ! Devine CE, Das P, Badgwell BD, **Ajani JA**. Potentially curable gastric adenocarcinoma ! treated without surgery. *Eur J Cancer* 98:23-29, 7/2018. e-Pub 5/2018. PMID: 29859338. ! **Impact Factor 7.191**
567. ! **Ajani JA**, Bhutani MS, Swisher SG. Oesophageal preservation in locally advanced ! oesophageal cancer. *Lancet Oncol* 19(9):e430, 9/2018. PMID: 30191840. **Impact Factor ! 53.254**
568. ! Vicente D, Ikoma N, Chiang YJ, Fournier K, Tzeng CD, Song S, Mansfield P, **Ajani J**, ! Badgwell BD. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor ! Oncologic Outcomes in Patients with Complications After Gastrectomy. *Ann Surg Oncol* ! 25(9):2720-2730, 9/2018. e-Pub 7/2018. PMID: 29987602. **Impact Factor 3.857 !**
569. ! Song S, **Ajani JA**. Reply. *Gastroenterology* 155(3):934-935, 9/2018. e-Pub 8/2018. PMID: ! 30098926. **Impact Factor 20.773 !**
570. ! Gu J, Zhang J, Zheng L, **Ajani JA**, Wu X, Ye Y. Serum miR-331-3p predicts tumor ! recurrence in esophageal adenocarcinoma. *Sci Rep* 8(1):14006, 9/2018. e-Pub 9/2018. ! PMCID: PMC6143616. **Impact Factor 4.122 !**
571. ! Harada K, Abdelhakeem AAF, **Ajani JA**. A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. *Nat Rev Clin Oncol*. e-Pub 10/2018. PMID: 30291292.
572. ! Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, **Ajani JA**. Cancer stem cells in ! esophageal cancer and response to therapy. *Cancer* 124(20):3962-3964, 10/2018. e-Pub ! 10/2018. PMCID: PMC6234092. !
573. ! Ikoma N, Das P, Hofstetter W, **Ajani JA**, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. *Gastric Cancer* 21(6):1004-1013, 11/2018. e-Pub 5/2018. PMID: 29730720. **Impact Factor 5.045**
574. ! Ikoma N, Estrella JS, Hofstetter WL, **Ajani JA**, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD. Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. *J Gastrointest Surg* 22(11):2013-2019, 11/2018. e-Pub 7/2018. PMID: 30054780. **Impact Factor 2.813**
575. ! Additional publications can be found <https://www.ncbi.nlm.nih.gov/pubmed/?term=Ajani+j>
576. ! Current H-Index = 103 (Please visit SCOPUS site)

#### Invited Articles

1. ! Bodey GP, Yap BS, **Ajani JA**, Aboud AA, Yap HW, Estey EH. Clinical trials of 4'-epidoxorubicin. 13th International Congress of Chemotherapy. Vienna, Austria, SY 88, part 215, 1983.
2. ! **Ajani JA**, Sahu SK, Spitzer G, Hug V, Bodey GP. Cloning of human tumor stem cells in the soft agar - An overview. *Cancer Bull* 35:16-19, 1983.
3. ! Boddie AW, Patt YZ, McBride CN, Wallace S, **Ajani JA**, Charnsangavej C, Soski M, Levin B. MDAH surgical experience with implantable infusaid pump and Medtronic drug administration device. International conference on Regional Therapy. Giessen, West Germany., 8/1985.
4. ! Feldman L **Ajani J**. 5-Fluorouracil induced dermatitis. *JAMA*, Dec, 1985.
5. ! **Ajani JA**. Value of predictive tests for clinical chemotherapy. *Cancer Bull* 39:263, 1987.
6. ! **Ajani JA** Spitzer G. Adhesive tumor cell culture system. *J Clin Oncol* 6:178, 1988.
7. ! **Ajani JA**. Adjuvant chemotherapy for colorectal carcinoma. *Cancer Bulletin* 40:235-237, 1988.
8. ! **Ajani JA**. Book review. (Gastric Cancer. Contemporary Issues in Clinical Oncology. H. O. Douglass (ed), Churchill Livingstone, New York). *Cancer Bull* (book review) 40:323, 1988.



9. ! **Ajani** JA Jackson DE. Carcinomas of the esophagus and stomach. *Consultant* 28:93-109, ! 1988. !
10. ! **Ajani** JA. Highlights: 1988 Meeting of American Society of Clinical Oncology (ASCO 1988). New Orleans, May 23-25. *J Cancer Res Clin Oncol* 114:533-535, 1988.
11. ! Rich TA, Jessup JM, Ota DM, Ames FC, Hohn DC, Martin RG, **Ajani** JA, Abbruzzese JL. Conservative management of anal and low rectal cancers with combined modality therapy. *Cancer Bulletin*, 1989.
12. ! **Ajani** JA. American College of Physician Medical Oncology Course (UT MDACC). Review of Carcinoid and Islet Cell Tumors, 1991.
13. ! **Ajani** JA. American College of Physician Medical Oncology Course. Review of Carcinoma of the Esophagus and GE Junction, 1991.
14. ! **Ajani** JA. American College of Physician Medical Oncology Course. Review of Gastric Carcinoma, 1991.
15. ! **Ajani** JA, Ota DM, Jackson DE. Current strategies in the management of locoregional and metastatic gastric carcinoma. *Cancer* 67(1 Suppl):260-5, 1991. PMID: 1984825.
16. ! **Ajani** JA, Dumas P. Phase II study of oral etoposide in patients with gastric carcinoma: A preliminary report. *Semin Oncol*, 12/1992.
17. ! **Ajani** JA. Management of Gastric Cancer; edited by PH Sugarbaker, MD; Kluwer Academic Publishers; Boston/Dordrecht/London. *JNCI* 84:1597, 1992.
18. ! Ota DM, Mansfield P, **Ajani** JA. Operative and adjuvant treatment strategies for gastric carcinoma. *Cancer Bulletin* 44:286-291, 1992.
19. ! **Ajani** JA. Carcinoma of the Esophagus. Staging and therapy. Proceedings ACT-AAPI-MCI Symposium. Recent Advances in Oncology. New Delhi, India:pp. 1-11. (an extended abstract), 12/1993.
20. ! **Ajani** JA. American College of Physician Medical Oncology Course. Carcinoma of the Esophagus and GE Junction. UT MDACC Course, 1993.
21. ! **Ajani** JA. American College of Physician Medical Oncology Course. Gastric Carcinoma. UT MDACC Course, 1993.
22. ! **Ajani** JA. American College of Physician Medical Oncology Course. Hepatocellular Carcinoma. UT MDACC Course, 1993.
23. ! **Ajani** JA. American College of Physician Medical Oncology Course. Pancreatic Neuroendocrine Tumors and Carcinoid Tumors. UT MDACC Course, 1993.
24. ! Ota DM, **Ajani** JA, Mansfield P. Preoperative Therapy for Gastric Carcinoma. *Surgical Clinics of North America* 2:493-497, 1993.
25. ! **Ajani** JA. Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary. *Semin Oncol* 21(4):474-82, 8/1994. PMID: 8042045.
26. ! **Ajani** JA. Etiology and therapy of gastric carcinoma. Proceedings 2nd Oncology Conference on Gastric Carcinoma; Athens, Greece, 9/1994.
27. ! **Ajani** JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy. *Ann N Y Acad Sci* 733:479-87, 9/1994. PMID: 7978898.
28. ! Kelsen D, **Ajani** JA, Ilson D, Daugherty K, Pazdur R. A phase II trial of paclitaxel in advanced esophageal cancer. Preliminary report. *Semin Oncol* 21:44-48, 1994.
29. ! **Ajani** JA. Cancer of the Esophagus. Approaches to Etiology by Valda M. Craddock. Cambridge University Press. *Cancer Bulletin* 46:284-285, 1994.
30. ! **Ajani** JA. Carcinoma of the Esophagus. Carcinoma of the Stomach. Carcinoma of the Colon and Rectum. American College of Gastroenterology Syllabus and Q + A for the Annual Meeting in Sept. San Francisco, 1994.
31. ! Vassilopoulou-Sellin R, **Ajani** J. Islet cell tumor of the pancreas. *Endocrine Clinics of North America* 23:53-65, 1994.
32. ! Chesnut JR **Ajani** JA. Role of escalating dose of octreotide in the relief of carcinoid syndrome. Sandoz publication, 1994.
33. ! **Ajani** JA. Vascular Occlusion Therapy of Liver Metastases. Review: Soulen MC. Chemoembolization of hepatic malignancies. *Oncology* 8:90-93, 1994.
34. ! **Ajani** JA. What re the therapeutic options for a 60-year old woman with stage II well-differentiated adenocarcinoma of the proximal jejunum? *The Oncology Times. Tumor Board* 5:19, 1994.

35. ! **Ajani** JA, Ilson DH, Daugherty K, Kelsen DP. Paclitaxel in the treatment of carcinoma of the esophagus. *Semin Oncol* 22(3 Suppl 6):35-40, 6/1995. PMID: 7541155.
36. ! **Ajani** JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. *Semin Oncol* 22(5 Suppl 12):46-50; discussion 51-3, 10/1995. PMID: 7481861.
37. ! Leach SD, Lowy AM, Mansfield PF, **Ajani** JA. Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials. *J Infus Chemother* 5(3):104-11, 1995. PMID: 8528966.
38. ! Holmes FA, Kudelka AP, Kavanagh JJ, **Ajani** JA, Valero V. Clinical Studies of Taxol, in, *Taxane Anticancer Agents: Basic Science and Current Status*. American Chemical Society Symposium, eds, G. I. Georg, T. C. Chen, I. Ojima, and D. M. Vyas:31-38, 1995.
39. ! **Ajani** JA. Current status of biology and therapy of gastric carcinoma. *J Infusional Th* 5:91-93, 1995.
40. ! Philip PA, **Ajani** JA. Gastrointestinal Cancer in the Elderly. *Cancer Bulletin*, 1995.
41. ! Rajiman I, Wallace S, **Ajani** JA. Interventional Management of malignant biliary obstruction. Review of an article by MJ Shapiro to appear in *Oncology*, 1995.
42. ! **Ajani** JA, Mansfield P, Ota DM. Potentially resectable gastric carcinoma: Current approaches to staging and preoperative therapy. *World J Surg* 19:216-220, 1995.
43. ! **Ajani** JA. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. *Eur J Cancer* 31A(5):790-3, 1995. PMID: 7640055.
44. ! **Ajani** JA. Current Status of Chemotherapy of Advanced Gastric Carcinoma. Proceedings WHO Conference on Gastric Carcinoma, Seoul, Korea, 9/1996.
45. ! **Ajani** JA, Ilson DH, Kelsen DP. Paclitaxel in the treatment of patients with upper gastrointestinal carcinomas. *Semin Oncol* 23(5 Suppl 12):55-8, 10/1996. PMID: 8941411.
46. ! **Ajani** JA, Ilson D, Kelsen DP. Paclitaxel in the therapy of upper GI carcinomas. *Semin Oncol* 23(suppl. no. 12):55-58, 1996.
47. ! **Ajani** JA. Radiotherapy, chemotherapy, and combined modality therapy of gastric carcinoma. *International Gastric Cancer Association News*, April Newsletter no. 1:7, 1996.
48. ! **Ajani** JA. Too much too late. Case discussion in *The Oncology Times*. Patient with upper GI tumor and synchronous colon carcinoma. *The Oncology Times*, 1996.
49. ! **Ajani** JA. New Chemotherapy agents with properties of radiation sensitization and chemoradiotherapy in patients with gastric carcinoma. *Proc Chemoradiotherapy Summit*, Yosemite, CA, 4/1997.
50. ! **Ajani** JA. Current options for patients with local-regional gastric carcinoma. Proceeding Gastric Cancer Conference. Yonsai University, Seoul, Korea, 9/1997.
51. ! **Ajani** JA. Esophageal Carcinoma. Proceeding Medical Oncology Board Review. U. T. M. D. Anderson Cancer Center, Houston, TX, 9/1997.
52. ! **Ajani** JA. Gastric Carcinoma. Proceeding Medical Oncology Board Review. U. T. M. D. Anderson Cancer Center, Houston, TX, 9/1997.
53. ! **Ajani** JA. Treatment of patients with upper gastrointestinal carcinomas. *Semin Oncol* 24(6 Suppl 19):S19-72-S19-76, 12/1997. PMID: 9427271.
54. ! **Ajani** JA. New and old chemotherapy agents for gastric carcinoma. *International Gastric Cancer Association News*, Newsletter 9, 1997.
55. ! Diamandidiu E **Ajani** JA. What treatment for this man with esophageal cancer? *Primary Care and Cancer* 17:2 and 6, 1997.
56. ! **Ajani** JA. Gastric Carcinoma Update: New drugs, new radiosensitizers, and multimodality therapy. Proceedings Eighth International Congress on Anti-Cancer Treatment. Paris, France, 2/1998.
57. ! **Ajani** JA. Current status of therapy for advanced gastric carcinoma. *Oncology (Williston Park)* 12(8 Suppl 6):99-102, 8/1998. PMID: 9726100.
58. ! **Ajani** JA. Carcinomas of the esophagus and stomach: An update. *Medical Oncology Board Review*. UT M. D. Anderson Cancer Center:23 pp., 50+ refs, 10/1998.
59. ! **Ajani** JA. Chemotherapy for gastric carcinoma: new and old options. *Oncology (Williston Park)* 12(10 Suppl 7):44-7, 10/1998. PMID: 9830625.
60. ! Partyka S **Ajani** JA. Chemotherapy of colorectal cancer. *Current Treat Options Gastroenterology*, 1998.

61. ! **Ajani** JA. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. *Chest* 113(1 Suppl):112S-119S, 1998. PMID: 9438700.
62. ! **Ajani** JA. The value of chemoradiotherapy in the management of patients with upper gastrointestinal carcinomas. *Proc 9th Anticancer Therapy Congress (SOMPS)*. Paris, France, 2/1999.
63. ! **Ajani** JA. New chemotherapy agents for gastric and esophageal carcinomas. *Proceeding Japan and US Chemotherapy/Radiotherapy Symposium*. Hiroshima, Japan, 4/1999.
64. ! **Ajani** JA. New Developments in the Treatment of Colorectal and Upper Gastrointestinal Carcinomas. *Proceeding Russian Academy of Medical Sciences*. (published in Russian in a journal book), 9/1999.
65. ! **Ajani** JA. An Overview of the treatment of Colorectal Carcinoma. *Proceeding 5th Annual Oncology Symposium*. Saginaw, MI, 11/1999.
66. ! **Ajani** JA. New Developments in the Treatment of Esophageal and Gastroesophageal Junction Carcinomas. *Proceeding Radiology Society of North America meeting*, 11/1999.
67. ! **Ajani** JA. New Developments in the Treatment of Esophageal and Gastroesophageal Junction Carcinomas. *Refresher's Course of Radiology Society of North America*, Chicago, Illinois, 11/1999.
68. ! **Ajani** JA. Adjuvant Therapy of Gastric Carcinoma. *Posted on WebMD.com*, 12/1999.
69. ! **Ajani** JA. Carcinoma of the esophagus. An update. *Cancer Consultant*, 1999.
70. ! **Ajani** JA. Chemotherapy options for patients with gastric carcinoma. *Proceeding Hematology/Oncology Conference*, Merida City, Mexico, 1999.
71. ! **Ajani** JA Fairweather F. Cisplatin plus CPT-11 in Patients with Advanced Gastric or Gastroesophageal Junction Carcinoma. *Preliminary Results of an Ongoing Phase II Study*. *Chemotherapy Conference Highlights*, 1999.
72. ! **Ajani** JA. Current Therapy of Colorectal Carcinoma. *Proceeding Texas Society Medical Oncology*. Held in Austin:September, 1999.
73. ! **Ajani** JA. Esophageal carcinoma. An update on combined modality therapy. *Proceeding Hematology/Oncology Conference*, Merida City, Mexico, 1999.
74. ! **Ajani** JA, Takiuchi H. Recent developments in oral chemotherapy options for gastric carcinoma. *Drugs* 58 Suppl 3:85-90, 1999. PMID: 10711846.
75. ! **Ajani** JA. A Review of Therapy of Colorectal Carcinoma. *Ohio Conference*. Canton, OH, 1/2000.
76. ! **Ajani** JA. Current Status of Treatment in the Management of Esophageal Carcinoma. *Manuscript for distribution*. Tampa, Florida. *Conference on Esophageal carcinoma*, 4/2000.
77. ! Yao JC, **Ajani** JA. Gastric cancer. *Curr Opin Gastroenterol* 16(6):516-21, 11/2000. PMID: 17031130.
78. ! Swisher SG, Pisters PW, Komaki R, Lahoti S, **Ajani** JA. Gastroesophageal junction adenocarcinoma. *Curr Treat Options Oncol* 1(5):387-98, 12/2000. PMID: 12057146.
79. ! **Ajani** JA, Fairweather J, Pisters PW, Charnsangavej C. Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma. *Oncology (Williston Park)* 14(12 Suppl 14):19-21, 12/2000. PMID: 11200143.
80. ! **Ajani** JA. Cisplatin plus CPT-11 in Patients with Advanced Gastric or Gastroesophageal Junction Carcinoma. *Preliminary Results of an Ongoing Phase II Study*. *Oncology (USA)*, 2000.
81. ! Introduction. *St croix no 2 (Oncology supplement)*., 2000.
82. ! Introduction. *St. Croix no. 3 (Oncology supplement)*., 2000.
83. ! Introduction. *St. Croix no. 4 (Oncology supplement)*., 2000.
84. ! Introduction. *St. Croix no. 5 (Oncology supplement)*., 2000.
85. ! Introduction: *Oncology. Sonoma meeting Oncology Thought Leader Advisory Board Meeting (Oncology supplement)*, 2000.
86. ! Introduction: *Paris meeting (to be printed in Seminars in Oncology)*., 2000.
87. ! Introduction: *St croix no. 1 (Oncology supplement)*., 2000.
88. ! **Ajani** JA. Standard Chemotherapy for Advanced Gastric Carcinoma: Is it a myth? *J Clin Oncol* 18:4001-4003, 2000.

89. ! **Ajani** JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. *Oncology (Williston Park)* 15(3 Suppl 5):52-4, 3/2001. PMID: 11301842.
90. ! Najam A **Ajani** JA. Anatomic consideration: Uper Gastrointestinal Tract. *Atlas of Cancer*, 2001.
91. ! Komaki R, **Ajani** JA et al. CPT-11 and radiotherapy. *Oncology*, 2001.
92. ! Ho L, Rashid A, Kaw M, **Ajani** J. Predictors of Response to Treatment of Adenocarcinoma of the Stomach. *Atlas of Cancer*, 2001.
93. ! **Ajani** JA, Baker J, Pisters PW, Ho L, Feig B, Mansfield PF. First Line Therapy of Untreated, Advanced Gastric or Gastroesophageal Junction Carcinoma with CPT-11 Plus Cisplatin. *Oncology supplement, Cancer* 94(3):641-646, 2/2002.
94. ! Yao JC **Ajani** JA. Adjuvant and preoperative chemotherapy for gastric cancer. *Curr Oncol Rep* 4(3):222-8, 5/2002. PMID: 11937012.
95. ! **Ajani** JA. Docetaxel for gastric and esophageal carcinomas. *Oncology (Williston Park)* 16(6 Suppl 6):89-96, 6/2002. PMID: 12108902.
96. ! **Ajani** JA. Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus: are we still confused? *Ann Surg Oncol* 9(7):605-6, 8/2002. PMID: 12167571.
97. ! **Ajani** JA. Docetaxel in combination for advanced gastric cancer. *Gastric Cancer* 5 Suppl 1:31-4, 2002. PMID: 12772885.
98. ! **Ajani** JA. Taxotere in Gastric and Esophageal Carcinomas. *Semin Oncol*, 2002.
99. ! **Ajani** JA. Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. *Oncology (Williston Park)* 17(9 Suppl 8):10-2, 9/2003. PMID: 14569840.
100. ! **Ajani** JA, Faust J, Yao J, Komaki R, Stevens C, Swisher S, Putnam JB, Vaporciyan A, Smythe R, Walsh G, Rice D, Roth J. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. *Oncology (Williston Park)* 17(9 Suppl 8):20-2, 9/2003. PMID: 14569843.
101. ! Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, **Ajani** JA. Combined-modality therapy for gastric cancer. *Semin Surg Oncol* 21(4):223-7, 2003. PMID: 14648779.
102. ! Phan AT, **Ajani** JA. Gastric carcinoma. *Curr Oncol Rep* 6(3):192-8, 5/2004. PMID: 15066230.
103. ! Xiong HQ, **Ajani** JA. Treatment of colorectal cancer metastasis: the role of chemotherapy. *Cancer Metastasis Rev* 23(1-2):145-63, 2004. PMID: 15000155.
104. ! **Ajani** JA. Carcinoma of the esophagus: is biology screaming in my deaf ears? *J Clin Oncol* 23(19):4256-8, 7/2005. PMID: 15781878.
105. ! **Ajani** JA. Standard of care for gastric cancer based on meta-analysis? Treading on thin ice or it is very nice! *J Clin Oncol* 24(34):5473-4; author reply 5474-6, 12/2006. PMID: 17135655.
106. ! **Ajani** JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D'Amico TA, Das P, Denlinger C, Fuchs CS, Gerdes H, Hayman JA, Hazard L, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn M, Meredith K, Mulcahy MF, Orringer MB, Osarogiagbon RU, Posey JA, Sasson AR, Scott WJ, Shibata S, Strong VE, Washington MK, Willett C, Wood DE, Wright CD, Yang G, NCCN Gastric Cancer Panel. Gastric Cancer. *J Natl Compr Canc Netw* 8(4):378-409, 4/2010. PMID: 20410333.
107. ! Cohen DJ, **Ajani** J. An expert opinion on esophageal cancer therapy. *Expert Opin ! Pharmacother* 12(2):225-39, 2/2011. PMID: 21226634. !
108. ! **Ajani** JA. GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. ! *Gastrointest Cancer Res* 4(2):39, 3/2011. PMCID: PMC3109889. !
109. ! **Not updating these anymore**

#### Editorials

1. ! **Ajani** JA. Crescendos and decrescendos: gastric and esophageal cancers. *J Natl Compr Canc Netw* 9(8):811-3, 8/2011. PMID: 21900215.
2. ! Blum MA, **Ajani** JA. Many a mickle makes a muckle. Translating a gastric cancer phenotype into a bigger thing. *Onkologie* 34(10):499-500, 2011. e-Pub 9/2011. PMID: 21985847.
3. ! **Not updating these anymore**

#### Other Articles

N/A

**Abstracts**

N/A

**Book Chapters**

1. ! Umbach GE, Spitzer G, **Ajani** JA, Thames H, Hug V, Rudolph F, Drewinko B. Factors determining methotrexate cytotoxicity in human bone marrow progenitor cells: Implications for in vitro drug testing of human tumors. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 443-450, 1984.
2. ! Spitzer G, Baker F, Umbach G, Hug V, Tomasovic B, **Ajani** JA, Haynes M, Sahu SK. Growth factor enhancement of the in vitro stem cell assay. In: Predictive Test in Human Cancer; Recent Results in Cancer Research. Springer-Verlag, 1984.
3. ! **Ajani** JA, Spitzer G, Baker F, Umbach GE, Tomasovic B, Sahu SK. Human tumor cloning assay with prospective clinical correlations and association between in vitro sensitivity and the number of drugs tested. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 595-604, 1984.
4. ! Spitzer G, Singletary E, Tomasovic B, Umbach G, Merchant N, Hug V, **Ajani** JA. Human tumor cloning culture supplements. In: Cloning of Human Tumor Stem Cells. Grune and Stratton, 215-228, 1984.
5. ! Patt Y, **Ajani** JA, Boddie A, Charnsangavej C, Claghorn L, Soski M. Arterial cisplatin and floxuridine for colorectal cancer metastatic to the liver. In: Recent Advances in Chemotherapy. University of Tokyo Press, 1166-1167, 1985.
6. ! Stroehlein JR **Ajani** JA. Gastric carcinoma. In: Current Therapy in Gastrointestinal and Liver Diseases. B. C. Decker, Inc, 120-123, 1986.
7. ! **Ajani** JA Samaan NA. Carcinoids and Islet Cell Neoplasms. (Selected abstracts) . In: ! ONCOLOGY OVERVIEW NCI/ICRDB, December, 1987. !
8. ! Nishioka K, Grossie VB, Ota DM, **Ajani** JA. Changes in polyamine metabolism in tumor-bearing hosts with total parenteral nutrition and intravenous infusion of alpha-difluoromethylornithine. In: The Physiology of Polyamines. CRC Press Inc, 1987.
9. ! Bodey GP **Ajani** JA. Chemotherapeutic and hormonal approaches to treatment of carcinoma of the pancreas. In: Surgical Diseases of the Pancreas. Lea and Febiger, 748-761, 1987.
10. ! **Ajani** JA. Diagnosis and treatment of esophageal carcinoma (selected abstracts). In: ! ONCOLOGY OVERVIEW NCI/ICRDB, June, 1987. !
11. ! **Ajani** JA, McMurtrey M, Rich TA, Blackburn R, Chang-Tung E, Levin B, Roth J A, Mountain CF. Carcinoma of the esophagus: Contribution of chemotherapy. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 272-281, 1988.
12. ! Baker FL, Spitzer G, **Ajani** JA, Brock WA. Drug and radiation sensitivity testing of primary human tumor cells using the adhesive-tumor-cell culture system. In: Prediction of Response to Chemotherapy. Alan R. Liss, Inc, 1988.
13. ! Wallace S, Carrasco C, **Ajani** J, Charnsangvej C, Samaan N. Embolization of neuroendocrine hepatic metastases. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 337-349, 1988.
14. ! Rich TA **Ajani** JA. Radiotherapy of esophageal carcinoma. In: Gastrointestinal Cancer: Current Approaches to Diagnosis and Treatment. University of Texas Press, 261-271, 1988.
15. ! Hall JT, Wallace S, Carrasco CH, Charnsangavej C, Richli W, **Ajani** JA, Samaan N, Dodd GD. Gastrointestinal and pancreatic endocrine tumors. In: FL Chan and C Wang. Vol 3, No. 1; May. Baillere Tindall, 121-152, 1989.
16. ! **Ajani** JA, Levin B, Wallace S. Systemic and regional therapy of advanced islet cell tumors. In: Gastrointestinal Endocrinology, The Gastroenterology Clinics of North America. 18(4). W. B. Saunders, 923-930, 1989.
17. ! Roth JA, **Ajani** JA, Rich TA. Multidisciplinary therapy for esophageal cancer. In: Advances in Surgery. 23. Year Book Medical Publishers, 239-260, 1990.
18. ! **Ajani** JA, Roth JA, Ryan B, McMurtrey M, Rich TA. Resectable Adenocarcinoma of the Esophagus:A Study of Pre- and Postoperative Chemotherapy. In: Adjuvant Therapy of ! Cancer VI. W.B. Saunders, 396-404, 1990. !
19. ! Rich TA, **Ajani** JA. Chemoradiation therapy for Rectal cancer. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 151-162, 1991.

20. ! Rich TA, **Ajani** JA. Chemoradiotherapy approaches for treatment of loco-regional bile duct carcinoma. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 135-142, 1991.
21. ! Rich TA, **Ajani** JA. Chemoradiotherapy approaches for treatment of loco-regional pancreatic carcinoma. In: Combined Modality Cancer Therapy. Radiation and Infusional Chemotherapy. Precept Press, 143-1150, 1991.
22. ! Rich TA, Ochran T, Boyer A, Ames F, Ota D, Evans D, **Ajani** JA. Electron beam ! intraoperative radiotherapy at M. D. Anderson Cancer Center: Preliminary results. In: ! Intraoperative Radiation Therapy. Paragamon Press, 81-83, 1991. !
23. ! **Ajani** JA Rich TA. Combination of chemotherapy and radiotherapy in the treatment of colorectal carcinomas. In: Chemoradiation Therapy of Gastrointestinal Tract. Lea & Febiger, 330-336, 1993.
24. ! Soh LT, **Ajani** JA. Gastric carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 175-184, 1993.
25. ! Soh LT, **Ajani** JA. Pancreatic carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 163-174, 1993.
26. ! Arcenas AG, **Ajani** JA. Pancreatic Islet Cell and Carcinoid Tumors. In: Medical Oncology: A Comprehensive Review. RPR, 185-198, 1993.
27. ! Rich TA **Ajani** JA. Radiotherapy plus concomitant chemotherapy for cancers of the stomach, pancreas, and biliary system. In: Chemoradiation Therapy of Gastrointestinal Tract. Lea & Febiger, 303-314, 1993.
28. ! Arcenas AG, **Ajani** JA, Carrasco CH, Levin B, Wallace S. Vascular occlusive therapy of pancreatic endocrine tumor metastatic to the liver. In: Frontiers of Gastrointestinal Research, Endocrine Tumors of the Pancreas-Recent Advances. Karger, 1994.
29. ! **Ajani** JA, Kelsen DP, Rich TA, Roth JA. Chemotherapy and radiation therapy for squamous cell carcinoma and adenocarcinoma of the esophagus and gastroesophageal junction. In: Thoracic Oncology. W. B. Saunders Company, 433-441, 1995.
30. ! Touroutoglou N, Arcenas AG, **Ajani** JA. Biology and Therapy of neuroendocrine tumors of the gastrointestinal tract.. RPR, 285-298, 1996.
31. ! Philip PA, **Ajani** JA. Carcinoma of the Esophagus. In: Medical Oncology: A Comprehensive Review. RPR, 225-234, 1996.
32. ! Nishioka K, Mitchell MF, **Ajani** JA. Clinical studies of polyamines and their anti-metabolite. In: Polyamines in Cancer: Basic Mechanisms and Clinical Approaches. Chapman and Hall Publishing Company, 251-278, 1996.
33. ! Philip PA, **Ajani** JA. Gastric Carcinoma. In: Medical Oncology: A Comprehensive Review. RPR, 235-246, 1996.
34. ! **Ajani** JA. Adjuvant therapy of colon and rectal carcinoma. In: Progress in Anti-Cancer ! Chemotherapy. Blackwill Science, 135-142, 1997. !
35. ! **Ajani** JA. Current approaches to local-regional gastric carcinoma. In: Polish Society of ! Gastric Carcioma, 1997. !
36. ! **Ajani** JA. Current therapy of advanced gastric carcinoma. In: Polish Society of Gastric Carcioma, 1997. !
37. ! **Ajani** JA. Multimodality therapy of local-regional gastric carcinoma. In: Book of Japanese Gastric Cancer Surgical Society. Tokyo, Japan. June, 1999.
38. ! Phan A, **Ajani** JA. Chemoradiotherapy of Gastric, Esophageal, Pancreatic, and Biliary Carcinomas., 2002. !
39. ! **Not updating these anymore**

**Books (edited and written)**

N/A

**Letters to the Editor**

1. ! **Ajani** JA. Bolus fluorouracil for metastatic colorectal carcinoma? J Clin Oncol 7(9):1366-7, 9/1989. PMID: 2769332.
2. ! Rich TA, Hughes L, **Ajani** JA, Brock W. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys 18(3):710, 3/1990. PMID: 2318708.

3. ! **Ajani JA.** In rectal carcinoma, colostomy or no colostomy: is this the question? J Clin Oncol 11(1):193-4, 1993. PMID: 8418233.
4. ! **Ajani JA.** Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol 18(23):4001-3, 12/2000. PMID: 11099333.
5. ! **Ajani JA.** It's the poison that killed him, you say! J Clin Oncol 21(20):3885, 10/2003. PMID: 14551310.
6. ! **Vauthey JN, Ajani JA.** Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. J Clin Oncol 21(23):4265-7, 12/2003. PMID: 14581443.
7. ! **Ajani JA.** Operate on my stomach cancer? Oh, no--not you, or not yet! J Clin Oncol 22(9):1763-4; author reply 1764-5, 5/2004. PMID: 15118003.
8. ! **Hofstetter W, Ajani J, Swisher SG.** Author reply. Cancer 109:1449, 2/2007. PMID: 17328056.
9. ! **Ajani JA.** Reply to D. Vordermark. J Clin Oncol. e-Pub 5/2009. PMID: 19414659.
10. ! **Ajani JA, Blum MA, Welsh J, Hofstetter WL, Swisher SG.** Celebrate or Calibrate? We Say Calibrate. J Clin Oncol 29(19):2732, 7/2011. e-Pub 5/2011. PMID: 21606421.
11. ! **Not updating these anymore (please visit PubMed)**

**Manuals, Teaching Aids, Other Teaching Publications**

N/A

**Other Publications**

N/A

**EDITORIAL AND REVIEW ACTIVITIES**

**Editor/Service on Editorial Board(s)**

Journal of Clinical Oncology, 1995-1997 !

American Journal of Gastroenterology (Literature Review Panel, 1995 !

Journal of Clinical Oncology, 2000 !

Edit Board, Gastric Breast Cancer (www.gastricbreastcancer.com) !

Associate Editor, Gastric Cancer !

Guest Editor, Gastric Cancer Supplement !

Edit Board, Internal Society of GI Oncology !

Edit Board, J of National Comprehensive Cancer Network !

Guest Editor, Oncology, for more than 6 supplements !

Guest Editor, Seminars in Oncology !

**Member of Editorial Review Board**

N/A

**Journal Reviewer**

Annals of Internal Medicine !

Annals of Oncology !

Archives of Internal Medicine !

British Journal of Cancer !

Canadian J of Gastroenterology !

Cancer !

Cancer Chemotherapy Pharmacology !

Cancer Investigation !

Cancer Research !

Clinical Cancer Research !

Current Drugs, Ltd (Review chemotherapy drugs periodically)  
European Journal of Cancer  
European Organization for Research and Treatment of Cancer (EORTC): Protocol Reviewer  
Gastric Cancer  
International J of Radiation Oncology Bio Physics  
International Journal of Cancer  
Investigational New Drugs  
Italian Association of Cancer Research (Grants review)  
J Am Acad Derm  
J Clinical Gastroenterology  
J Natl Cancer Inst  
J of Am Gastroenterology  
J of Cancer Control  
Journal of Clinical Oncology  
Journal of Surgical Oncology  
NCI/NIH (grants review)  
Oncology (Basel)  
Oncology (USA)  
Oncology Research (an International Journal)  
Surgery  
The Lancet  
The New England Journal of Medicine  
The New York Academy of Sciences  
Nature Press

**Other Editorial and Review Activities**

N/A

**TEACHING**

**Teaching Within Current Institution -**

**Formal Teaching**

**Courses Taught**

N/A

**Training Programs**

Lecturer, CME Program; Chemotherapy induced diarrhea and management of carcinoid syndrome

8/1999

**Other Formal Teaching**

Lecturer, Grand Rounds; Therapy of localized gastric carcinoma

8/1995

Lecturer, Grand Rounds; The role of new drugs and chemoradiotherapy for cancer of the esophagus

6/1996

Lecturer, Grand Rounds; Therapy of malignant carcinoid syndrome

1/1998



Lecturer, Lecture to Medical Oncology Fellows; Neuroendocrine tumors of the GI tract. !  
Diagnosis and management !  
5/1998 !

**Supervisory Teaching**

**Committees !**

**Advisory Committees**

N/A

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students !**

N/A

**Medical Students**

N/A

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

N/A

**Training Programs**

N/A

**Other Formal Teaching**

Lecturer, Medical Oncology Rounds, New York University !  
3/1991 !

Lecturer, Medical Grand Rounds; Cancer of the Esophagus, Methodist Hospital  
10/1992

Lecturer, Grand Rounds; Current Approaches in Upper Gastrointestinal Cancer, St. Louis  
University Hospital  
3/1993

Lecturer, Grand Rounds; Multimodality approaches to the treatment of gastric and  
esophageal carcinomas, University of Nebraska Medical Center  
4/1995

Lecturer, Grand Rounds; An update on gastric cancer management, George Washington  
University  
9/2000

Lecturer, Cancer Rounds; Recent advances in the treatment of UGI Cancers, Tulane  
University, New Orleans  
5/2001

**Supervisory Teaching**

**Committees !**

**Advisory Committees !**

N/A

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

, Florence, Italy, Organizers Meeting for the International Conference, 10/1991

International Conference on Treatment and Biology of Gastrointestinal Cancers, Frankfurt, Germany, Co-Chairman, 2/1992

, Frankfurt, Germany, Co-Chairman and speaker at an International GI conference, 2/1992

10th Conference on Future Trends in Chemotherapy, Geneva, Switzerland, Co-Chairman of the session and speaker on Current Management of Upper GI Cancers, 3/1992

New Perspective in Colon Carcinoma, Philadelphia, PA, Co-chairman and speaker on the Adjuvant therapy of colon carcinoma, 5/1992

New Perspective in Colon Carcinoma, Boston, MA, Co-chairman and speaker on the Adjuvant therapy of rectal carcinoma, 10/1992

International Conference on Polyamines and Cancer, Del Lago, TX, Organizer, 11/1992

International Symposium on Polyamines and Cancer, Montgomery, TX, Organizer, Fund raiser, Speaker and Moderator, 11/1992

CME symposium, New Delhi, Chairing the session on Esophageal carcinoma and leucuring on staging, treatment, and neoadjuvant therapy, 12/1993

Greek Society of Cancer Study, Conference on Gastric Cancer, Athens, Greece, Organizer, 9/1994

Gastric Cancer Symposium, Athen, Greece, Chairman, 9/1994

International Conference on Biology, Prevention, and Treatment of GI Malignancies, Koln, Germany, Organized an International Conference , 1/1995

Second International Conference on Biology, Prevention, Therapy of Gastrointestinal Malignancy, Köln, Germany, Organizer, 1/1995

1st International Gastric Cancer Congress, Kyoto, Japan, "Organizer, Speaking on ""Advantages and disadvantages of preoperative chemotherapy of resectable gastric carcinoma"" and chairing poster discussion", 3/1995

First International Gastric Cancer Congress, Kyoto, Japan, Organizer, 3/1995

Sino-American Conference on Colorectal Carcinoma, Palm Springs, CA, Chairman, 10/1995

Sixth International Congress on Anti-Cancer Treatment, Paris, France, Chair GI cancer session , 2/1996

International GI Cancer Conference, Deusseldorf, Germany, Organizing Committee , 10/1996

2nd International Conference of Gastric Carcinoma, Munich, Germany, Chairman: Oral Presentations on Gene and Adjuvant Therapy of Gastric Carcinoma, 4/1997

2nd International Conference of Gastric Carcinoma, Munich, Germany, Moderator: Oral Session on Is There Still a Place for Postoperative Chemo- or Radiotherapy? , 4/1997

2nd International Conference of Gastric Carcinoma, Munich, Germany, Chairman: Oral Presentations on Postoperative Therapy and Targeting in Gastric Carcinoma, 4/1997

Second International Gastric Cancer Congress, Munich, Germany, Organizer, 4/1997

International Gastric Cancer Congress of Poland, Krakow, Poland, Chairman: Session on , 5/1997

8th International Conference of Regional Cancer Treatment, Ulm/New Ulm, Germany, Member: International Scientific Committee , 10/1997

Conference on International Update on GI Malignancies: Opportunities and Challenges in the Next Century, New Delhi, India, International Coordinator and Organizer for the conference, 12/1997

International Conference on GI Malignancies, New Delhi, India, Organizer, 12/1997

National Comprehensive Cancer Network Annual Symposium, Ft. Lauderdale, FL, Chaired the session on Gastric and Esophageal Cancers, 3/1998

Middle East Taxol Investigators Meeting, Istanbul, Turkey, Chaired the Session on Other Tumor Types, 3/1998

Middle East Taxol Investigators Meeting., Bangkok, Thailand, Chaired the Session on Other Tumor Types. , 3/1998

10th International Conference on Gastric Carcinoma, Tokyo, Japan, Chaired a Session on "Current Difficulties in the Surgical Therapy of Gastric Carcinoma", 4/1998

Krebscongress of German Cancer Society, Berlin, Germany, Chair a session on Neoadjuvant Therapy, 6/1998

4th Asian Clinical Oncology Society International Conference, Jakarta, Indonesia, Member: International Scientific Advisory Committee , 8/1998

11th International Conference on Gastrointestinal Malignancies, Bordeaux, France, Member: International Scientific Advisory Committee, 9/1998

International Conference on Biology, Prevention, Therapy of Gastrointestinal Malignancy, Köln, Germany, Organizer, 9/1998

Third International Conference on Biology, Prevention, and Treatment of Gastrointestinal Malignancies, Koln, Germany, Organized and conducted the Conference , 9/1998

Japan-US Symposium on Oncology, Hiroshima, Japan, Chairman: Session-Biology and Early Detection of Gastric Carcinoma , 4/1999

3rd Conference of International Gastric Cancer Association, Seoul, Chairman: Preoperative Chemotherapy Session. Attended Executive Committee meeting, WHO Gastric Cancer Meeting, 4/1999

3rd International Gastric Cancer Congress, Seoul, Member: International Advisory Committee , 4/1999

New Frontiers in the Clinical Development of Irinotecan. U.T. M. D. Anderson Cancer Center Conference, Sonoma, CA, Organizer and Chairman, 7/1999

Asian Society of Clinical Oncology, Bali, Indonesia, Chairman, Session: Gastric Cancer Chemotherapy and lectured on "Preoperative Approaches to Localized Gastric Carcinoma", 8/1999

Carcinoid Research Conference, Chicago, IL, Organizer and Chairman, 8/1999

Conference on New Drugs in GI Malignancies, Paris, France, Organizational Committee , 1/2000

New Drugs in GI Malignancies-A look to the Next Century, Paris, France, Organized and Chaired the MDACC symposium, 1/2000

New Drugs in GI Malignancies: A look to the Next Century. Sponsored by U.T. M. D. Anderson Cancer Center and SOMPS, Paris, France, Organizer and Chairman, 1/2000

Yale Carcinoid Reserch Conference, New Haven, CT, Co-Chair Session I: Current Status, 5/2000

M. D. Anderson Cancer Center Investigators' Workshop, St. Croix, Organizer and Chairman, 7/2000

Gastrointestinal Research Conference 2000., Orlando, FL, Organizer and Chairman, 11/2000 !

Gastrointestinal Cancer Research Conference 2000, Orlando, FL, Organizer and Chairperson, ! 11/2000 !

Innovations in GI Oncology, Paris, France, Organizer and Chairman, 2/2001 !

Conference on Innovations In GI Oncology, Paris, France, Organizer and Chairperson, 2/2001 !

Conference on Innovations In GI Oncology, Paris, France, Chair: Symposium on Gemcitabine in ! Pancreatic and Genitourinary Cancers, 2/2001 !

Management of Cancer Treatment-induced Diarrhea and Carcinoid Syndrome, New Orleans, LA, ! Organizer and Chairperson, 3/2001 !

Management of Cancer Treatment-induced Diarrhea and Carcinoid Syndrome, New Orleans, LA, ! Organizer and Chairman, 3/2001 !

4th International Gastric Cancer Association Meeting, New York City, NY, Executive Committee , ! 4/2001 !

ASCO, San Francisco, CA, Program Committee of ASCO, Chaired a Slide Presentation Session ! on "Non-Colorectal Cancer", 5/2001 !

BMS-Japan: Gastric Cancer Symposium, San Francisco, CA, co-chaired the discussion , 5/2001 !

Apton Symposium on Gastrin, San Francisco, CA, Chairman of the symposium, 5/2001 !

UT M. D. Anderson Cancer Center Investigators' Workshop, Colorado Springs, CO, Organizer ! and Chairman, 7/2001 !

International Gastric cancer meeting, Cairns, Australia, Co-Chair "Review of the Advisory Board ! Proceedings" , 8/2001 !

4th International Symposium on the treatment, biology, and prevention of gastrointestinal cancer, ! Colongne, Germany, chair, multiple sessions, 9/2001 !

4th International Conference on Biology, Prevention, Therapy of Gastrointestinal Malignancy, ! Koln, Germany, Organizer and member Scientific Committee, 9/2001 !

Interactive in GI Oncology, Paris, France, Organizer and Chairman, 2/2002 !

2th ESMO Congress "Neoadjuvant and Adjuvant therapies", Nice, France, Chairperson, 10/2002 !

UT M. D. Anderson Cancer Center GI Research Conference 2002, Orlando, FL, Organizer and ! Chairman, 11/2002

GI Cancer Conference, Paris, France, Organizer and Chairman, 2/2003

14th International Congress on Anti-cancer Treatment. Scientific Symposium, Paris, France, Chairperson "Where are we with the management of esophageal cancer?", 2/2003

The 2004 Gastrointestinal Oncology Conference, Arlington, VA, Organizer and Chairman, 7/2004

ISGIO, 2006 Gastrointestinal Oncology Conference, Arlington, VA, Chair, 9/2006

The University of Texas MD Anderson Cancer Center, 3rd Annual Esophageal & Barrett's Metaplasia Conference, Las Vegas, NV, Chair, 11/2006 !

ISGIO, 2007 Gastrointestinal Oncology Conference, Philadelphia, PA, Chair, 9/2007 !

International Society of Gastrointestinal Oncology (ISGIO), 2008 Gastrointestinal Oncology Conference, Arlington, VA, Chair, 9/2008

**Can be updated upon request**

### **Presentations at National or International Conferences**

#### **Invited**

New horizons in the management of Gastric cancer, Sanofi-Aventis Gastric Cancer Symposia, Lahore, Pakistan, 8/12/2006

Gastric cancer, Sanofi-Aventis Lecture, Lisbon, Portugal, 10/19/2006

Advanced gastroesophageal cancers; contributions of docetaxel & further developments, Chemotherapy Foundation Symposium XXIV; Innovative Cancer Therapy for Tomorrow, Mount Sinai School of Medicine, New York, NY, 11/7/2006

Gastric Cancer Biology and Genetics, 1st Asia-Pacific Gastric Cancer Conference, National University, Singapore, 11/20/2006

Current and future perspective of TS-1 relating to gastric cancer, 20th World Congress of Digestive Surgery, Rome, Italy, 11/29/2006

Therapeutic agents directed against molecular targets in esophageal/gastric cancer, XIV International Symposium Advances in Treatment of Gastrointestinal Tumors, Cordoba, Spain, 12/14/2006

S-1, SAGE New Products Meeting, Paris, France, 2/9/2007

Recent advances in the management of upper GI malignancy, International Conference: Recent Advances in Clinical Oncology, Tawam Hospital, Al Ain, United Arab Emirates, 2/19/2007

Advances in management of gastric cancer, Gastric Cancer Practice in India, Gao, India, 4/7/2007

Advances in the treatment of early gastric cancer, Sanofi-Aventis Latin America Oncology Meeting, Cancun, Mexico, 4/21/2007

S-1, WCGIC 2007 S-1 Symposium, Barcelona, Spain, 6/28/2007

Phase data of TS-1 plus CDDP and the current status of FLAGS (FP vs SP), 2007 Japan-Korea DIF Meeting, Tokyo, Japan, 7/26/2007

Gastric cancer, 2007 Best of ASCO Cancun, Cancun, Mexico, 9/7/2007

The TCF Regimen: Optimizing clinical outcomes in Gastric Cancer, International GI Cancer Meeting "Optimizing outcomes in gastric cancer: Taxotere as the cornerstone of gastric cancer chemotherapy," , Rio de Janeiro, Brazil, 9/15/2007

Current treatment strategies for advanced gastric cancer, International GI Cancer Meeting, Bangkok, Thailand, 10/13/2007

Neoadjuvant & adjuvant chemotherapy for gastric cancer, Sanofi-Aventis GI Meeting, Salvador, Brazil, 11/10/2007

Predictive and prognostic biomarkers of the outcome in gastroesophageal cancers, 15th International Symposium- Advances in Treatment of Digestive Tumors, Alicante, Spain, ! 12/13/2007 !

Overview of NCCN Gastric Cancer Guidelines, 1st Annual Emirates Oncology Symposium, Prime Oncology, Al Ain, United Arab Emirates, 2/21/2008

Esophageal Cancer, CR-UK Strategic workshop on esophageal cancer, London, United Kingdom, 3/4/2008

Enhancing Cooperative Group and Industry Collaboration: Opportunities and Hurdles, Sanofi-Aventis GI Summit Meetign, Seville, Spain, 3/15/2008

Gastric cancer, SAGE Gastrointestinal Cancers Meeting, Barcelona, Spain, 6/24/2008

Gastric cancer: Which new targets are on the horizon?, ESMO International Symposium: 10th World Congress on GI Cancer, Barcelona, Spain, 6/26/2008

#### **Other, Including Scientific Exhibitions**

Pre- and postoperative Therapy of Gastric Carcinoma, Third Neoadjuvant Therapy Congress, Paris, France, 2/7/1991

Poster presentation, Prolonged chemotherapy for carcinoma of the esophagus, ASCO 92, San Diego, CA, 5/19/1992

Slide presentation, Pre- and postoperative therapy of resectable gastric carcinoma, ASCO 92, San Diego, CA, 5/19/1992

Locally advanced and metastatic gastric carcinoma also meet the professor session, 6th Symposium on Advances in Oncology, Mexico City, Mexico, 1/20/1993

Carcinoma of the esophagus: Chemoradiotherapy, GI Oncology workshop, Zurs, Austria, 1/28/1993

Localized carcinoma of the pancreas, GI Oncology workshop, Zurs, Austria, 1/28/1993

Resectable carcinoma of the stomach, GI Oncology workshop, Zurs, Austria, 1/29/1993

Pre- and postoperative therapy of resectable carcinoma of the stomach, 4th International Conference on Anti-Cancer Therapy, Paris, France, 2/4/1993

The role of Biologic Response Modifiers in GI Malignancies, EORTC GI Oncology Symposium, Oporto, Portugal, 4/22/1993 !

The management of Resectable Gastric Carcinoma, EORTC GI Oncology Symposium, ! Oporto, Portugal, 4/23/1993 !

Therapy of carcinoma of the esophagus, International Surgical Week, Hong Kong, 8/21/1993

Vascular occlusion therapy of neuroendocrine tumors, International conference on the molecular biology and clinical aspects of neuroendocrine tumors, Berlin, Germany, 11/3/1993

Phase II study of Taxol, Taxol Symposium, Boca Raton, FL, 2/23/1994

Therapy of carcinoma of the esophagus, Taxol Symposium, Madrid, Spain, 3/11/1994

Therapy of carcinoma of the esophagus, Taxol Symposium, Rome, Italy, 3/14/1994

New agents in the treatment of Upper GI Tumors, 5th Biennial Conference on chemotherapy of Malignancies, Salzburg, Austria, 3/20/1994

Give 4 lectures on Gastric carcinoma and neuroendocrine tumors. Strike collaborations to study Gastric Cancer Family, Chilean Cancer Society Symposium., Santiago, Chile, 4/13/1994  
ASCO, Dallas, TX, 5/14/1994

Preoperative therapy of resectable gastric carcinoma, Symposium on Gastric Ccarcinoma, Tubingen, Germany, 6/1/1994

Two lectures on gastric carcinoma, Gastric Cancer Symposium, Athen, Greece, 9/22/1994

GI cancers, Am Soc of Gastroenterology Symposium on GI Cancer, San Francisco, CA, 9/30/1994

Treatment of upper gastrointestinal cancer with Taxol, Sydney, Australia, 10/17/1994

Treatment of upper gastrointestinal cancer with Taxol, Beijing, China, 10/23/1994

Treatment of Colorectal Carcinoma and Esophageal Carcinoma, Neuro-Science/Oncology Symposium organized by Doctors Medical Center and California Cancer Center, Monterey, CA, 2/10/1995

Current Status of Treatment of Cancer of the Esophagus, GI Cancer Symposium arranged by Sacred Heart Cancer Center and Research Institute, Spokane, WA, 3/9/1995

Esophageal carcinoma, "Advances in Medical Oncology" arranged by European School of Oncology, Thessaloniki, Greece, 6/14/1995

Controversy in the treatment of Esophageal carcinoma, GI symposium arranged by Instituto Europeo di Oncologia. (European School of Oncology Symposium), Milano, Italy, 9/15/1995

Therapy of upper gastrointestinal tumors, GI Symposium arranged by Roswell Park Memorial Institute, Buffalo, NY, 10/6/1995

Colorectal Carcinoma: Adjuvant therapy and therapy of the Advanced Disease, Sino-American Conference on Colorectal Carcinoma, Palm Springs, CA, 10/7/1995

Educational lecture on colorectal carcinoma, Sixth International Congress on Anti-Cancer Treatment, Paris, France, 2/6/1996

New chemotherapeutic regimens and combined modality treatment of esophageal carcinoma, International Symposium on Thoracic Malignancies, Pittsburgh, PA, 4/25/1996

Current Status of Therapy of Advanced Gastric Carcinoma, WHO Conference on Gastric Carcinoma, Seoul, 9/12/1996

Pharmacology, toxicity, phase I trials, and activity of Taxol, Symposium on Innovation in Chemotherapy, Istanbul, Turkey, 9/28/1996

Multimodality approach to local-regional gastric carcinoma, Gastrointestinal Cancer Group of Spain Conference (TTD), Zaragoza, Spain, 11/20/1996

Combined modality approaches to the treatment of gastric and esophageal carcinomas, 4th International Shanghai Gastroenterology Conference, Shanghai, China, 11/26/1996

Educational lecture on combined modality therapy of carcinoma of the esophagus, Sixth International Congress on Anti-Cancer Treatment, Paris, France, 2/2/1997

New drugs as radioenhancers for GI malignancies and chemoradiotherapy of gastric carcinoma, Chemoradiotherapy Summit, Yosemite, CA, 4/20/1997

Phase II Study of Taxol in the Treatment of Advanced Gastric Carcinoma, American Society of Clinical Oncology, Denver, CO, 5/17/1997

Preoperative Strategies in Local-regional Gastric Carcinoma., Gastric Cancer Symposium, Seoul, 9/20/1997

Recent Approaches to GI Malignancies, Dubai General Oncology Symposium, Dubai, 9/26/1997

Intrahepatic Chemotherapy of Liver Metastases from Colorectal Carcinoma Should be Investigational, 8th International Conference of Regional Cancer Treatment, Ulm/New Ulm, Germany, 10/22/1997

(1) Update on Cancer of the Pancreas and (2) Current Therapy of Hepatocellular Carcinoma., Conference on International Update on GI Malignancies: Opportunities and Challenges in the Next Century, New Delhi, 12/19/1997

Gastric carcinoma: New Drugs, New Radiosensitizers, Current status of Combined Modality Therapy, 8th Anti-Cancer Therapy conference (SOMPS), Paris, France, 2/3/1998

Current Therapy of Gastric Carcinoma, Advances in Cancer Therapy, Mexico City, Mexico, 2/19/1998

(1) Value of Old Drugs and Oral Etoposide in Patients with Gastric Cancer and (2) Role of New Drugs and UFT in patients with Gastric Cancer, Symposium on Oral Therapy of Various Malignancies, Cancun, Mexico, 2/26/1998

(1) Therapy of Esophageal and Gastric Carcinoma and (2) Presentation of Guidelines for Therapy of Gastric and Esophageal Carcinomas, National Comprehensive Cancer Network Annual Symposium, Ft. Lauderdale, FL, 3/1/1998

Value of Taxol in Gastrointestinal, Head/Neck and other Tumor Types, Middle East Taxol Investigators Meeting, Istanbul, Turkey, 3/9/1998

Value of Taxol in Gastrointestinal, Head/Neck and other Tumor Types, Middle East Taxol Investigators Meeting., Bangkok, Thailand, 3/12/1998

Western View: Current Therapy of Gastric Carcinoma, 10th International Conference on Gastric Carcinoma, Tokyo, Japan, 4/21/1998

Role of Chemoradiotherapy of Gastric Carcinoma, British-Japan Conference on the Advances in the Treatment of Gastrointestinal Malignancies, Tokyo, Japan, 4/24/1998

Treatment of Advanced Gastric Carcinoma and Rationale for the study, Rhone-Poulanc Rhore Investigators meeting for the International Taxotere Study, Philadelphia, PA, 5/9/1998

Anal study design and data on Multi-institutional Trial of Preoperative therapy of resectable gastric carcinoma, ASCO, Los Angeles, CA, 5/16/1998

Current options in the Treatment of Patients with Gastric Carcinoma, University of Chicago symposium on Oral Therapy of Cancer, Chicago, IL, 7/11/1998

Keynote address: Recent Advances in the Adjuvant Therapy of Colorectal Carcinoma. Lecture on: Definitive Chemoradiotherapy of patients with Esophageal Carcinoma, World Congress of Gastroenterology, Vienna, Austria, 9/6/1998

Oral fluoropyrimidines enhance the intratumoral levels of 5-FU; their clinical application. Second lecture on: Preoperative Chemoradiotherapy of Gastric Carcinoma, Fifth Annual International Conference on Gastrointestinal Oncology: Cancers of the Upper Gastrointestinal Tract, Bordeaux, France, 9/16/1998

Opening remarks. "Is radiotherapy is necessary for carcinoma of the esophagus?," Third International Conference on Biology, Prevention, and Treatment of Gastrointestinal Malignancies, Koln, Germany, 9/23/1998

Oral Therapy of Upper GI Tumors, International UFT meeting, Boca Raton, FL, 10/14/1998

Combined modality therapy of esophageal carcinoma, Symposium on Upper GI Cancers: Organized by Georgia Cancer Specialists, Atlanta, GA, 10/15/1998

Recent Advances in the Therapy of colorectal carcinoma, Baptist Cancer Center Symposium on Colorectal Carcinoma, Beaumont, TX, 11/7/1998

Chemoradiotherapy of Upper GI Tumors with emphasis on Continuous Infusion of Drugs, Universitatsklinikum, Humboldt University, Campus Charite Mitte, Berlin, Germany, 11/26/1998

The value of Chemoradiotherapy in the Management of Upper GI Tumors, 9th Anti-Cancer Chemotherapy Conference: SOMPS, Paris, France, 2/3/1999

Conference on Chemotherapy-induced diarrhea. Participated in a roundtable discussion to develop guidelines for oncology patients developing diarrhea., Northwestern University, Robert H. Lauri Comprehensive Cancer Center, Chicago, IL, 2/17/1999



M. D. Anderson Experience on therapy of Esophageal carcinoma, Fox Chase Cancer Center Symposium, Lanai, HI, 3/4/1999

Combined modality therapy of carcinoma of the esophagus, 4th Coloquial Hematology/Oncology Symposium. Sponsored by Glaxo-Wellcome Foundation, Merida City, Mexico, 3/17/1999

Current status of therapy of advanced gastric carcinoma, 4th Coloquial Hematology/Oncology Symposium. Sponsored by Glaxo-Wellcome Foundation, Merida City, Mexico, 3/17/1999

New Drugs for Esophageal Carcinoma and Multimodality Therapy of Carcinoma of the Esophagus, American Radium Society Symposium, Kona, HI, 4/17/1999

New Drugs in Gastric and Esophageal Carcinomas, Japan-US Symposium on Oncology, Hiroshima, Japan, 4/23/1999

(1) Advant Therapy of Gastric Carcinoma: Western Experience, (2) Rationale and Status of Preoperative Treatment Strategies for Gastric Carcinoma: A Perspective; (3) Therapeutic Options for Advanced Gastric Carcinoma, 3rd Conference of International Gastric Cancer Association, Seoul, 4/27/1999

New Strategies and New Drugs in the Treatment of Esophageal Carcinoma, University of Chicago International Symposium on Head and Neck, and Chest Malignancies, Chicago, IL, 9/30/1999

Western Approaches to the Treatment of Gastric Carcinoma, Aventis Symposium on Gastric Cancer, Japan, 4/15/2000

Colon cancer treatment., ASCO, Cleveland, OH, 6/3/2000

On RFS2000 trial at UTMDACC, Rubitecan conference sponsored by Supergen, Maui, HI, 6/17/2000

Current Approaches for the Management of Gastric Cancer, Investigators Meeting for Gastric Cancer, Current Perspectives and the Future, Hamburg, Germany, 10/15/2000

The Recent Advance of Chemotherapy for Gastric Cancer, Chang Gung Memorial Hospital, 4th Annual Terry Fox International Symposium on Gastric Cancer, Taipei, 10/21/2000

Treatment of Advanced Disease, Gastrointestinal Cancer Research Conference 2000, Orlando, FL, 11/16/2000

Refresher Course entitled, "Treatment of Cancer of the Esophagus.," 86th RSNA Scientific Assembly & Annual Meeting, Chicago, IL, 11/26/2000

Standards and controversies in the treatment of carcinoma of the esophagus and gastroesophageal junction, International Symposium on Esophageal Cancer, Dusseldorf, Germany, 12/15/2000

Current therapy of Gastric carcinoma. The Western experience, Investigators' Meeting: Taxol, Bangkok, Thailand, 2/23/2001

Recent advances in the treatment of GI Cancers, Investigators' Meeting: Taxol, Bangkok, Thailand, 2/23/2001

Protocol concept for phase III randomized study of preoperative therapy, State of Science Gastric Cancer Meeting at the NCI, Washington, DC, 3/5/2001

Management of CPT-11-induced diarrhea, Management of Cancer Treatment-induced Diarrhea and Carcinoid Syndrome, New Orleans, LA, 3/23/2001

Methods of Assessing Response to Therapy in Localized Gastric Carcinoma, 4th International Gastric Cancer Association Meeting, New York City, NY, 4/30/2001

Gastric Cancer. UT MDACC Experience, BMS-Japan: Gastric Cancer Symposium, San Francisco, CA, 5/13/2001

G17DT plus chemotherapy in advanced gastric carcinoma. Preliminary results of a phase II trial, Apton Symposium on Gastrin, San Francisco, CA, 5/14/2001

Taxotere in Gastric Cancer, International Gastric cancer meeting, Cairns, Australia, 8/7/2001

Treatment of Advanced Gastric Cancer, International Gastric cancer meeting, Cairns, Australia, 8/7/2001

Markers of Predictors for Upper GI Cancers, International Surgical Week., Brussels, Belgium, 8/27/2001

anti-gastrin antibody therapy for gastric cancer, 4th International Symposium on the treatment, biology, and prevention of gastrointestinal cancer, Colongne, Germany, 9/5/2001

Therapy of Advanced Gastric Carcinoma, Japanese Society of Clinical Oncology, Hiroshima, Japan, 11/6/2001

Upper GI Database and Translational Research at UTMDACC, EORTC GI Cancer meeting, Roermond, Netherlands, 11/29/2001

The Role of TAXOL in Gastrointestinal Cancer, TAXOL Investigators Workshop, Bangkok, Thailand, 1/10/2002

Current treatments and future perspectives, "Symposium on ""Interactive GI Oncology"" , " , Paris, France, 2/7/2002

Predictive and Prognostic Markers, Clinical Investigators Update Meeting, Sardinia, 4/21/2002

Antigastrin immunization fo the treatment of gastraic and gastroesophageal carcinomas, Beyond Chemotherapy 2002, Orlando, FL, 5/17/2002

ASCO Annual Meeting, Chicago, IL, 5/31/2002

Correlating Clinical Outcomes with Mollecular Markers in Gastric/Esophageal Cancer and Neoadjuvant Chemoradiotherapy for Gastric Cancer, 9th Annual International Conference on Gastrointestinal Oncology, Washington, DC, 11/7/2002

Curren Opinions in GI Oncology, 14th International Congress on Anti-cancer Treatment. Scientific Symposium, Paris, France, 2/2/2003

Facing Cancer Challenges Toda, Interantional Sanofi-Synthelabo, Atfhens, Greece, 3/28/2003

Chemotherapy Foundation Symposium XXI: Innovative Cancer Therapy for Tomorrow, New York, NY, 11/12/2003

6th International Conference of The Asian Clinical Oncology Society (ACOS), Soul, 11/16/2003

Recent Advances in Gastric Cancer, The 17th International Symposium of Foundation for Promotion of Cancer Research, Tokyo, Japan, 3/15/2004

Facing Cancer Challenges Today, 3rd Eloxatin International Meeting, Madrid, Spain, 3/27/2004

12th Pan-Hellenic Congress of Clinical Oncology, Athens, Greece, 4/22/2004

The Japan Esophageal Society Meeting, Tokyo, Japan, 6/24/2004

OSIP GOAB Meeting, London, 10/8/2004

19th World Congress of ISDS, Yokohama, Japan, 12/8/2004

ISGIO European Scientific Conference, Paris, France, 2/2/2005

4th International Eloxatin Investigator Advisory Workshop Meeting, Lisbon, Portugal, 3/12/2005

19th Annual Cancer Symposium, Oakbrook, IL, 4/22/2005

6th International Gastric Cancer Congress, Yokohama, Japan, 5/5/2005

ASCO Annual Meeting, Orlando, FL, 5/14/2005 !

4th Annual SAGE Meeting, Barcelona, Spain, 6/14/2005 !

GI Cancer, 2005 Gastrointestinal Oncology Conference (ISGIO), Arlington, VA, 7/14/2005 !

Chemotherapy as treatment for gastric cancer in the adjuvant and metastatic settings, 3rd !  
Annual Conference on Advances in the Multidisciplinary Treatment of Gastrointestinal !  
Neoplasms, City of Hope National Medical Center, San Diego, CA, 9/16/2005 !

GI, 18th Asia Pacific Cancer Conference, Seoul, Korea, Republic of, 9/16/2005 !

Overview of GI Cancer, Taxotere GI Consultant Meeting, St. Louis, MT, 10/15/2005 !

Esophageal Cancer, 2nd Annual Esophageal & Barrett's Metaplasia Conference, Las Vegas, !  
NV, 11/10/2005 !

Updates in GI Cancer, Sanofi-Aventis SAGE GI Meeting, San Francisco, CA, 1/24/2006 !

Esophageal Cancer, 17th International Congress on Anti-Cancer Treatment (ICACT/ISGIO !  
European Conference), Paris, France, 1/30/2006 !

Stomach cancer treatment, Annual Meeting of Japanese Gastric Cancer Association, Osaka !  
Itami, Japan, 3/8/2006 !

The search for a standard treatment of gastric cancer, International Gastrointestinal Cancer !  
Summit, Warsaw, Poland, 3/18/2006 !

Intergroup RTOG 98-11, 42nd Annual ASCO Meeting, Atlanta, GA, 6/2/2006 !

Presenting Abstract, RTOG Semi-Annual Meeting, Toronto, Canada, 6/24/2006 !

The disease and the advantages of Taxotere, WGIC Barcelona, Barcelona, Spain, 6/26/2006 !

Gastric cancer - future regimens, GI Sage Meeting, Barcelona, Spain, 7/2/2006 !

Updates on gastric cancer, Post ASCO Update Meeting, Pittsburgh, PA, 7/15/2006 !

Molecular biology of Barrett's progression to cancer and that of the esophageal !  
adenocarcinoma, 4th International Society of Gastroenterological Carcinogenesis Conference, !  
The University of Texas MD Anderson Cancer Center, Honolulu, HI, 8/24/2006 !

Updates, RTOG Semi-Annual Meeting, Tampa, FL, 2/1/2007 !

Gastric cancer: specific problems or general strategy?, GI Summit Experts Meeting: Cure of !  
cancer in 2020: Reality or Illusion?, Monte-Carlo, Monaco, 3/16/2007 !

S1, 3rd Hellenic Anticancer Meeting, Athens, Greece, 4/26/2007 !

Chemotherapy/radiation as the first line curative treatment for early esophageal cancer: The  
ultimate goal, Digestive Disease Week 2007, Washington, DC, 5/22/2007 !

Preoperative Approaches in Upper GI Malignancies, 2007 ASCO Annual Meeting, Chicago, !  
IL, 6/1/2007 !

Gastric Cancer, Best of ASCO in Japan, Japan Society of Medical Oncology, Tokyo, Japan, !  
7/7/2007 !

Gastric cancer, ASCO Symposium: Best of ASCO San Francisco, San Francisco, CA, !  
7/20/2007 !

Gastric Cancer, 45th Annual Meeting for Japanese Society of Clinical Oncology (JSCO), Kyoto !  
University, Kyoto, Japan, 10/24/2007 !

GI, 2008 ASCO 43rd Annual Meeting, Chicago, IL, 5/30/2008 !

Treatment options for Gastrointestinal Malignancies, Emerging Treatments and Advances in !  
Oncology, International Cancer Network, San Antonio, TX, 7/18/2008 !

Future Direction of Taxotere in gastric cancer, Taxotere Advisory Board Meeting, Sanofi-  
Aventis, Tokyo, Japan, 9/3/2008 !

Current and future treatment of esophageal and gastric cancer: a multimodality approach, The Gastroenterology Approach to GI Cancer: What to do and when, MDACC, San Antonio, TX, 10/24/2008

Modified docetaxel-based regimens for advanced gastroesophageal cancers, Chemotherapy Foundation Symposium XXVI, Mount Sinai School of Medicine, New York, NY, 11/4/2008

Jaffer A. Ajani, Wuilbert Rodriguez, Gyorgy Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, Vera Gorbunova, Ihor Vynnychenko, August Garin, Istvan Lang, and Silvia Falcon for the FLAGS Investigators. : "Multicenter phase III comparison of cisplatin/S-1(CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses., Taiho Pharmaceutical, ASCO, Orlando, FL, 6/1/2009

I give numerous international and national speeches. Serve many societies. Can be updated upon request

#### **Seminar Invitations from Other Institutions**

Management of Neuroendocrine tumors and Resectable Gastric Carcinoma, Army Hospital, El Paso, TX, 5/7/1993

Treatment of Advanced Carcinoma of the Esophagus, USC Symposium, Riverside, CA, ! 1/19/1995 !

Round Table Discussion on Therapeutic and Research Aspects of GI Malignancies, Tata ! Memorial Hospital, Bombay, India, 8/30/1996 !

Round Table Discussion on Therapeutic and Research Aspects of Hepatobiliary Carcinomas, Apollo Hospital, New Delhi, India, 9/6/1996

Adjuvant Therapy of Colon Carcinoma, Inha University College of Medicine, Seoul, 9/12/1996

Adjuvant Therapy of Colon Carcinoma, Korea University Medical School, Seoul, 9/13/1996

Combined Modality Approaches to Potentially Resectable Carcinoma of the Stomach, University of Munster: Gastric Cancer Symposium, Munster, Germany, 1/28/1997

Multidisciplinary approaches to upper GI tumors, Medical Oncology Rounds/Case Presentation, Houston, TX, 8/22/1997

Current Approaches to Chemoradiotherapy for Patients with Upper GI Tumors, Klinikum rechts der Isar. Der Technischen Universi, Munich, Germany, 10/23/1997

Taxol-Based Three-Step Therapy of Resectable Carcinoma of the Esophagus, Free University of Netherlands and Fox Chase Cance, St. Thomas, 3/26/1998

Management of Gastric and Esophageal Carcinoma, University of Munster Hospital and Clinic, Munster, Germany, 11/27/1998

An Update on Gastric Cancer Management., Grand Rounds. George Washington University, Washington, DC, 9/8/2000

Recent Advances in the Treatment of UGI Cancers, Cancer Rounds. Tulane University, New Orleans, LA, 5/17/2001

Taxotere combinatin therapy for Gastric Cancer and Taxotere is better for outpatients, Hokkaido University, Ichiki, Japan, 4/14/2002

Undates in Gastric and Esophageal Cancers, 2nd Annual Fall Oncology Conference, Vanderbilt University School of Medicine, Braselton, GA, 10/23/2005

Clinical Problems in Esophageal Cancer/ New Frontiers in Chemotherapeutics for Esophageal Cancer, 2nd Annual Moffitt Interdisciplinary GI Oncology Conference, Moffitt Cancer Center & Research Institute, Tampa, FL, 3/10/2007

GI Track Cancer, Gastric and GE Junction, Doctors Medical Center Oncology Symoisum, Doctors Medical Center, Modesto, CA, 5/19/2007

Gastric/Esophageal Cancer, The Multidisciplinary Management of Gastric & Esophageal Cancer, Penn State Hershey Medical Center, Hershey, PA, 12/5/2007

Lessons Learned from the Clinical Biology of Esophageal Cancer and Looking Ahead, !  
Developmental Cancer Therapeutics Program, City of Hope, Los Angeles, CA, 2/5/2008 !

Clinical biology-based approach to the management of localized gastroesophageal cancers,  
Anniversary Special Lecture at the China Medical University Hosp., China Medical University and  
Hospitals, Taipei, Taiwan, 11/14/2008

Gastric/Esophageal Cancer, Grand Rounds - Banner MD Anderson Cancer Center, Medical  
Oncology, Gilbert, AZ, 4/18/2014

I give numerous international and national speeches. Can be updated upon request

### **Lectureships and Visiting Professorships**

N/A

### **Other Presentations at State and Local Conferences**

Recent Advances in the treatment of Upper GI Cancers, Orlando-Orlando Regional Medical  
Center, Orlando, FL, 1/10/1991

Recent Advances in the treatment of Upper GI Cancers, St. Vincent Hospital Tumor Board,  
Jacksonville, FL, 1/11/1991

Advanced Carcinoid Tumors, MDACC-Medical Oncology Fellows Lecture, Houston, TX,  
1/18/1991

Neoadjuvant therapy of Gastric Carcinoma, MDACC-Surgical Seminar on Gastric Cancer,  
Houston, TX, 1/19/1991

Chemotherapy for Carcinoma of the Esophagus, MDACC-Radiotherapy Grand Rounds, Houston,  
TX, 1/21/1991

Recent Advances in GI Malignancies, Dentan Regional Medical Center, Dentan, TX, 1/24/1991

Current Issues in the Management of Upper GI Malignancies, Round Table of  
Hematology/Oncology, at Kansas City, KS, 2/21/1991

Recent Advances in the Treatment of GI Malignancies, Kansas University Medical School and  
Hospital, Kansas City, KS, 2/22/1991

Approaches to resectable upper GI malignancies-MDACC experience, Memorial Sloan-Kettering  
Cancer Center, New York, NY, 3/6/1991

Adjuvant therapy of colorectal carcinoma and management of gastric carcinoma, Opelousas  
General Hospital, Opelousas, LA, 4/25/1991

Recent Advances in Treatment of GI Malignancies, East Texas Regional Medical Center, Lufkin,  
TX, 7/13/1991

Recent Advances in the Treatment of Upper GI Malignancies, Spartanburg Regional Medical  
Center, Spartanburg, SC, 8/6/1991

Current Therapy of Neuroendocrine Tumors, Methodist Hospital, Houston, TX, 8/26/1991

Preoperative Therapy of Gastric Carcinoma, Investigators Meeting, The EMMES Corporation,  
Bethesda, MD, 9/12/1991

Recent Advances in the Treatment of Upper GI Malignancies, Wesley Medical Center, Wichita,  
KS, 9/17/1991

Treatment of Carcinoma of the Esophagus, Houston Thorax Institute, Houston, TX, 10/5/1991

Current Management of Upper GI Malignancies, Brown Medical Oncology Cancer Symposium,  
Providence, RI, 10/8/1991

Current Management of of Upper GI Malignancies, Baptist Hospital Tumor Board, Oklahoma City, !  
OK, 10/11/1991 !

Cancers of the Stomach, Esophagus, and Pancreas, American College of Physician Medical !  
Oncology Board Review, Houston, TX, 10/15/1991 !

Neuroendocrine Tumors of the GI Tract, American College of Physician Medical Oncology Board !  
Review, Houston, TX, 10/15/1991 !

GI Peptide Therapy, Mini-Conference arranged by Sandoz, Houston, TX, 11/13/1991 !

Etoposide Symposium, Boca Raton, FL, 12/4/1991 !

Presentation at the Tumor Board, St. Lukes Medical Center, Houston, TX, 2/28/1992 !

Advances in the Treatment of Upper GI Malignancies, The Cancer Institute Cancer Symposium, !  
San Jose, CA, 3/15/1992 !

Chemotherapy of Esophageal carcinoma, Genolier Oncology Clinic, Switzerland, 3/27/1992 !

Chemotherapy of gastric carcinoma, San Francisco Oncology Dinner Club, San Francisco , CA, !  
4/22/1992 !

Current Management of Gastric Carcinoma, California Pacific Medical Center Tumor Board, San !  
Francisco, CA, 4/22/1992 !

New Perspective in Colon Carcinoma, Co-chairman and speaker on the Adjuvant therapy of colon !  
carcinoma, Washington, DC, 6/12/1992 !

New Perspective in Colon Carcinoma, Co-chairman and speaker on the Adjuvant therapy of colon !  
carcinoma, New York , NY, 6/19/1992 !

New Perspective in Colon Carcinoma, Co-chairman and speaker on the Adjuvant therapy of rectal !  
carcinoma, Miami, FL, 6/26/1992 !

New Perspective in Colon Carcinoma, Co-chairman and speaker on the Adjuvant therapy of rectal !  
carcinoma, Houston, TX, 7/11/1992 !

New Perspective in Colon Carcinoma, Co-chairman and speaker on the Adjuvant therapy of rectal !  
carcinoma, Chocago, IL, 7/18/1992 !

CSFs and Dose-Intensification, New York , NY, 8/28/1992 !

Role of chemoradiother in the treatment of esophageal cancer, Texas Radiological Society, !  
Houston, TX, 8/29/1992 !

Hosting a disucussion in an internation forum on gastric cancer, Round Table Discussion, Los  
Angeles, CA, 11/21/1992 !

Therapy of Upper Gastrointestinal Cancer, Midland Medical Center, Midland, MI, 12/8/1992 !

use of GM-CSF in GI cancers, Scherring Symposium for visiting Chinese MDs, Houston, TX, !  
1/8/1993 !

Lecture on Biology of Treatment Induced Remission, Advisory Committee on GM-CSF, !  
sponsored by Sandoz-Schering Corporation, Palm Beach, FL, 5/13/1993 !

Therapeutic options for neuroendocrine tumors, Regional Therapy Congress, Weisbaden, !  
Germany, 7/13/1993 !

Chemotherapy of Gastric Carcinoma, Southern Oncology Association Annual Meeting, St. !  
Thomas, 7/23/1993 !

treatment of gastric, esophageal, neuroendocrine and hepatocellular carcinomas, ACP course, !  
Houston, TX, 9/30/1993 !

Chemotherapy of carcinoma of the esophagus, Bethesda Memorial Hospital Symposium on !  
esophageal carcinoma, Westpalm Beach, FL, 11/13/1993 !

Therapy of Carcinoma of the Esophagus, Thoracic Surgery Educational Program at MDACC, Houston, TX, 2/4/1994

Biotherapy and chemotherapy of Cancer, merical Cancer Society Post-graduate Course, San Juan, Puerto Rico, 2/13/1994

Approaches to Upper GI Carcinomas, Medical Oncology Fellows at MDACC, Houston, TX, 2/14/1994

Treatment of Neuroendocrine Tumors with Occlusive Therapy, Department of Radiology, Houston, TX, 1/23/1995

Adjuvant Therapy of Colorectal Carcinoma, MDACC Symposium on GI Malignancies, Houston, TX, 3/2/1995

Treatment of Colorectal Carcinoma, Symposium on GI Malignancies arranged by Deaconess Hospital, Evansville, IN, 4/20/1995

New developments in the treatment of colorectal and esophageal carcinomas, Tumor Board at Memorial Hospital of South Bend, South Bend, IN, 5/17/1995

Multi-institutional trial of Taxol/cisplatin/5-FU in the treatment of carcinoma of the esophagus, JCO editorial board meeting, Los Angeles, CA, 5/20/1995

Primary Chemotherapy of Gastric Carcinoma, Istituto Nazanale Tumori, Milano, Italy, 9/14/1995

Treatment of Carcinoma of the Esophagus with Taxol, ECCO Meeting, Paris, France, 10/30/1995

Adjuvant Therapy of Rectal Carcinoma, Houston Surgical Society, Houston, TX, 11/13/1995

Current status of Gastric and Colorectal Therapy, Arlington Cancer Center, Arlington, TX, 2/23/1996

indications and contraindications for hepatic artery embolization, UT Medical School: Clinical Medical Oncology Conference, Houston, TX, 3/18/1996

Treatment of locally advanced carcinoma of the stomach, Georgia Cancer Specialists Meet the Professor Forum, Atlanta, GA, 3/21/1996

Slide Presentation: Preoperative therapy of resectable gastric carcinoma. Slide presentation: Role of preoperative therapy for localized esophageal carcinoma, ASCO, Philadelphia, PA, 5/19/1996

New Advances in the Therapy of GI Cancers, Indian Society of Gastrointestinal Surgeons, New Delhi, India, 9/6/1996

Poster discussion: Taxol/radiotherapy; Taxol in gastric Carcinoma; Taxol-phase I study, Investigators' meeting organized by Bristol-Myers, Atlanta, GA, 4/5/1997

Taxol in the treatment of Carcinoma of the esophagus, Investigators' meeting organized by Bristol-Myers, Atlanta, GA, 4/5/1997

Poster discussion: Taxol/radiotherapy; Taxol in gastric Carcinoma; Taxol-phase I study, Investigators' meeting organized by Bristol-Myers, Dallas, TX, 4/11/1997

Taxol in the treatment of Carcinoma of the esophagus, Investigators' meeting organized by Bristol-Myers, Dallas, TX, 4/11/1997

Round Table Discussion: Management of Chemotherapy-Induced Diarrhea, Sponsored by Novartis, New York, NY, 4/26/1997

New Agents in the Treatment of Gastric Cancer and Their Potential for Multimodality Programs, 2nd International Conference of Gastric Carcinoma, Munich, Germany, 4/27/1997

Poster Discussant: Chemotherapy of gastric carcinoma, 2nd International Conference of Gastric Carcinoma, Munich, Germany, 4/27/1997

Current Approaches to the Treatment of Esophageal Cancer, Memorial Southwest Hospital-Oncology Group, Houston, TX, 6/9/1997

Current management of gastric carcinoma, Oriental Physicians on Preceptorship, Houston, TX, 8/18/1997

The Treatment of Gastric and Esophageal Carcinoma, Medical Oncology Board Review (UTMDACC0), Houston, TX, 9/18/1997

Lecture on Recent Advances in Chemotherapy of GI Malignancies, Yonsei University Medical School, Seoul, 9/20/1997

Therapy of Gastric Carcinoma: Current Options, Rhone-Poulan-Rohr Worldwide Oncology Symposium, Washington, DC, 10/7/1997

Review of Posters on Therapy of Esophageal Carcinoma, Taxol Investigator's Meeting Sponsored by Bristol-Myers Squibb, Pittsburgh, PA, 10/25/1997

Review of Taxol-based Therapy of Esophageal/Head & Neck Cancers, Taxol Investigator's Meeting Sponsored by Bristol-Myers Squibb, Pittsburgh, PA, 10/25/1997

Current management of gastric carcinoma, Visiting Physicians on a Preceptorship Program, Houston, TX, 11/12/1997

Advances in Therapy of Carcinoid Syndrome, Novartis Oncology Advisory Board, New York, NY, 11/13/1997

Anal Cancer and Gastric Carcinoma, the NCI GI Cooperative Group Strategy Meeting, Washington, DC, 12/3/1997

Current Therapy of Gastric Carcinoma, CPT-11 Investigators Meeting, Houston, TX, 1/22/1998

Current Therapy of Gastric Carcinoma, UFT investigators meeting, Orlando, FL, 1/23/1998

Role of UFT in Gastric Carcinoma, UFT investigators meeting, Kiawah Island, SC, 3/19/1998

Current Advances in the Treatment of Carcinoma of the Esophagus, Southern California Academy of Clinical Oncology. Keynote Speaker, Los Angeles, CA, 4/7/1998

Presentation of the International Phase II-III Study of Taxotere Combinations, FDA meeting, Washington, DC, 4/8/1998

gastric and esophageal cancer studies at MDACC, ASCO, Los Angeles, CA, 5/16/1998

Gastric Carcinoma, American Cancer Society. Fort Bend County, Sugarland, TX, 7/22/1998

Combined Modality Therapy of Gastric Carcinoma and Esophageal Carcinoma, M.D. Anderson Cancer Center International Marketing Conference, Lima, Peru, 10/1/1998

Gastric and Esophageal Carcinoma, UT MDACC Medical Oncology Board Review, Houston, TX, 10/8/1998

Chemotherapy-induced Diarrhea and its Management plus Carcinoid syndrome, American Cancer Society and Nashville Society of Clinical Oncology, Nashville, TN, 11/17/1998

Management of Carcinoid Syndrome, Nashville VA Hospital, Nashville, TN, 11/17/1998

Colorectal Carcinoma: Therapy in the adjuvant and advanced setting, Refreshers course of Radiology Society of North America, Chicago, IL, 11/29/1998

data on Preoperative Therapy of Resectable Gastric Carcinoma, NCI GI Intergroup meeting, Washington, DC, 12/9/1998

Combined modality therapy of esophageal carcinoma and new combinations, Bristol-Myers Squibb Advisory Board on Head & Neck and Esophageal Carcinoma, Scottsdale, AZ, 3/13/1999

Current status of therapy of Gastric carcinoma., The Valley Hospital, Ridgewood, NJ, 4/8/1999

Chemotherapy/multimodality approaches, USC organized conference, New York, NY, 5/1/1999

Panelist on a USC organized conference on "Biology and Treatment of Esophageal and Gastric Carcinoma," USC organized conference, New York, NY, 5/1/1999



Multimodality Therapy of Carcinoma of the Esophagus, Dinner Symposium: Whipney, Whipney, NJ, 5/24/1999

New Frontiers in the treatment of GI and Lung Cancers with Irinotecan, MD Anderson Symposium, San Francisco, CA, 7/15/1999

Recent Developments in the Treatment of Gastrointestinal Malignancies, Russian Academy of Medical Sciences Oncology Symposium, Moscow, 9/24/1999

Data on Current Therapy of Gastric Carcinoma, Sponsored by Pharmacia and Upjohn, Washington, DC, 10/8/1999

Current Therapy of Carcinoid Tumors, NorthOakland Medical Center GI syposium, Pontiac, MI, 10/16/1999

Therapy of Gastric and Esophageal Carcinomas, Advisory Board Meeting for Pharmacia and Upjohn, Chicago, IL, 10/29/1999

Results of the Phase II study of CPT-11 and cisplatin, Chemotherapy Foundation Meeting, New York, NY, 11/3/1999

Carcinoma of the Esophagus. Current Management, VA Hospital. Tumor Board, Seattle, WA, 11/10/1999

Combined Modality Therapy of Carcinoma of the Esophagus, University of Washington Symposium on Carcinoma of the Esophagus, Seattle, WA, 11/10/1999

Evolving role of chemotherapy in advanced and adjuvant colorectal carcinoma, 5th Annual Oncology Symposium, Saginaw, MI, 11/17/1999

Current Therapy of Esophageal Carcinoma, Radiology Society of North America, Chicago, IL, 11/28/1999

New Developments in the Treatment of Colorectal Carcinomas, Aultman Hospital, Colorectal cancer symposium, Canton, OH, 1/25/2000

new protocols for esophageal and gastric cancers, NCI GI Club Meeting, Washington, DC, 2/16/2000

Therapeutic Options for Advanced Gastric Cancer, Clinical Hematology and Oncology, La Jolla, CA, 2/20/2000

Taxol based therapy, Attend meeting sponsored by Bristol-Myers Squibb, Bangkok, Thailand, 2/28/2000

CPT-11 in GI malignancies, Tel-Aviv, Israel, 3/1/2000

Therapy of Carcinoma of the Esophagus, Fox Chase Cancer Center Investigator Workshop and Consensus Conference, Lanai, HI, 3/11/2000

Gastric Cancer, Instituto Nacional de Cancerologia – Mexico, 1st Reunion Internacional del Capitulo Mexicano Mayo Alumni Association, Mexico City, Mexico, 4/6/2000

Phase I & II Trials: CPT-11 in Gastric Cancer, Participate as a faculty member in the Key Thought Leaders Meeting, Miami, FL, 4/27/2000

new developments in the treatment of gastric cancer, Shanghai, China, 5/30/2000

Treatment strategies for localized and advanced esophageal and gastric carcinomas, American Cancer Society/UC San Diego Colloquium, San Diego, CA, 6/13/2000

New Developments in the Management of GI Malignancies, Myers Squibb Oncology Visiting Faculty Program. Host is the American Cancer Society., Pittsburgh, PA, 6/16/2000

Irinotecan in Gastric Cancer and CPT-11 plus Radiotherapy, University of Texas M. D. Anderson Cancer Center Investigators' Workshop, St. Croix, 7/13/2000

Barrett's Esophagus and Esophageal Cancer, Enron Field, at the Briefing at the Ballpark: Best of DDW Conference 2000, Houston, TX, 8/19/2000

CPT-11 in Gastric Cancer, Topoisomerase Inhibitors: Focus on CPT-11, Las Vegas, NV, !  
10/28/2000 !

Recent Advances in Gastric Cancer Therapy, Tumor Board, Baton Rouge, LA, 4/4/2001 !

Database and Trends in the Treatment of Gastric Cancer, Gastric Cancer Symposium, Sendai, !  
Japan, 4/12/2001 !

Treatment of Gastric Carcinoma, Tokyo Gastric Club, Tokyo, Japan, 4/14/2001 !

Current Advances in the Treatment of Advanced Gastric Carcinoma, Korean Cancer Society, !  
Seoul, 6/6/2001 !

CPT-11-based protocols for gastric and esophageal carcinomas, UT MDACC Investigators' !  
Meeting, Colorado Springs, CO, 7/26/2001 !

CPT-11 and cisplatin in Advanced Gastric Cancer, South Florida Oncology Retreat, Ft. Myers, FL, !  
9/29/2001 !

Taxotere in GI Malignancies, Taxotere Investigators Meeting, Phoenix, AZ, 10/5/2001 !

Treatment of Gastric and Esophageal Carcinomas, UT MDACC Board Review, Houston, TX, !  
10/11/2001 !

Treatment of Advanced Gastric Carcinoma, International Oncology Foundation, Atlanta, GA, !  
10/20/2001 !

Treatment of Gastric Carcinoma, UT MDACC Physician Assistant Conference, Houston, TX, !  
10/20/2001 !

Therapy of Advanced Gastric Carcinoma, and Chair the symposium, Apton-Aventis Investigators !  
Meeting, Houston, TX, 11/17/2001 !

Toxotere in the Management of GI Cancer, Taxotere Regional Advisory Board Meeting, Aventura, !  
FL, 2/9/2002 !

Advances in the treatment of Gastric Cancer, "Aventis Programs ""Centre community Hospital"" , !  
, Pittsburgh, PA, 2/26/2002 !

Practical Applications of New Drugs in Pancreas and Gastric Malignancies, Continuing Medical !  
Education Program: Practical Applications of New Agents in Oncology, San Antonio, TX, 3/2/2002 !

Bryostatin-I for Carcinoma of the Stomach or Gastroesophageal Junction, 13th Annual !  
community Clinical Oncology Program: Update on Current and Proposed Trials, Houston, TX, !  
3/9/2002 !

Review of CPT-11 and Taxotere for Gastric Cancer, The Second Pharmacia Oncology GI !  
consortium, Scottsdale, AZ, 3/14/2002 !

Colorectal Cancer, "The Cleveland Clinic Cancer center at Fairview Hospital Symposium ""Care !  
of the Cancer Patient: Evidence-based Practice," , Cleveland OH, 4/10/2002 !

Management of CTID, Chemotherapy-Induced Diarrhea (CTID) Advisory Board Meeting, Orlando, !  
FL, 5/17/2002 !

Novartis Oncology – "Innovative Minds" in conjunction to 38th Annual Meeting of the American !  
Society of Clinical Oncology,, Orlando, FL, 5/20/2002 !

Introduction of ALIMTA in Gastric Cancer, Lilly Oncology – Gastric Advisory Board Meeting, !  
Orlando, FL, 5/20/2002 !

Treatment of Chemotherapy Induced Diarrhea and Carcinoid Syndrome, Novartis  
Pharmaceuticals Consultant Meeting, Jacksonville, FL, 6/15/2002 !

Esophageal Cancer and Gastric, Pharmacia Oncology Speakers Bureau, Los Angeles, CA, !  
10/10/2002 !

Esophageal/Gastric Cancer, NCCN Panel, Rockledge, PA, 1/3/2003 !

Aventis Satellite Symposium, Eilat, Israel, 1/14/2003 !  
New Development in the treatment of Colorectal Cancer, CBCE Speaker Corps, Tampa, FL, !  
2/18/2003 !  
Treatment of GI Cancers, Network for Oncology communication & Research "Challenging Cases  
in Oncology," , New York, NY, 3/8/2003 !  
New Treatment Options in Gastric Cancer, Envision Communications, Inc., Coral Gable, FL, !  
3/14/2003 !  
Advances in the treatment of Gastric and Esophageal Cancer, Envision Communications, Inc., !  
Richmond, VA, 3/25/2003 !  
Colorectal Cancer Regional Advisory Board Meeting, Pharmacia Oncology and Roche !  
Pharmaceuticals Advisory Board, Philadelphia, PA, 4/11/2003 !  
Esophageal Cancer, Medicine-Hematology/Oncology Program, Augusta, GA, 4/15/2003 !  
Gastric and Esophageal, Hematology Oncology Associates, Case Presentations, Fredericksburg, !  
MD, 4/25/2003 !  
Protocol Review, PEG-Camptothecin Advisory Committee Meeting, Short Hill, NY, 4/29/2003 !  
NOCR, Los Angeles, CA, 5/10/2003 !  
Colorectal Cancer Expert Panel, Washington, DC, 5/23/2003 !  
Aventis, New York, NY, 6/1/2003 !  
5th Annual Comprehensive Review, Philadelphia, PA, 6/12/2003 !  
Oncology Clinical Practice Cancer Foundation, Stone Mountain, GA, 6/21/2003 !  
Taxotere GI Clinical Development Panel, NOCR, Rosemont, IL, 7/9/2003 !  
Challenging Cases in GI Oncology, NOCR, New York, NY, 7/11/2003 !  
MD Anderson Investigators' Workshop, Amelia Island, NY, 7/16/2003 !  
NCCN/GI Malignancies Advisory Board, Chicago, IL, 8/6/2003 !  
Challenging Cases in Oncology, NMCR, New York, NY, 10/18/2003 !  
Challenging Cases in Oncology, NOCR, Atlanta, GA, 10/24/2003 !  
Challenging Cases in Oncology & Hematology, NOCR, New York, NY, 5/22/2004 !  
ASCO, New Orleans, LA, 6/3/2004 !  
Recent Advances & New Directions in Cancer Therapy, 4th Annual California Cancer Consortium !  
Conference, Napa Valley, CA, 3/11/2005 !  
Challenging Cases in Gastrointestinal Cancer, NMCR, New Orleans, LA, 4/2/2005 !  
Challenging Cases in Oncology, NOCR, Chicago, IL, 6/11/2005 !  
Breakthroughs in Colon Cancer Treatment, NOCR, Atlanta, GA, 7/23/2005 !  
Breakthroughs in Colon Cancer Treatment, NOCR, Atlanta, GA, 7/23/2005 !  
Challenging Cases in GI Cancer, NMCR, Miami, FL, 7/30/2005 !  
Challenging Cases in GI Cancer, NOCR, Montreal, Canada, 8/20/2005 !  
Metastatic Gastric Cancer, NMCR, Las Vegas, NV, 10/22/2005 !  
GI Cancer, NOCR, San Diego, CA, 11/19/2005 !  
Advanced Gastric cancer, NMCR, New York, NY, 4/8/2006 !  
Advanced Gastric cancer, NMCR, New York, NY, 5/20/2006 !  
Advanced Gastric cancer, NMCR, Las Vegas, NV, 6/10/2006 !

Advanced Gastric cancer, NMCR, Chicago, IL, 7/22/2006

Advanced Gastric cancer, NMCR, Scottsdale, AZ, 9/9/2006

Advanced Gastric cancer, NMCR, New York, NY, 10/7/2006

Advanced Gastric cancer, NMCR, Sunny Isles Beach, FL, 11/4/2006

Taxotere(docetaxel) injection concentrate for the treatment of advanced gastric cancer and cancer of the gastro-esophageal junction, Oncology Speakers Bureau Meeting, Envision, Sanofi-Aventis, Denver, CO, 11/14/2006

Gastric/esophageal cancer, Sanofi-Aventis Speaker Programs, Sanofi-Aventis, Chicago, IL, 2/13/2007

Taxotere(docetaxel) injection concentrate for the treatment of advanced gastric cancer and cancer of the gastro-esophageal junction, Sanofi-Aventis Speaker Programs, Sanofi-Aventis, Chicago, IL, 2/13/2007

Taxotere(docetaxel) injection concentrate for the treatment of advanced gastric cancer and cancer of the gastro-esophageal junction, Envision, Sanofi-Aventis, Roseville, CA, 5/18/2007

Taxotere(docetaxel) injection concentrate for the treatment of advanced gastric cancer and cancer of the gastro-esophageal junction, Envision, Sanofi-Aventis, Beverly Hills, CA, 6/12/2007

Advances in hepatocellular and pancreatic cancer, Emerging Trends in Oncology, Per Group, Physicians' Education Resource, 6/23/2007

Gastrointestinal cancer, 5th Annual Therapeutic Advances in Gastrointestinal Malignancies Conference, CBCE, Newport Beach, CA, 7/12/2007

Taxotere(docetaxel) injection concentrate for the treatment of advanced gastric cancer and cancer of the gastro-esophageal junction, Envision, Sanofi-Aventis, Temple, TX, 7/31/2007

Gastric cancer, Sanofi-Aventis Multi-Tumor Speaker Training Mtg, Envision, Sanofi-Aventis, Dallas, TX, 8/3/2007

Gastric cancer, Steering Committee Meeting, Imclone Systems Inc., New York, NY, 9/20/2007

Erbix, Erbix Cross-Tumor Advisory Board Mtg, Bristol-Myers Squibb, Irving, TX, 9/21/2007

Esophageal Cancer, Eisai's E7974 Advisory Board Meeting, Eisai, Teaneck, NJ, 12/8/2007

Taxotere(docetaxel) injection concentrate for the treatment of advanced gastric adenocarcinoma., Sanofi-Aventis Oncology Lecture Series Meeting, Envision, Sanofi-Aventis, Memphis, TN, 6/10/2008

Discussion of treatment dynamics for colorectal cancer and the role of Xeloda, Xeloda Colorectal Cancer National Advisory Board Meeting, Cadent Medical Communications, San Francisco, CA, 6/21/2008

I give numerous international and national speeches. Can be updated upon request

## **PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

### **Professional Society Activities, with Offices Held**

#### **National and International**

American Association for Advancement of Science !

American Association for Cancer Research !

American College of Surgeons !

American Medical Association !

American Society of Clinical Oncology !

American Society of Therapeutic Radiotherapy !

Chilean Society of Oncology (Santiago) !  
Greek Society of Cancer Studies (Athens) !  
Harris County Medical Society !  
International Society for Gastric Carcinoma (Founding member), headquartered in Tokyo, !  
Japan !  
International Society for the Study of Comparative Oncology !  
International Society of Gastrointestinal Oncology !  
M. D. Anderson Associates  
Member Peruvian Society of Medical Oncology  
Radiation Therapy Oncology Group (RTOG)  
Sierra Club  
Texas Medical Association  
The International Biographical Center Advisory Council. Headquartered in Cambridge,  
England

**Local/State**

Am Society of Therapeutic Radiotherapy., San Antonio, TX !  
American College of Surgeons, Chicago, IL !  
Radiation Therapy Oncology Group, Boston, MA !

**UNIQUE ACTIVITIES**

1. Fund Raising: 1) The Scott Petty Foundation Award for Gastrointestinal Cancer Family Research. (1992) \$40000 2) Various Donors for Research in GI Cancer & Associated Disorders. (1993) \$153026 3) Various Donors Pancreatic Research. (1993) \$28639 4) Bettie

**DATE OF LAST CV UPDATE**

04/25/2019